Converted by EDGARwiz

0001511164-18-000658.txt : 20181114 0001511164-18-000658.hdr.sgml : 20181114 20181114155341 ACCESSION NUMBER: 0001511164-18-000658 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 68 CONFORMED PERIOD OF REPORT: 20180930 FILED AS OF DATE: 20181114 DATE AS OF CHANGE: 20181114 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BIOTRICITY INC. CENTRAL INDEX KEY: 0001630113 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 472548273 STATE OF INCORPORATION: NV FISCAL YEAR END: 0331 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 333-201719 FILM NUMBER: 181183350 BUSINESS ADDRESS: STREET 1: 75 INTERNATIONAL BLVD., SUITE 300 CITY: TORONTO STATE: A6 ZIP: M9W 6L9 BUSINESS PHONE: (416) 214-3678 MAIL ADDRESS: STREET 1: 75 INTERNATIONAL BLVD., SUITE 300 CITY: TORONTO STATE: A6 ZIP: M9W 6L9 FORMER COMPANY: FORMER CONFORMED NAME: METASOLUTIONS, INC. DATE OF NAME CHANGE: 20150107 10-Q 1 biotricity10_q.htm FORM 10-Q Converted by EDGARwiz

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

________________

Form 10-Q



(Mark One)
[X]	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934.
	For the quarterly period ended September 30, 2018
[ ]	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934.
	For the period from ______________ to_______________

Commission file number: 333-201719

BIOTRICITY INC.

(Exact name of registrant in its charter)



Nevada	47-2548273
State or Other Jurisdiction of Incorporation or Organization)	(I.R.S. Employer Identification No.)
275 Shoreline Drive, Suite 150 Redwood City, California 94065
(Address of principal executive offices)

(650) 832-1626

(Registrant’s Telephone Number, Including Area Code)

Indicate by check whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes [X] No [ ]

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (Section 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes [X] No[ ]

Indicate by check mark whether registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act).

Large accelerated filer [ ] Accelerated filer [ ]

Non-accelerated filer [X] Smaller reporting company [X]

Emerging growth company [X]

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial standards provided pursuant to Section 13(a) of the Exchange Act. [X]

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

Yes [ ] No [X]

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date: 29,029,120 shares of Common Stock, $0.001 par value, at November 13, 2018. The Company also has 4,868,484 Exchangeable Shares outstanding as of November 13, 2018, that convert directly into common shares, which when combined with its Common Stock produce an amount equivalent to 33,897,584 outstanding voting securities.

BIOTRICITY INC.




Part I – Financial Information

Item 1 – Condensed Consolidated Financial Statements	3
Item 2 - Management's Discussion and Analysis of Financial Condition and Results of Operations	26
Item 3 – Quantitative and Qualitative Disclosures About Market Risk	35
Item 4 - Controls and Procedures	35
Part II - Other Information
Item 1 - Legal Proceedings	36
Item 2 – Unregistered Sales of Equity Securities and Use of Proceeds	36
Item 3 – Defaults Upon Senior Securities	36
Item 4 – Mine Safety Disclosures	36
Item 5 - Other Information	36
Item 6 – Exhibits	36
Signatures	37

PART 1

FINANCIAL INFORMATION


Item 1 – Condensed Consolidated Financial Statements
Condensed Consolidated Balance Sheets at September 30, 2018 (unaudited) and March 31, 2018 (audited)	4
Condensed Consolidated Statements of Operations and Comprehensive Loss for the three and six months ended September 30, 2018 and 2017 (unaudited)	5
Condensed Consolidated Statements of Cash Flows for the six months ended September 30, 2018 and 2017 (unaudited)	6
Notes to the Condensed Consolidated Financial Statements	7


BIOTRICITY, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS AS AT SEPTEMBER 30, 2018 (unaudited) and MARCH 31, 2018 (audited)
(Expressed in US Dollars)

	As at September 30, 2018	As at March 31, 2018
	(unaudited)	(audited)
	$	$
CURRENT ASSETS
Cash	83,254	843,643
Accounts receivable, no allowance	43,436	-
Inventory, net	179,430	-
Harmonized sales tax recoverable	51,316	35,737
Deposits and other receivables	28,984	17,046
Total current assets	386,420	896,426

Deposits and other receivables	33,000	33,000
TOTAL ASSETS	419,420	929,426

CURRENT LIABILITIES
Accounts payable and accrued liabilities [Note 4]	1,047,896	756,179
TOTAL LIABILITIES	1,047,896	756,179

STOCKHOLDERS' (DEFICIENCY) EQUITY
Preferred stock, $0.001 par value, 10,000,000 authorized as at September 30, 2018 and March 31, 2018, respectively, 1 share issued and outstanding as at September 30, 2018 and March 31, 2018, respectively [Note 7]	1	1
Common stock, $0.001 par value, 125,000,000 authorized as at September 30, 2018 and March 31, 2018, respectively. Issued and outstanding common shares: 27,605,567 as at September 30, 2018 and 23,713,602 as at March 31, 2018, respectively, and exchangeable shares of 5,725,041 and 8,143,937 outstanding as at September 30, 2018 and March 31, 2018, respectively [Note 7]	33,331	31,858
Shares to be issued [Note 7]	80,216	69,963
Additional paid-in-capital	30,935,575	27,161,984
Accumulated other comprehensive loss	(632,912)	(643,129)
Accumulated deficit	(31,044,687)	(26,447,430)
Total stockholders' (deficiency) equity	(628,476)	173,247
TOTAL LIABILITIES AND STOCKHOLDERS' (DEFICIENCY) EQUITY	419,420	929,426

Commitments and contingencies [Note 9]

Subsequent Events [Note 10]

See accompanying notes to condensed consolidated interim financial statements


BIOTRICITY, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
FOR THE THREE AND SIX MONTHS ENDED SEPTEMBER 30, 2018 AND 2017
(Expressed in US Dollars)

	Three Months Ended September 30, 2018	Three Months Ended September 30, 2017	Six Months Ended September 30, 2018	Six Months Ended September 30, 2017
	(unaudited)	(unaudited)	(unaudited)	(unaudited)
	$	$	$	$

REVENUE	84,760	-	102,420	-
Cost of revenue	47,118	-	56,918	-
NET REVENUE	37,642	-	45,502	-

EXPENSES
General and administrative expenses [Notes 7, 8 and 9]	2,026,523	1,041,275	4,154,829	2,129,474
Research and development expenses	187,859	413,624	487,930	728,734
TOTAL OPERATING EXPENSES	2,214,382	1,454,899	4,642,759	2,858,208

Accretion expense [Note 5]	-	-	-	879,416
Change in fair value of derivative liabilities [Note 6]	-	-	-	20,588
NET LOSS BEFORE INCOME TAXES	(2,176,740)	(1,454,899)	(4,597,257)	(3,758,212)

Income taxes	-	-	-	-
NET LOSS	(2,176,740)	(1,454,899)	(4,597,257)	(3,758,212)

Translation adjustment	112,866	(83,858)	10,217	(170,348)

COMPREHENSIVE LOSS	(2,063,874)	(1,538,757)	(4,587,040)	(3,928,560)

LOSS PER SHARE, BASIC AND DILUTED	(0.066)	(0.048)	(0.142)	(0.127)

WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING	32,819,848	30,590,667	32,377,274	29,529,534

See accompanying notes to unaudited condensed consolidated interim financial statements


BIOTRICITY, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS FOR THE SIX MONTHS ENDED SEPTMEBER 30, 2018 and 2017
(Expressed in US Dollars)

	Six Months Ended September 30, 2018	Six Months Ended September 30, 2017
	(unaudited)	(unaudited)
	$	$

CASH FLOWS FROM OPERATING ACTIVITIES
Net loss	(4,597,257)	(3,758,212)
*Adjustments to reconcile net loss to net cash used in operations*
Stock based compensation	728,162	442,155
Issuance of shares for services	898,025	419,217
Issuance of warrants for services, at fair value	368,352	174,976
Accretion expense	-	879,416
Change in fair value of derivative liabilities	-	20,588
Fair value of warrants issued	-	-

*Changes in operating assets and liabilities:*
Accounts receivable	(43,436)	-
Inventory	(179,430)	-
Harmonized sales tax recoverable	(15,580)	(19,602)
Deposits and other receivables	(11,939)	7,983
Accounts payable and accrued liabilities	182,465	(374,650)
Net cash used in operating activities	(2,670,638)	(2,208,129)

CASH FLOWS FROM FINANCING ACTIVITIES
Issuance of shares, net	1,739,943	2,340,409
Proceeds from exercise of warrants	50,835	-
Issuance of convertible debentures, net	-	-
Due to shareholders	-	-
Net cash provided by financing activities	1,790,778	2,340,409

Effect of foreign currency translation	119,471	50,001

Net (decrease) increase in cash during the period	(879,860)	132,280

Cash, beginning of period	843,643	424,868

Cash, end of period	83,254	607,149

See accompanying notes to unaudited condensed consolidated interim financial statements

BIOTRICITY, INC.

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

September 30, 2018 (Unaudited)

(Expressed in US dollars)

1. NATURE OF OPERATIONS

Biotricity Inc. (formerly MetaSolutions, Inc.) (the “Company”) was incorporated under the laws of the State of Nevada on August 29, 2012.

iMedical Innovations Inc. (“iMedical”), a wholly-owned subsidiary of the Company, was incorporated on July 3, 2014 under the laws of the Province of Ontario, Canada.

The Company, through its wholly-owned subsidiary iMedical, is engaged in research and development activities within the remote monitoring segment of preventative care. The Company is focused on a realizable healthcare business model that has an existing market and commercialization pathway. As such, our efforts to date have been devoted in building technology that enables access to this market through the development of a tangible product.

On February 2, 2016, the Company entered into an exchange agreement with 1061806 BC LTD. (“Callco”), a British Columbia corporation and wholly owned subsidiary (incorporated on February 2, 2016), 1062024 B.C. LTD., a company existing under the laws of the Province of British Columbia (“Exchangeco”), iMedical, and the former shareholders of iMedical (the “Exchange Agreement”), whereby Exchangeco acquired 100% of the outstanding common shares of iMedical, taking into account certain shares pursuant to the Exchange Agreement. These subsidiaries were solely used for the issuance of exchangeable shares in the reverse takeover transaction and have no other transactions or balances. After giving effect to this transaction, the Company acquired all of iMedical’s assets and liabilities and commenced operations through iMedical.

As a result of the Share Exchange, iMedical is a wholly-owned subsidiary of the Company. This transaction has been accounted for as a reverse merger. Consequently, the assets and liabilities and the historical operations reflected in the consolidated financial statements for the periods prior to February 2, 2016 are those of iMedical and are recorded at the historical cost basis. After February 2, 2016, the Company’s consolidated financial statements include the assets and liabilities of both iMedical and the Company and the historical operations of both after that date as one entity.

2. BASIS OF PRESENTATION, MEASUREMENT AND CONSOLIDATION

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“US GAAP”) for interim financial information and the Securities and Exchange Commission (“SEC”) instructions to Form 10-Q and Article 8 of SEC Regulation S-X. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements and should be read in conjunction with Biotricity’s audited financial statements for the years ended March 31, 2018 and 2017 and their accompanying notes.

The accompanying unaudited condensed consolidated financial statements are expressed in United States dollars (“USD”). In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation of financial position and results of operations for the interim periods presented have been reflected herein. Operating results for the six months ended September 30, 2018 are not necessarily indicative of the results that may be expected for the year ending March 31, 2019. The Company’s fiscal year-end is March 31.

The unaudited condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. Significant intercompany accounts and transactions have been eliminated.

Liquidity and Basis of Presentation

The Company is an emerging growth entity that is in the early stages of commercializing its first product and is concurrently in development mode, operating a research and development program in order to develop, obtain regulatory approval for, and commercialize other proposed products. The Company has incurred recurring losses from operations, and as at September 30, 2018, has an accumulated deficit of $31,044,687 and a working capital deficit of $661,476. During the six months ended September 30, 2018, the Company launched its first commercial sales program, having already hired an experienced professional in-house sales team. Management anticipates the Company will improve its liquidity through continued business development and after additional equity or debt capitalization of the Company. The Company has developed and continues to pursue sources of funding that management believes if successful would be sufficient to support the Company’s operating plan and alleviate any substantial doubt as to its ability to meet its obligations at least for one year from the date these condensed consolidated financial statements are issued. As an example of this, the Company filed a shelf prospectus under which it conducted its first registered direct sale of shares during December 2017, which raised gross proceeds of $2,475,901. In June 2018, the Company conducted a further registered direct sale of shares which raised gross proceeds of $500,000. The investor, a private equity fund also entered into agreements with the Company to commit themselves to purchase up to $25 million in additional shares of the Company at the direction and sole discretion of the Company, subject to certain conditions (see Note 7 – Stockholders’ Equity (Deficiency)).

The Company’s operating plan is predicated on a variety of assumptions including, but not limited to, the level of product demand, cost estimates, its ability to continue to raise additional debt and equity financing, the planned repayment dates of outstanding operating liabilities, and the state of the general economic environment in which the Company operates. There can be no assurance that these assumptions will prove to be accurate in all material respects, or that the Company will be able to successfully execute its operating plan. In the absence of additional financing, the Company may have to modify its operating plan to slow down the pace for development and commercialization of its proposed products.

3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Revenue Recognition

The Company has adopted the Financial Accounting Standards Board’s (“FASB”) Accounting Standards Codification (“ASC”) Topic 606.

The Bioflux mobile cardiac telemetry device, a wearable device, is worn by patients for a monitoring period up to 30 days. The cardiac data that the device monitors and collects is curated and analyzed by the Company’s proprietary algorithms and then securely communicated to a remote monitoring facility for electronic reporting and conveyance to the patient’s prescribing physician or other certified cardiac medical professional. The device, together with its licensed software, is available for sale to the medical center or physician, who is responsible for the delivery of clinical diagnosis and therapy. The remote monitoring, data collection and reporting services performed by the technology culminate in a patient study that is generally billable when it is complete and is issued to the physician. In order to recognize revenue, management considers whether or not the following criteria are met: persuasive evidence of a commercial arrangement exists, and delivery has occurred or services have been rendered. For sales of devices, which are invoiced directly, additional revenue recognition criteria include that the price is fixed and determinable and collectability is reasonably assured; for revenue that is earned based on customer usage of the proprietary software to render a patient’s cardiac study, the Company recognizes revenue when the study ends based on a fixed billing rate. Costs associated with providing the services are recorded as the service is provided regardless of whether or when revenue is recognized.

Inventory

Inventory is stated at the lower of cost or net realizable value, cost being determined on a standard cost basis for material costs and on actual cost basis for labor and overhead, which approximates actual cost on a weighted average basis, and market being determined as the lower of cost or net realizable value. The Company records write-downs of inventory that is obsolete or in excess of anticipated demand or market value based on consideration of product lifecycle stage, technology trends, product development plans and assumptions about future demand and market conditions. Actual demand may differ from forecasted demand, and such differences may have a material effect on recorded inventory values. Inventory write-downs are charged to cost of revenue and establish a new cost basis for the inventory.

Use of Estimates

The preparation of the condensed consolidated financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Areas involving significant estimates and assumptions include: allowance for doubtful accounts, valuation of inventory, deferred income tax assets and related valuation allowance, accruals and valuation of derivatives, convertible promissory notes, stock options and warrants, as well as assumptions used by management in its assessment of liquidity. Actual results could differ from those estimates. These estimates are reviewed periodically, and, as adjustments become necessary, they are reported in earnings in the period in which they become known.

Earnings (Loss) Per Share

The Company has adopted the Financial Accounting Standards Board’s (“FASB”) Accounting Standards Codification (“ASC”) Topic 260-10 which provides for calculation of “basic” and “diluted” earnings per share. Basic earnings per share includes no dilution and is computed by dividing net income or loss available to common stockholders by the weighted average number of common shares outstanding for the period. Diluted earnings per share reflect the potential dilution of securities that could share in the earnings of an entity. Diluted earnings per share exclude all potentially dilutive shares if their effect is anti-dilutive. There were no potentially dilutive shares outstanding as at September 30, 2018 and 2017.

Cash

Cash includes cash on hand and balances with banks.

Foreign Currency Translation

The functional currency of the Company’s Canadian-based subsidiary is the Canadian dollar and the US-based parent is the U.S. dollar. Transactions denominated in currencies other than the functional currency are translated into the functional currency at the exchange rates prevailing at the dates of the transaction. Monetary assets and liabilities denominated in foreign currencies are translated using the exchange rate prevailing at the balance sheet date. Non-monetary assets and liabilities are translated using the historical rate on the date of the transaction. All exchange gains or losses arising from translation of these foreign currency transactions are included in net income (loss) for the period. In translating the financial statements of the Company’s Canadian subsidiaries from their functional currency into the Company’s reporting currency of United States dollars, balance sheet accounts are translated using the closing exchange rate in effect at the balance sheet date and income and expense accounts are translated using an average exchange rate prevailing during the reporting period. Adjustments resulting from the translation, if any, are included in cumulative other comprehensive income (loss) in stockholders’ equity. The Company has not, to the date of these consolidated financial statements, entered into derivative instruments to offset the impact of foreign currency fluctuations.

Accounts Receivable

Accounts receivable consists of amounts due to the Company from medical facilities, which receive reimbursement from institutions and third-party government and commercial payors and their related patients, as a result of the Company’s normal business activities. Accounts receivable is reported on the balance sheets net of an estimated allowance for doubtful accounts. The Company establishes an allowance for doubtful accounts for estimated uncollectible receivables based on historical experience, assessment of specific risk, review of outstanding invoices, and various assumptions and estimates that are believed to be reasonable under the circumstances, and recognizes the provision as a component of selling, general and administrative expenses. Uncollectible accounts are written off against the allowance after appropriate collection efforts have been exhausted and when it is deemed that a balance is uncollectible.

Fair Value of Financial Instruments

ASC 820 defines fair value, establishes a framework for measuring fair value and expands required disclosure about fair value measurements of assets and liabilities. ASC 820-10 defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820-10 also establishes a fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The standard describes three levels of inputs that may be used to measure fair value:


●		Level 1 – Valuation based on quoted market prices in active markets for identical assets or liabilities.

●		Level 2 – Valuation based on quoted market prices for similar assets and liabilities in active markets.

●		Level 3 – Valuation based on unobservable inputs that are supported by little or no market activity, therefore requiring management’s best estimate of what market participants would use as fair value.

In instances where the determination of the fair value measurement is based on inputs from different levels of the fair value hierarchy, the level in the fair value hierarchy within which the entire fair value measurement falls is based on the lowest level input that is significant to the fair value measurement in its entirety. The Company’s assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment, and considers factors specific to the asset or liability.

Fair value estimates discussed herein are based upon certain market assumptions and pertinent information available to management. The respective carrying value of certain on-balance-sheet financial instruments approximated their fair values due to the short-term nature of these instruments or interest rates that are comparable to market rates. These financial instruments include cash, due to stockholders, accounts receivable, deposits and other receivables, convertible promissory notes, derivative liabilities, and accounts payable. The Company's cash and derivative liabilities, which are carried at fair value, are classified as a Level 1 financial instruments. The Company’s bank accounts are maintained with financial institutions of reputable credit, therefore, bear minimal credit risk.

Operating Leases

The Company leases office space and certain office equipment under operating lease agreements. The lease term begins on the date of initial possession of the leased property for purposes of recognizing lease expense on a straight-line basis over the term of the lease. Lease renewal periods are considered on a lease-by-lease basis and are generally not included in the initial lease term.

Income Taxes

The Company accounts for income taxes in accordance with ASC 740. The Company provides for federal and provincial income taxes payable, as well as for those deferred because of the timing differences between reporting income and expenses for financial statement purposes versus tax purposes. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the carrying amount of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Deferred tax assets and liabilities are measured using the enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recoverable or settled. The effect of a change in tax rates is recognized as income or expense in the period of the change. A valuation allowance is established, when necessary, to reduce deferred income tax assets to the amount that is more likely than not to be realized.

Research and Development

Research and development costs, which relate primarily to product and software development, are charged to operations as incurred. Under certain research and development arrangements with third parties, the Company may be required to make payments that are contingent on the achievement of specific developmental, regulatory and/or commercial milestones. Before a product receives regulatory approval, milestone payments made to third parties are expensed when the milestone is achieved. Milestone payments made to third parties after regulatory approval is received are capitalized and amortized over the estimated useful life of the approved product.

Stock Based Compensation

The Company accounts for share-based payments in accordance with the provision of ASC 718, which requires that all share-based payments issued to acquire goods or services, including grants of employee stock options, be recognized in the statement of operations based on their fair values, net of estimated forfeitures. ASC 718 requires forfeitures to be estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. Compensation expense related to share-based awards is recognized over the requisite service period, which is generally the vesting period.

The Company accounts for stock based compensation awards issued to non-employees for services, as prescribed by ASC 718-10, at either the fair value of the services rendered or the instruments issued in exchange for such services, whichever is more readily determinable, using the guidelines in ASC 505-50. The Company issues compensatory shares for services including, but not limited to, executive, management, accounting, operations, corporate communication, financial and administrative consulting services.

Convertible Notes Payable and Derivative Instruments

The Company has adopted the provisions of ASU 2017-11, which addresses the accounting for (I) certain financial instruments with down round features and (II) replacement of the indefinite deferral for mandatorily redeemable financial instruments of certain nonpublic entities and certain mandatorily redeemable non-controlling interests with a scope exception. The main provisions of Part I of ASU 2017-11 “change the classification analysis of certain equity-linked financial instruments (or embedded features) with down round features. When determining whether certain financial instruments should be classified as liabilities or equity instruments, a down round feature no longer precludes equity classification when assessing whether the instrument is indexed to an entity’s own stock. The amendments also clarify existing disclosure requirements for equity-classified instruments. As a result, a freestanding equity-linked financial instrument (or embedded conversion option) no longer would be accounted for as a derivative liability at fair value as a result of the existence of a down round feature. For freestanding equity classified financial instruments, the amendments require entities that present earnings per share (EPS) to recognize the effect of the down round feature when it is triggered. That effect is treated as a dividend and as a reduction of income available to common shareholders in basic EPS.” Under previous US GAAP, warrants with a down round feature are not being considered indexed to the entity’s own stock, which results in classification of the warrant as a derivative liability. Under ASU 2017-11, the down round feature qualifies for a scope exception from derivative treatment. ASU 2017-11 is effective for public companies as of December 15, 2018 and interim periods within that fiscal year. Early adoption is permitted, including adoption in an interim period, with adjustments reflected as of the beginning of the fiscal year. The Company has issued financial instruments with down round features. The Company opted to adopt ASU 2017-11 in its three-month interim period ended September 30, 2017, which is effective from April 1, 2017, with adjustments reflected in the accumulated deficit of stockholders’ deficiency as of April 1, 2017. Please refer to Note 6.

Recently Issued Accounting Pronouncements

In June 2018, the FASB issued an accounting pronouncement (FASB ASU 2018-07) to expand the scope of ASC Topic 718, Compensation - Stock Compensation, to include share-based payment transactions for acquiring goods and services from nonemployees. The pronouncement is effective for fiscal years, and for interim periods within those fiscal years, beginning after December 15, 2018, with early adoption permitted. We are currently in the process of evaluating the effects of this pronouncement on our consolidated financial statements, including potential early adoption.

On April 1, 2018, the Company adopted the accounting pronouncement issued by the Financial Accounting Standards Board (“FASB”) to clarify existing guidance on revenue recognition. This guidance includes the required steps to achieve the core principle that a company should recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. The Company adopted this pronouncement on a modified retrospective basis.

On January 1, 2018, the Company adopted the accounting pronouncement issued by the FASB to clarify how entities should present restricted cash and restricted cash equivalents in the statement of cash flows. This guidance requires entities to show changes in the total of cash, cash equivalents and restricted cash in the combined statement of cash flows. This guidance was adopted on a retrospective basis, and such adoption did not have a material impact on combined financial position and/or results of operations.

4. ACCOUNTS PAYABLE AND ACCRUED LIABILITIES


	As at September 30, 2018	As at March 31, 2018
	$	$
Accounts payable	817,171	547,858
Accrued liabilities	230,725	208,321
	1,047,896	756,179

Accounts payable as at September 30, 2018, and March 31, 2018 include $246,303 and $161,481, respectively, due to a shareholder and executive of the Company, primarily owing as a result of that individual’s capacity as an employee.

5. CONVERTIBLE PROMISSORY NOTES

Prior to April 1, 2016, pursuant to a term sheet offering of up to $2,000,000, the Company issued convertible promissory notes to various accredited investors amounting to $1,368,978 in face value. These notes had a maturity date of 24 months and carried an annual interest rate of 11%. The note holders had the right to convert any outstanding and unpaid principal portion of the note, and accrued interest, into fully paid and non-assessable shares of common stock any time until the note was fully paid. The notes had a conversion price initially set at $1.78. Upon any future financings completed by the Company, the conversion price was to reset to 75% of the future financing pricing. These notes did not contain prepayment penalties upon redemption. These notes were secured by all of the present and after acquired property of the Company. However, the Company could force conversion of these notes, if during the term of the agreement, the Company completed a public listing and the common share price exceeded the conversion price for at least 20 consecutive trading days. At the closing of the notes, the Company issued cash (7%) and warrants (7% of the number of common shares into which the notes may be converted) to a broker. The broker received 3% in cash and warrants for those investors introduced by the Company. The warrants had a term of 24 months and a similar reset provision based on future financings.

Pursuant to the conversion provisions, in August 2016, promissory notes in the aggregate face value of $1,368,978 were converted into 912,652 shares of common stock as detailed below. The fair value of the common shares was $2,907,912 and $1,538,934 was allocated to the related derivative liabilities (see note 6) and the balance to the carrying value of the notes.


	$
Accreted value of convertible promissory notes as at December 31, 2015	783,778
Face value of convertible promissory notes issued during March 2016	175,000
Discount recognized at issuance due to embedded derivatives	(74,855)
Accretion expense for three months March 31, 2016	73,572
Accreted value of convertible promissory notes as at March 31, 2016	957,495
Accretion expense - including loss on conversion of $88,530	411,483
Conversion of the notes transferred to equity	(1,368,978)
Accreted value of convertible promissory notes at September 30, 2018 and March 31, 2018	-

In March 2016, the Company commenced a bridge offering of up to an aggregate of $2,500,000 of convertible promissory notes. Up to March 31, 2017, the Company issued, to various investors, a new series of convertible notes (“Bridge Notes”) in the aggregate face value of $2,455,000 (December 31, 2016 – $2,230,000). The Bridge Notes had a maturity date of 12 months from issuance and carried an annual interest rate of 10%. The Bridge Notes principal and all outstanding accrued interest were convertible into common stock based on the average of the lowest 3 trading days volume weighted average price over the last 10 trading days plus an embedded warrant at maturity. However, all the outstanding principal and accrued interest would convert into units/securities upon the consummation of a qualified financing, based upon the lesser of: (i) $1.65 per units/securities and (ii) the quotient obtained by dividing (x) the balance on the forced conversion date multiplied by 1.20 by (y) the actual price per unit/security in the qualified financing. Upon the maturity date of the notes, the Company also has an obligation to issue warrants exercisable into a number of shares of the Company securities equal to (i) in the case of a qualified financing, the number of shares issued upon conversion of the note and (ii) in all other cases, the number of shares of the Company's common stock equal to the quotient obtained by dividing the outstanding balance by 2.00.

In connection with the Bridge Notes offering, the accreted value of this offering was as follows as at March 31, 2017:


As at March 31, 2017	$
Face value of Bridge Notes issued	2,455,000
Day one derivative loss recognized during the year	35,249
Discount recognized at issuance due to embedded derivatives	(1,389,256)
Cash financing costs	(174,800)
Accretion expense	630,797
Accreted value of Bridge Notes	1,556,990

On May 31, 2017, all Bridge Notes, having a face value of $2,436,406, were converted into Units of a private placement offering of the Company’s common stock:


	$
Accreted value of Bridge Note as of March 31, 2017	1,556,990
Accretion expense	879,416
Conversion of Bridge Notes transferred to equity (Note 7, c)	(2,436,406)
Face value of Bridge Notes as of September 30, 2018 and March 31, 2018	-

The embedded conversion features and reset feature in the notes and broker warrants were initially accounted for as a derivative liability based on FASB guidance that was current at that time (see Note 6).

6. DERIVATIVE LIABILITIES

The Accounting Pronouncements ASU 2017-11 provided a change to the classification analysis of certain equity-linked financial instruments (or embedded features) with down round features. When determining whether certain financial instruments should be classified as liabilities or equity instruments, a down round feature no longer precludes equity classification when assessing whether the instrument is indexed to an entity’s own stock. During the quarter ended September 30, 2017, the Company adopted the provisions of ASU 2017-11 to account for the down round features of its warrants issued with its private placements effective April 1, 2017. The Company used a modified retrospective approach to adoption, which does not restate its financial statements as at the prior year end, March 31, 2017. Adoption is effective as of April 1, 2017, the beginning of the Company’s current fiscal year. The cumulative effect of this accounting standard update adjusted accumulated deficit as of April 1, 2017 by $483,524, with a corresponding adjustment to derivative liabilities:


Balance Sheet Impacts Under ASU 2017-11	As of April 1, 2017
Accumulated Deficit	$ 483,524
Derivative Liabilities	(483,524)

The impact on the unaudited June 30, 2017 Balance Sheet and Statement of Operations is as follows:


Balance Sheet Impacts Under ASU 2017-11	As of June 30, 2017
Derivative Liabilities	$ (4,074,312)
Additional Paid in Capital	3,569,248
Accumulated Deficit	483,524

Income Statement Impacts Under ASU 2017-11

As of June 30, 2017

Reversal of change in fair value of derivative liabilities

21,540

In connection with the sale of debt or equity instruments, the Company may sell options or warrants to purchase its common stock. In certain circumstances, these options or warrants have previously been classified as derivative liabilities, rather than as equity. Additionally, the debt or equity instruments may contain embedded derivative instruments, which in certain circumstances may be required to be bifurcated from the associated host instrument and accounted for separately as a derivative instrument liability.

Previously, the Company's derivative instrument liabilities were re-valued at the end of each reporting period, with changes in the fair value of the derivative liability recorded as charges or credits to income in the period in which the changes occurred. For options, warrants and bifurcated embedded derivative features that were accounted for as derivative instrument liabilities, the Company estimated fair value using either quoted market prices of financial instruments with similar characteristics or other valuation techniques. The valuation techniques require assumptions related to the remaining term of the instruments and risk-free rates of return, our current common stock price and expected dividend yield, and the expected volatility of our common stock price over the life of the option. The details of derivative liabilities (pre and post adoption of ASU 2017-11) were as follows:


	Total
	$
Derivative liabilities as at March 31, 2017	2,163,884
Derivative fair value at issuance	3,569,249
Transferred to equity upon conversion of notes (Notes 5 and 7)	(1,700,949)
Change in fair value of derivatives	42,128
Derivative liabilities as at June 30, 2017 (pre-adoption)	4,074,312
Adjustments relating to adoption of ASU 2017-11
Reversal of fair value	(21,540)
Transferred to accumulated deficit	(483,524)
Transferred to additional paid-in-capital	(3,569,248)
Derivative liabilities as at September 30, 2018 and March 31, 2018 (post adoption)	-

The lattice methodology was used to value the derivative components, using the following assumptions:


	Assumptions
Dividend yield	0.00%
Risk-free rate for term	0.62% – 1.14%
Volatility	103% – 118%
Remaining terms (Years)	0.01 – 1.0
Stock price ($ per share)	$2.50 and $2.70

The projected annual volatility curve for valuation at issuance and period end was based on the comparable company’s annual volatility. The Company used market trade stock prices at issuance and period end date.

7. STOCKHOLDERS’ EQUITY (DEFICIENCY)

Authorized stock

As at September 30, 2018, the Company is authorized to issue 125,000,000 (March 31, 2018 – 125,000,000) shares of common stock ($0.001 par value) and 10,000,000 (March 31, 2018 – 10,000,000) shares of preferred stock ($0.001 par value).

At September 30, 2018, there were 27,605,567 (March 31, 2018 – 23,713,602) shares of common stock issued and outstanding. Additionally, at September 30, 2018, there were 5,725,041 (March 31, 2018 – 8,143,937) outstanding exchangeable shares. There is currently one share of the Special Voting Preferred Stock issued and outstanding held by one holder of record, which is the Trustee in accordance with the terms of the Trust Agreement.

Exchange Agreement

As initially described in Note 1 above, on February 2, 2016:

The Company issued approximately 1.197 shares of its common stock in exchange for each common share of iMedical held by the iMedical shareholders who in general terms, are not residents of Canada (for the purposes of the Income Tax Act (Canada). Accordingly, the Company issued 13,376,947 shares;

Shareholders of iMedical who in general terms, are Canadian residents (for the purposes of the Income Tax Act (Canada)) received approximately 1.197 Exchangeable Shares in the capital of Exchangeco in exchange for each common share of iMedical held. Accordingly, the Company issued 9,123,031 Exchangeable Shares;

Each outstanding option to purchase common shares in iMedical (whether vested or unvested) was exchanged, without any further action or consideration on the part of the holder of such option, for approximately 1.197 economically equivalent replacement options with an inverse adjustment to the exercise price of the replacement option to reflect the exchange ratio of approximately 1.197:1;

Each outstanding warrant to purchase common shares in iMedical was adjusted, in accordance with the terms thereof, such that it entitles the holder to receive approximately 1.197 shares of the common stock of the Company for each warrant, with an inverse adjustment to the exercise price of the warrants to reflect the exchange ratio of approximately 1.197:1

Each outstanding advisor warrant to purchase common shares in iMedical was adjusted, in accordance with the terms thereof, such that it entitles the holder to receive approximately 1.197 shares of the common stock of the Company for each advisor warrant, with an inverse adjustment to the exercise price of the Advisor Warrants to reflect the exchange ratio of approximately 1.197:1; and

The outstanding 11% secured convertible promissory notes of iMedical were adjusted, in accordance with the adjustment provisions thereof, as and from closing, so as to permit the holders to convert (and in some circumstances permit the Company to force the conversion of) the convertible promissory notes into shares of the common stock of the Company at a 25% discount to purchase price per share in Biotricity’s next offering.

Issuance of common stock, exchangeable shares and cancellation of shares in connection with the reverse takeover transaction as explained above represents recapitalization of capital retroactively adjusting the accounting acquirer’s legal capital to reflect the legal capital of the accounting acquiree.

During the six months ended September 30, 2018, shareholders holding 2,418,900 exchangeable shares with voting rights and other attributes corresponding to the Company’s common stock (but with the additional right to cashlessly exchange on a one-for-one basis into common stock) retracted and exchanged their exchangeable shares for the corresponding number of shares of common stock.

Share issuances

Share issuances during the year ended March 31, 2018

During the year ended March 31, 2018, the Company sold to accredited investors a further total of 1,282,767 Units, (each Unit consisting of one share of common stock one-half of one warrant to purchase a share of common stock) for gross proceeds of $2,244,845 (net proceeds of $1,926,780).

During the year ended March 31, 2018, prior to closing its private placement offering on or about July 31, 2017, the Company sold to accredited investors a further total of 263,188 Units for gross proceeds of $460,579 (net proceeds of $413,629). Cash issuance costs of $46,950 have been adjusted against additional paid in capital. In connection with this private placement, the Company also issued 21,055 broker warrants and 131,594 warrants to investors (refer to warrant issuances).

During the year ended March 31, 2018, the Company completed a registered offering, which raised net proceeds of $2,520,561 million through the issuance of 450,164 common shares.

Cash issuance costs of $320,355 relating to the above private placements have been adjusted against additional paid in capital. In connection with the above private placements and conversion of notes as detailed in Note 5, the Company issued broker warrants and warrants to investors having fair values of $385,635 and $3,183,614, respectively, which were initially classified as derivative liabilities with corresponding debit to additional paid in capital.

The raising of a total of $3,000,000 in aggregate proceeds from the common share offering would qualify that offering as a Qualified Financing that would allow the Company, at its discretion, to convert the principal amount of the Bridge Notes (discussed in Note 5), along with accrued interest thereon, into units of the common share offering. Conversion would be based upon the price that is the lesser of: (i) $1.60 per share and (ii) the quotient obtained by dividing (x) the Outstanding Balance on the conversion date multiplied by 1.20 by (y) the actual price per share in the Qualified Financing. The notes and the warrants were further subject to a “most-favored nation” clause in the event the Company, prior to maturity of the notes, consummates a financing that is not a Qualified Financing. Upon completion of a Qualified Financing, in connection with the conversion of the Bridge Notes, the Company would also pay the Placement Agent up to 8% in cashless broker warrants with an exercise price of $3.00 and an expiry date of two years from the date of issuance. Based on achieving this milestone, on May 31, 2017, the Company converted Bridge Notes with the aggregate principal amount of $2,455,000 plus accrued interest thereon, into a further 1,823,020 Units of its common share offering (each of which corresponded to one share and half of one warrant).

During the year ended March 31, 2018, the Company issued an aggregate of 527,941 shares of common stock and has recognized its obligation to issue a further 20,250 shares of common stock (see paragraph d, below), to various consultants. The fair value of these shares amounted to $1,908,481 were recognized as general and administrative and research and development expenses, as applicable, in the statement of operations, with a corresponding credit to additional paid-in-capital.

During the year ended March 31, 2018, the Company also issued an aggregate of 252,798 shares of its common stock upon exercise of warrants and received $428,311 of exercise cash proceeds. In addition, during this year, the Company issued 58,795 shares of common stock to brokers who opted to perform cashless exercise of their 108,799 warrants. See paragraph e, below

Share issuances during the six months ended September 30, 2018

During the six months ended September 30, 2018, the Company entered into an agreement with a private equity investment fund (the “Investor”) to establish a committed equity purchase facility, which allows the Company, at its sole option, subject to certain conditions, to direct the Investor to make multiple common share purchases that in aggregate can be up to $25 million (the “Aggregate Amount”) during the term of the facility, which will be up to 36 months. As part of the initial closing of this transaction, the Investor purchased 128,750 shares of common stock of the Company, at a price of $4,00 per share, for gross proceeds of $515,000 and paid the Investor $15,000 in issuance costs. As compensation for providing this equity purchase facility, the Company also issued to the Investor an additional 121,344 shares (representing a dollar value equal to 1.6% of the aggregate amount, or $400,000, at a price per share that was equal to the average of the closing sale prices of the common shares for the ten (10) consecutive business days prior to the closing date of the transaction). The size and purchase price for each future drawdown under this agreement is governed by the purchase facilities agreement and is predicated on trading volumes as well as the average trading and closing prices of the common stock on the day of drawdown and the prior ten (10) trading days, such that the purchase price is always fixed and know at the time the Company elects to sell shares to the Investor. During the six months ended September 30, 2018, the Company sold a further 669,226 shares under this facility and raised aggregate gross proceeds of $1,819,943.

During the six months ended September 30, 2018, the Company issued an aggregate of 326,333 shares of common stock to various advisors, contractors and consultants, including 62,500 shares of common stock to non-executive directors of its Board as part of their annual compensation program. Not including 14,000 shares, that were accounted for as common shares to be issued in relation to issuance obligations as at March 31, 2018, the fair value of the remaining 312,333 shares amounted to $840,546 and has been expensed to general and administrative expenses in the condensed consolidated statement of operations, with a corresponding credit to additional paid-in-capital.

During the six months ended September 30, 2018, the Company issued 164,574 shares of common stock upon the exercise of options of its legacy 2015 equity incentive plan; during the same period the Company also issued 62,838 shares of its common stock upon exercise of warrants and received $50,835 of exercise cash proceeds.

Shares to be issued

Common stock to be issued of 32,083 shares ($80,216) is comprised of:

19,583 shares of common stock issued to consultants in connection with services rendered during the quarter with a fair value of $37,404; and

12,500 shares of common stock to be issued to a consultant, which represents an obligation recognized in prior periods, with a fair value of $42,812.

The fair value of these shares was determined by using the market price of the common stock as at the date of issuance obligation.

Warrant issuances

Warrant issuances during the year ended March 31, 2018

During December 2017, 112,798 broker warrants were exercised at exercises price of between $1.04 and $1.49, such that the Company received cash proceeds of $124,718. Also during December 2017, 140,000 consultant warrants were exercised at exercise prices between $2.00 and 2.58, for cash proceeds to the Company of $303,200.

During March 2018, 108,799 broker warrants were exercised into 58,795 common shares through the cashless exercise. The holder may, in its sole discretion, exercise all or any part of this warrant in a “cashless” or “net-issue” (or cashless) exercise and receive a number of shares calculated by using the following formula: X = Y (A - B)/A with: X = the number of shares to be issued to the holder Y = the number of shares with respect to which the warrant is being exercised A = the fair value per share of common stock on the date of exercise of the warrant B = the then-current exercise price of the warrant.

Warrant issuances during the six months ended September 30, 2018

During the six months ended September 30, 2018, the Company issued 458,333 warrants as compensation for advisor and consultant services, which were fair valued at $368,352 and expensed in general and administrative expenses, with a corresponding credit to additional paid in capital. Their fair value has been estimated using a multi-nomial lattice model with an expected life of 3 years, a risk free rate ranging from 2.13% to 2.81%, stock price of $1.24 to $4.15 and expected volatility of 97.8% to 138.27%.

Warrant issuances, exercises and expirations or cancellations during the three months ended September 30, 2018 and preceding periods resulted in warrants outstanding at the end of those respective periods as follows:


	Broker Warrants	Consultant Warrants	Warrants Issued on Conversion of Convertible Notes	Private Placement Warrants	Total
As at March 31, 2017	380,682	916,466	-	390,744	1,687,892
Less: Exercised	(222,690)	(140,000)	-	-	(362,690)
Less: Expired/cancelled	(19,935)	(380,300)	-	-	(400,235)
Add: Issued	246,095	273,806	2,734,530	772,978	4,027,409
As at March 31, 2018	384,152	669,972*	2,734,530	1,163,722	4,952,376

Less: Exercised	(62,838)	-	-	-	(62,838)
Less: Expired/cancelled	-	(31,250)	-	-	(31,250)
Add: Issued	-	65,000	-	-	65,000
As at June 30, 2018	321,314	703,722*	2,734,530	1,163,722	4,923,288

Less: Exercised	-	-	-	-	-
Less: Expired/cancelled	-	- **	-	-
Add: Issued	-	393,333	-	-	393,333
As at September 30, 2018	321,314	1,097,055*	2,734,530	1,163,722	5,316,621

Exercise Price	$ 0.78-$3.00	$ 1.24-$7.59	2.00	3.00
Expiration Date	October 2019 to July 2022	October 2018 to September 2021	March 2020 to November 2022	April 2020 to July 2020

*Consultant Warrants as at September 30, 2018 include an aggregate of 188,806 warrants provided to an officer of the Company as compensation while he was not a member of any Company options plan.

** Subsequent to September 30, 2018, 210,416 warrants expired unexercised.

Warrant exercises

During the six months ended September 30, 2018, 62,838 warrants were exercised at an average exercise price of approximately $0.7839. The Company received $50,835 of cash proceeds.

Stock-based compensation

2015 Equity Incentive Plan

On March 30, 2015, iMedical approved its Directors, Officers and Employees Stock Option Plan, under which it authorized and issued 3,000,000 options. This plan was established to enable the iMedical to attract and retain the services of highly qualified and experience directors, officers, employees and consultants and to give such person an interest in the success of the Company. This is a legacy option plan established and utilized prior to the Company’s reorganization (see note 7b) Exchange Agreement, above). No other grants will be made under this plan. As of March 31, 2018, there were no outstanding vested options and 137,500 unvested options at an exercise price of $.0001 under this plan. These legacy options represented the right to purchase shares of the Company’s common stock using the same exchange ratio of approximately 1.1969:1; thus there were 164,590 (35,907 had been cancelled) adjusted unvested options as at March 31, 2018. During the six-month period ended September 30, 2018 the remaining 164,590 outstanding options vested and were exercised.

The following table summarizes the stock option activities of the Company:



	Number of options	Weighted average exercise price ($)
Granted	3,591,000	0.0001
Exercised	(3,390,503)	0.0001
Outstanding as of December 31, 2015	200,497	0.0001
Cancelled during 2016	(35,907)	0.0001
Outstanding as of March 31, 2018	164,590	0.0001
Exercised	(164,590)	0.0001
Outstanding as of September 30, 2018	-

The fair value of options at the issuance date were determined at $2,257,953 which were fully expensed during the twelve months ended December 31, 2015 based on vesting period and were included in general and administrative expenses with corresponding credit to additional paid-in-capital. During the twelve months ended December 31, 2015, 3,390,503 (2,832,500 Pre-exchange Agreement) options were exercised by those employees who met the vesting conditions; 50% of the grants either vest immediately or at the time of U.S. Food and Drug Administration (FDA) filing date and 50% will vest upon Liquidity Trigger. Liquidity Trigger means the day on which the board of directors resolve in favor of i) the Company is able to raise a certain level of financing; ii) a reverse takeover transaction that results in the Company being a reporting issuer, and iii) initial public offering that results in the Company being a reporting issuer.

2016 Equity Incentive Plan

On February 2, 2016, the Board of Directors of the Company approved 2016 Equity Incentive Plan (the “Plan”). The purpose of the Plan is to advance the interests of the Company and its stockholders by providing an incentive to attract, retain and reward persons performing services for the Company and by motivating such persons to contribute to the growth and profitability of the Company. The Plan seeks to achieve this purpose by providing for awards in the form of options, stock appreciation rights, restricted stock purchase rights, restricted stock bonuses, restricted stock units, performance shares, performance units and other stock-based awards.

The Plan shall continue in effect until its termination by the board of directors or committee formed by the board; provided, however, that all awards shall be granted, if at all, on or before the day immediately preceding the tenth (10th) anniversary of the effective date. The maximum number of shares of stock that may be issued under the Plan shall be equal to 3,750,000 shares; provided that the maximum number of shares of stock that may be issued under the Plan pursuant to awards shall automatically and without any further Company or shareholder approval, increase on January 1 of each year for not more than 10 years from the effective date, so the number of shares that may be issued is an amount no greater than 15% of the Company’s outstanding shares of stock and shares of stock underlying any outstanding exchangeable shares as of such January 1; provided further that no such increase shall be effective if it would violate any applicable law or stock exchange rule or regulation, or result in adverse tax consequences to the Company or any participant that would not otherwise result but for the increase.

During July 2016, the Company granted an officer options to purchase an aggregate of 2,499,998 shares of common stock at an exercise price of $2.20 subject to a 3 year vesting period, with the fair value of the options being expensed over a 3 year period. Two additional employees were also granted 175,000 options to purchase shares of common stock at an exercise price of $2.24 with a 1 year vesting period, with the fair value of the options being expensed over a 1 year period. One additional employee was also granted 35,000 options to purchase shares of common stock at an exercise price of $2.24 with a 2 year vesting period, with the fair value of the options expensed over a 2 year period.

During the year ended March 31, 2018, an additional 1,437,500 stock options were granted with a weighted average remaining contractual life from 2.76 to 9.51 years.

During the six months ended September 30, 2018, as part of their approved compensation, the Company granted its non-executive directors options to purchase an aggregate of 62,500 shares of common stock at an exercise price of $2.00, with an aggregate fair value of $31,959, subject to a 1-year vesting period. Six employees were also granted 95,000 options to purchase shares of common stock at exercise prices ranging from $1.40 to $1.84 per share, subject to a 3 year graded vesting period, with fair value of the options of $41,845 being expensed over that respective period.

As of September 30, 2018, the cumulative grant-date fair value of the options granted under the Plan was $3,863,813 (September 30, 2017 - $2,372,108). The following table summarizes the stock option activities of the Company:



	Number of options	Weighted average exercise price ($)
Granted	4,147,498	3.2306
Exercised	-	-
Outstanding as of June 30 and March 31, 2018	4,147,498	3.2306
Granted	157,500	1.8337
Exercised	-	-
Outstanding as of September 30, 2018	4,304,998	3.1795

During the six months ended September 30, 2018, the Company recorded stock based compensation of $728,163 in connection with the 2016 equity incentive plan (September 30, 2017 – $442,155) under general and administrative expenses with a corresponding credit to additional paid in capital.

The fair value of each option granted is estimated at the time of grant using multi-nomial lattice model using the following assumptions:


	2017-2018	2016-2017	2015-2016
Exercise price ($)	1.24-7.59	2.00 – 2.58	0.0001
Risk free interest rate (%)	1.98-2.81	0.45 - 1.47	0.04 - 1.07
Expected term (Years)	3.0	1.0 - 3.0	10.0
Expected volatility (%)	97.8-145.99	101 – 105	94
Expected dividend yield (%)	0.00	0.00	0.00
Fair value of option ($)	1.032	0.88	0.74
Expected forfeiture (attrition) rate (%)	0.00	0.00 – 5.00	5.00 - 20.00

8. RELATED PARTY TRANSACTIONS AND BALANCES

The Company’s transactions with related parties were carried out on normal commercial terms and in the course of the Company’s business. Other than those disclosed elsewhere in the financial statements, related party transactions are as follows:



	Three Months Ended September 30, 2018	Three Months Ended September 30, 2017	Six Months Ended September 30, 2018	Six Months Ended September 30, 2017
	$	$	$	$
Salary and allowance**	181,887	120,052	363,773	270,104
Stock based compensation***	421,028	183,981	744,168	374,472
Total	602,915	304,033	1,107,941	644,576

The above expenses were recorded under general and administrative expenses.

* Salary and allowance include salary, car allowance, vacation pay, bonus and other allowances paid or payable to key management of the Company.

** Stock based compensation represent the fair value of the options, warrants and equity incentive plan for directors and key management of the Company.

9. COMMITMENTS AND CONTINGENCIES

On January 8, 2016, the Company entered into a 40-month lease agreement for its office premises in California, USA. The monthly rent from the date of commencement to the 12th month is $16,530, from the 13th to the 24th month is $17,026, from the 25th to the 36th month is $17,536, whereas the final 3 months is $18,062.

There are no claims against the company that were assessed as significant, which were outstanding as at September 30, 2018 and, consequently, no provision for such has been recognized in the consolidated financial statements.

10. SUBSEQUENT EVENTS

The Company’s management has evaluated subsequent events up to November 14, 2018, the date the condensed consolidated financial statements were issued, pursuant to the requirements of ASC 855 and has determined the following material subsequent events:

During the period of October 1, 2018 through November 13, 2018, the Company issued an aggregate of 534,894 common shares under its common share finance facility with a private equity firm (the “Investor”). The size and purchase price for each drawdown is governed by the purchase facilities agreement and is predicated on trading volumes as well as the average trading and closing prices of the common stock on the day of drawdown and the prior ten (10) trading days, such that the purchase price is always fixed and known at the time the Company elects to sell shares to the Investor.

During this same period, shareholders holding 856,576 exchangeable shares with voting rights and other attributes corresponding to the Company’s common stock (but with the additional right to cashlessly exchange on a one-for-one basis into common stock) retracted and exchanged their exchangeable shares for the corresponding number of shares of common stock.

During July 2018, the Board of Directors of the company adopted a new compensation program for directors which includes cash compensation for the current fiscal year of $24,000, equity compensation for the current fiscal year to include 31,250 shares of the Company’s common stock and 31,250 options to purchase shares of the Company’s common stock at $2.00 per share, such options to vest and be fully exercisable upon the first anniversary from the date upon which a director was named to the Board. On November 4^,2018, the Company increased the size of its Board to 4 Directors and immediately filled the vacancy by appointing a new Director, , who will be compensated using this same compensation program.

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

Except for historical information contained herein, this “Management’s Discussion and Analysis of Financial Condition and Results of Operations” contains forward-looking statements. These statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance, or achievements of the Company to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. These forward-looking statements were based on various factors and were derived utilizing numerous important assumptions and other important factors that could cause actual results to differ materially from those in the forward-looking statements. Important assumptions and other factors that could cause actual results to differ materially from those in the forward-looking statements, include but are not limited to: (a) any fluctuations in sales and operating results; (b) risks associated with international operations; (c) regulatory, competitive and contractual risks; (d) development risks; (e) the ability to achieve strategic initiatives, including but not limited to the ability to achieve sales growth across the business segments through a combination of enhanced sales force, new products, and customer service; (f) competition in the Company’s existing and potential future product lines of business; (g) the Company’s ability to obtain financing on acceptable terms if and when needed; (h) uncertainty as to the Company’s future profitability; (i) uncertainty as to the future profitability of acquired businesses or product lines; and (j) uncertainty as to any future expansion of the Company. Other factors and assumptions not identified above were also involved in the derivation of these forward-looking statements and the failure of such assumptions to be realized as well as other factors may also cause actual results to differ materially from those projected. The Company assumes no obligation to update these forward-looking statements to reflect actual results, changes in assumptions or changes in other factors affecting such forward-looking statements, except as may be required under applicable law. Past results are no guaranty of future performance. You should not place undue reliance on any forward-looking statements, which speak only as of the dates they are made. When used in this Report, the words “believes,” “anticipates,” “expects,” “estimates,” “plans,” “intends,” “will” and similar expressions are intended to identify forward-looking statements.

This Management’s Discussion and Analysis of Financial Condition and Results of Operations should be read in conjunction with the financial statements and footnotes thereto included in this Quarterly Report on Form 10-Q (the “Financial Statements”).

Company Overview

Biotricity Inc. (“Company”, “Biotricity”, “we”, “us” or “our”)

We are a medical technology company focused on biometric data monitoring solutions. Our aim is to deliver innovative, remote monitoring solutions to the medical, healthcare, and consumer markets, with a focus on diagnostic and post-diagnostic solutions for lifestyle and chronic illnesses. We approach the diagnostic side of remote patient monitoring by applying innovation within existing business models where reimbursement is established. We believe this approach reduces the risk associated with traditional medical device development and accelerates the path to revenue. In post-diagnostic markets, we intend to apply medical grade biometrics to enable consumers to self-manage, thereby driving patient compliance and reducing healthcare costs. We are first focusing on a segment of the diagnostic mobile cardiac telemetry market, otherwise known as MCT.

To date, we have developed our Bioflux MCT technology which is comprised of a monitoring device and software component, verified our business model, and built strategic partnerships to accelerate our market strategy and growth. We started commercial sale of our technology to customers in April 2018. Starting with a small sales force to assist in establishing a limited market review with key anchor customers in 6 key cardiac markets across the United States has allowed the Company to place 204 of its devices in the field as at September 30, 2018. The Company plans to grow its sales force in order to address new markets and achieve sales penetration in the markets currently served.

We have established a research partnership with the University of Calgary to determine the predictive value of electrocardiogram (ECG) readings in preventative healthcare applications. The study is designed to identify novel patterns in ECG readings that may be translated into probability models for use in the development of proprietary algorithms for diagnostic applications, and to determine if ECG readings have predictive value for use in preventative healthcare applications, such as self-managed care. The research is partly funded by the National Research Council of Canada. As part of the collaboration, we have the right to license any intellectual property discovered, created or reduced to practice in the performance of the collaboration that was created solely by the University’s personnel. Otherwise, we own all intellectual property resulting from the collaboration. The term of the collaboration is until December 31, 2020.

We were incorporated on August 29, 2012 in the State of Nevada under the name Metasolutions, Inc. Effective as of February 1, 2016, we changed our name to Biotricity Inc.

On February 2, 2016, we acquired iMedical Innovation Inc., a company existing under the laws of Canada, through our indirect subsidiary 1062024 B.C. LTD., a company existing under the laws of the Province of British Columbia. Immediately prior to the closing of the acquisition, we transferred all of the then-existing business, properties, assets, operations, liabilities and goodwill of the Company, to W270 SA, a Costa Rican corporation. Accordingly, as of immediately prior to the closing of the acquisition, we had no assets or liabilities, and subsequent to the closing we commenced operations through iMedical. As a result, we treated the acquisition as a reverse merger and recapitalization for accounting purposes, with iMedical as the acquirer for accounting purposes.

Critical Accounting Policies

The Financial Statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“US GAAP”) and are expressed in United States Dollars. Significant accounting policies are summarized below:

Revenue Recognition

The Company has adopted the Financial Accounting Standards Board’s (“FASB”) Accounting Standards Codification (“ASC”) Topic 606.

Our Bioflux mobile cardiac telemetry device, a wearable device, is worn by patients for a monitoring period up to 30 days. The cardiac data that the device monitors and collects is curated and analyzed by our proprietary algorithms and then securely communicated to a remote monitoring facility for electronic reporting and conveyance to the patient’s prescribing physician or other certified cardiac medical professional. The device, together with its licensed software, is available for sale to the medical center or physician, who is responsible for the delivery of clinical diagnosis and therapy. The remote monitoring, data collection and reporting services performed by our technology culminate in a patient study that is generally billable when it is complete and is issued to the physician. In order to recognize revenue, we consider whether or not the following criteria are met: persuasive evidence of a commercial arrangement exists, and delivery has occurred or services have been rendered. For sales of devices, which we invoice directly, additional revenue recognition criteria include that the price is fixed and determinable and collectability is reasonably assured; for revenue that is earned based on customer usage of our proprietary software to render a patient’s cardiac study, we recognize revenue based on a fixed billing rate. If all revenue recognition criteria are met, revenue is recognized upon delivery of the patient study, on an accrual basis. Costs associated with providing our services are recorded as the service is provided regardless of whether or when revenue is recognized.

Use of Estimates

The preparation of the financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Areas involving significant estimates and assumptions include: deferred income tax assets and related valuation allowance, accruals and valuation of derivatives, convertible promissory notes, stock options and warrants, as well as assumptions used by management in its assessment of liquidity. Actual results could differ from those estimates. These estimates are reviewed periodically, and, as adjustments become necessary, they are reported in earnings in the period in which they become known.

Earnings (Loss) Per Share

We have adopted the Financial Accounting Standards Board’s (“FASB”) Accounting Standards Codification (“ASC”) Topic 260-10 which provides for calculation of “basic” and “diluted” earnings per share. Basic earnings per share includes no dilution and is computed by dividing net income or loss available to common stockholders by the weighted average number of common shares outstanding for the period. Diluted earnings per share reflect the potential dilution of securities that could share in the earnings of an entity. Diluted earnings per share exclude all potentially dilutive shares if their effect is anti-dilutive. There were no potentially dilutive shares outstanding as at September 30, 2018.

Cash

Cash includes cash on hand and balances with banks.

Accounts Receivable, net

Foreign Currency Translation

The functional currency of the US-based company is the US dollar and the Canadian-based company is the Canadian dollar. Transactions denominated in currencies other than the functional currency are translated into the functional currency at the exchange rates prevailing at the dates of the transaction. Monetary assets and liabilities denominated in foreign currencies are translated using the exchange rate prevailing at the balance sheet date. Non-monetary assets and liabilities are translated using the historical rate on the date of the transaction. All exchange gains or losses arising from translation of these foreign currency transactions are included in net income (loss) for the year. In translating the financial statements of the Company’s Canadian subsidiaries from their functional currency into the Company’s reporting currency of US dollars, balance sheet accounts are translated using the closing exchange rate in effect at the balance sheet date and income and expense accounts are translated using an average exchange rate prevailing during the reporting period. Adjustments resulting from the translation, if any, are included in cumulative other comprehensive income (loss) in stockholders’ equity. The Company has not, to the date of these consolidated financial statements, entered into derivative instruments to offset the impact of foreign currency fluctuations.

Fair Value of Financial Instruments

Accounting Standards Codification Topic 820 “Fair Value Measurements and Disclosures” (“ASC 820”) defines fair value, establishes a framework for measuring fair value and expands required disclosure about fair value measurements of assets and liabilities. ASC 820-10 defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820-10 also establishes a fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The standard describes three levels of inputs that may be used to measure fair value:

· Level 1 – Valuation based on quoted market prices in active markets for identical assets or liabilities.

· Level 2 – Valuation based on quoted market prices for similar assets and liabilities in active markets.

· Level 3 – Valuation based on unobservable inputs that are supported by little or no market activity, therefore requiring management’s best estimate of what market participants would use as fair value.

In instances where the determination of the fair value measurement is based on inputs from different levels of the fair value hierarchy, the level in the fair value hierarchy within which the entire fair value measurement falls is based on the lowest level input that is significant to the fair value measurement in its entirety. Our assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment, and considers factors specific to the asset or liability.

Fair value estimates discussed herein are based upon certain market assumptions and pertinent information available to management. The respective carrying value of certain on-balance-sheet financial instruments approximated their fair values due to the short-term nature of these instruments or interest rates that are comparable to market rates. These financial instruments include cash and accounts payable. Our cash, which is carried at fair value, is classified as a Level 1 financial instrument. Our bank accounts are maintained with financial institutions of reputable credit, therefore, bear minimal credit risk.

Income Taxes

We account for income taxes in accordance with ASC 740. We provide for federal and provincial income taxes payable, as well as for those deferred because of the timing differences between reporting income and expenses for financial statement purposes versus tax purposes. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the carrying amount of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Deferred tax assets and liabilities are measured using the enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recoverable or settled. The effect of a change in tax rates is recognized as income or expense in the period of the change. A valuation allowance is established, when necessary, to reduce deferred income tax assets to the amount that is more likely than not to be realized.

Inventory

Research and Development

We are engaged in research and development work. Research and development costs, which relate primarily to software development, are charged to operations as incurred. Under certain research and development arrangements with third parties, we may be required to make payments that are contingent on the achievement of specific developmental, regulatory and/or commercial milestones. Before a product receives regulatory approval, milestone payments made to third parties are expensed when the milestone is achieved. Milestone payments made to third parties after regulatory approval is received are capitalized and amortized over the estimated useful life of the approved product. Research and development costs were $187,859 for the three months ended September 30, 2018, compared to $413,624 for the corresponding periods ended September 30, 2017.

Impairment of Long-Lived Assets

In accordance with ASC Topic 360-10, we review the carrying amount of long-lived assets for the existence of facts or circumstances, both internally and externally, that suggest impairment. We determine if the carrying amount of a long-lived asset is impaired based on anticipated undiscounted cash flows, before interest, from the use of the asset. In the event of impairment, a loss is recognized based on the amount by which the carrying amount exceeds the fair value of the asset. Fair value is determined based on appraised value of the assets or the anticipated cash flows from the use of the asset or asset group, discounted at a rate commensurate with the risk involved.

Stock Based Compensation

We account for share-based payments in accordance with the provision of ASC 718, which requires that all share-based payments issued to acquire goods or services, including grants of employee stock options, be recognized in the statement of operations based on their fair values, net of estimated forfeitures. ASC 718 requires forfeitures to be estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. Compensation expense related to share-based awards is recognized over the requisite service period, which is generally the vesting period.

We account for stock based compensation awards issued to non-employees for services, as prescribed by ASC 718-10, at either the fair value of the services rendered or the instruments issued in exchange for such services, whichever is more readily determinable, using the guidelines in ASC 505-50. We issue compensatory shares for services including, but not limited to, executive, management, accounting, operations, corporate communication, financial and administrative consulting services.

Operating Leases

We lease office space and certain office equipment under operating lease agreements. The lease term begins on the date of initial possession of the leased property for purposes of recognizing lease expense on a straight-line basis over the term of the lease. Lease renewal periods are considered on a lease-by-lease basis and are generally not included in the initial lease term.

Convertible Notes Payable and Derivative Instruments

We account for conversion options embedded in convertible notes in accordance with ASC 815. ASC 815 generally requires companies to bifurcate conversion options embedded in convertible notes from their host instruments and to account for them as free-standing derivative financial instruments. ASC 815 provides for an exception to this rule when convertible notes, as host instruments, are deemed to be conventional, as defined by ASC 815-40.

We account for convertible notes deemed conventional and conversion options embedded in non-conventional convertible notes which qualify as equity under ASC 815, in accordance with the provisions of ASC 470-20, which provides guidance on accounting for convertible securities with beneficial conversion features. Accordingly, we record, as a discount to convertible notes, the intrinsic value of such conversion options based upon the differences between the fair value of the underlying common stock at the commitment date of the note transaction and the effective conversion price embedded in the note. Debt discounts under these arrangements are amortized over the term of the related debt.

Recently Issued Accounting Pronouncements

Results of Operations

As disclosed at the time of receiving the recent final Food and Drug Administration clearance, Biotricity immediately commenced the third-party manufacture of devices and hired its initial go-to-market sales force, choosing to launch limited market reviews of its device and the workflows associated with doctor and patient use, including the operations of the monitoring centers that this workflow entails. Though they can entail small amounts of revenue, the primary focus of these limited market reviews is the development of key opinion leaders that will work with the Company to improve the use of the device and all of the associated workflows in order to enhance commercialization and sales penetration in the areas we have chosen for initial launch.

From its inception in July 2009 through to September 30, 3018, Biotricity has generated a deficit of $31,044,687. We expect to incur additional operating losses, principally because of the anticipated initial limited sales we expect to be associated with a measured and well-executed commercialization path for Bioflux, our planned first product, as well as anticipated costs of continued research and development associated with product improvement and new product development. As we approach final stages of the commercialization, we also expect to devote significant resources towards capital expenditures in order to install an adequate operating infrastructure that can provide excellent customer service and sales support.

Three and Six Months Ended September 30, 2018 and September 30, 2017

Operating Revenues and Expenses

As described above, the Company has commenced the commercialization of its first product on April 1, 2018, rolling out a limited market review to carefully rollout of its sales program to identified anchor customers in targeted areas of the U.S. In this initial six month period, the company has earned gross revenues of $102,420.

Total operating expenses for the three and six month periods ended September 30, 2018 were $2,214,382 and $4,642,759, compared to $1,454,899 and $2,858,208, respectively, for the three and six month periods ended September 30, 2017, as further described below.

For the three and six month period ended September 30, 2018, we incurred general and administrative expenses of $2,026,523 and $4,154,829, compared to $1,041,275 and $2,129,474, respectively for the three and six month periods ended September 30, 2017. The increases were primarily due to increased payroll and compensation-related expenses associated with commercialization, including the building of a new sales force, as well as administrative and engineering staff to support customer deployment and further development of our products and processes; the increase was also due to professional fees, product marketing and promotion and other operating infrastructure required for the launch of a developed product.

For the three and six month periods ended September 30, 2018, we incurred research and development expenses of $187,859 and $487,930, compared to research and development expenses of $413,624 and $728,734 for the three and six month periods ended September 30, 2017. The decreases for the three and six month periods ended September 30, 2018 are mainly due to decreased activity associated with having completed our FDA approval process in the prior fiscal period, as offset by the preparation of Bioflux for commercialization and the engineering of future products and product enhancements.

Net Loss

Net loss for the three and six months ended September 30, 2018 was $2,176,740 and $4,597,257 compared to a net loss of $1,454,899 and $3,758,212 during the three and six months ended September 30, 2017, resulting in a loss per share of $0.066 and $0.142, respectively, for the three and six month periods ended September 30, 2018 (September 30, 2017 – $0.048 and $0.127).

Translation Adjustment

Translation adjustment for the three and six month periods ended September 30, 2018 was a gain of $112,866 and a gain of $10,217, respectively, as compared to losses of $83,858 and $170,348, respectively, for the three and six months ended September 30, 2017. This translation adjustment represents losses that resulted from the translation of currency in the financial statements, from our functional currency of Canadian dollars to the reporting currency in U.S. dollars.

Liquidity and Capital Resources

The Company is in development mode, operating a research and development program to develop, obtain regulatory approval for, and commercialize its proposed products.

We generally require cash to:

· fund our operations and working capital requirements,

· develop and execute our product development and market introduction plans,

· fund research and development efforts, and

· pay any debt obligations as they come due.

As a result of its being in development-mode, the Company has incurred recurring losses from operations, and as at September 30, 2018, has an accumulated deficit of $31,044,687. Management anticipates the Company will improve its liquidity through continued business development and after additional debt or equity investment in the Company. To do this, the Company has developed and continues to pursue sources of funding, including but not limited to those described below.

During the six months ended September 30, 2018, the Company entered into an arrangement with a private equity firm, to establish facility that allows it to raise up to $25 million in additional capital through sales of common stock, at its discretion, subject to certain conditions. During the six months ended September 30, 2018, the Company raised $1,819,943 in gross proceeds through sales of shares under this facility. Measured, discretionary use of this facility and any additional equity financing that the Company may undertake will be dilutive to existing stockholders.

During the six months ended September 30, 2018, the Company issued 326,330 shares of common stock as compensation to consultants that provide contractual services.

As we proceed with the commercialization of the Bioflux product development, we have devoted and expect to continue to devote significant resources in the areas of capital expenditures and research and development costs and operations, marketing and sales expenditures. We expect to require additional funds to further develop our business plan, including the continued commercialization of the Bioflux and the later introduction of Biolife products. Based on our current operating plans, we will require approximately $4 million ($7 million in order to accelerate commercialization) to grow our sales team and order devices that will be placed in the field to produce revenue. A portion of these funds will also go towards the further development of Bioflux in its next generation, in addition to including marketing, sales, regulatory and clinical costs to better introduce the product into the market place. Since it is impossible to predict with certainty the timing and amount of funds required to launch the Bioflux and Biolife product in any other markets or any of our other proposed products, we anticipate that we will need to raise additional funds through equity or debt offerings or otherwise in order to meet our expected future liquidity requirements.

Based on the above facts and assumptions, we believe our existing cash and cash equivalents, along with anticipated near-term equity financings, will be sufficient to meet our needs for the next twelve months from the filing date of this Quarterly Report on Form 10-Q. However, we will need to seek additional debt or equity capital to respond to business opportunities and challenges, including our ongoing operating expenses, protecting our intellectual property, developing or acquiring new lines of business and enhancing our operating infrastructure. The terms of our future financings may be dilutive to, or otherwise adversely affect, holders of our common stock. We may also seek additional funds through arrangements with collaborators or other third parties. There can be no assurance we will be able to raise this additional capital on acceptable terms, or at all. If we are unable to obtain additional funding on a timely basis, we may be required to modify our operating plan and otherwise curtail or slow the pace of development and commercialization of our proposed product lines.

Net Cash Used in Operating Activities

During the six months ended September 30, 2018, we used cash in operating activities of $2,670,638 compared to $2,208,129 for the six months ended September 30, 2017. These activities involved expenditures undertaken on business development, marketing and operating activities, as well as continued research and product development.

Net Cash from Financing Activities

Net cash provided by financing activities was $1,790,778 for the six months ended September 30, 2018 compared to $2,340,409 for the six months ended September 30, 2017. Financing activities during the six months ended September 30, 2018 related to the establishment of the Company’s new committed facility discussed above, whereas activities of the corresponding prior year period related to funds that were previously raised through a private placement offering of equity to accredited investors.

Net Cash Used in Investing Activities

The Company did not use any net cash in investing activities in the three months periods ended September 30, 2018 or 2017.

Off-Balance Sheet Arrangements

We have no off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources.

Item 3. Quantitative and Qualitative Disclosures About Market Risk

Not required for a smaller reporting company.

Item 4. Controls and Procedures.

Evaluation of Disclosure Controls and Procedures

The Company maintains disclosure controls and procedures that are designed to ensure that information required to be disclosed in the Company's Exchange Act reports is recorded, processed, summarized and reported within the time communicated to the Company's management, including its Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure based closely on the definition of “disclosure controls and procedures” in Rule 13a-15(e). The Company's disclosure controls and procedures are designed to provide a reasonable level of assurance of reaching the Company's desired disclosure control objectives. In designing and evaluating the disclosure controls and procedures, management recognized that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, and management necessarily was required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures. The Company's certifying officers have concluded that the Company's disclosure controls and procedures are effective in reaching that level of assurance. Internal control systems, no matter how well designed and operated, have inherent limitations. Therefore, even a system which is determined to be effective cannot provide absolute assurance that all control issues have been detected or prevented. Our systems of internal controls are designed to provide reasonable assurance with respect to financial statement preparation and presentation.

At the end of the period being reported upon, the Company carried out an evaluation, under the supervision and with the participation of the Company's management, including the Company's Chief Executive Officer and Chief Financial Officer, of the effectiveness of the design and operation of the Company's disclosure controls and procedures. Based on the foregoing, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective to ensure that the material information required to be included in our Securities and Exchange Commission reports is accumulated and communicated to our management, including our principal executive and financial officer, as well as recorded, processed, summarized and reported within the time periods specified in Securities and Exchange Commission rules and forms relating to the Company.

Changes in Internal Controls

There were no changes in the Company’s internal controls over financial reporting that occurred during the three-month period ended September 30, 2018 that have materially affected, or are reasonably likely to materially affect, our internal controls over financial reporting.

PART II

OTHER INFORMATION

Item 1. Legal Proceedings.

None.

Item 1A. Risk Factors

Not required for smaller reporting companies.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

None.

Item 3. Defaults Upon Senior Securities.

None.

Item 4. Mine Safety Disclosures.

Not applicable.

Item 5. Other Information.

None.

Item 6. Exhibits

31.1 Certification pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

31.2 Certification pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

32.1 Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

32.2 Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

101.1 XBRL Instance.

101.SCH XBRL Taxonomy Extension Schema.

101.CAL XBRL Taxonomy Extension Calculation.

101.DEF XBRL Taxonomy Extension Definition.

101.LAB XBRL Taxonomy Extension Labels.

101.PREXBRL Taxonomy Extension Presentation.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized, this 14 November, 2018.

BIOTRICITY INC.

By: /s/ Waqaas Al-Siddiq

Name: Waqaas Al-Siddiq

Title: Chief Executive Officer

(principal executive officer)

By: /s/John Ayanoglou

Name: John Ayanoglou

Title: Chief Financial Officer

(principal financial and accounting officer)

EX-31.1 2 exhibit31_1.htm EXHIBIT 31.1 Converted by EDGARwiz

Exhibit 31.1

BIOTRICITY INC.

CERTIFICATION PURSUANT TO RULE 13a-14(a) OR 15d-14(a) OF THE SECURITIES

EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO SECTION 302 OF THE

SARBANES-OXLEY ACT OF 2002

I, Waqaas Al-Siddiq, certify that:



1.	I have reviewed this Quarterly Report on Form 10-Q of Biotricity Inc.;

2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the Registrant as of, and for, the periods presented in this report;

4.	The Registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the Registrant and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the Registrant, including its consolidated subsidiary, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) Evaluated the effectiveness of the Registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) Disclosed in this report any change in the Registrant’s internal control over financial reporting that occurred during the Registrant’s most recent fiscal quarter (the Registrant’s fourth fiscal quarter in the case of an Quarterly Report) that has materially affected, or is reasonably likely to materially affect, the Registrant’s internal control over financial reporting; and



5.	The Registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the Registrant’s auditors and the audit committee of the Registrant’s board of directors (or persons performing the equivalent functions):

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the Registrant’s ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the Registrant’s internal control over financial reporting.

Date: November 14, 2018

/s/Waqaas Al-Siddiq

Waqaas Al-Siddiq

Chief Executive Officer

(principal executive officer)

EX-31.2 3 exhibit31_2.htm EXHIBIT 31.2 Converted by EDGARwiz

EXHIBIT 31.2

BIOTRICITY INC.

CERTIFICATION PURSUANT TO RULE 13a-14(a) OR 15d-14(a) OF THE SECURITIES

EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO SECTION 302 OF THE

SARBANES-OXLEY ACT OF 2002

I, John Ayanoglou, certify that:



	1.	I have reviewed this Quarterly Report on Form 10-Q of Biotricity Inc.;



	2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;



	3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the Registrant as of, and for, the periods presented in this report;



	4.	The Registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the Registrant and have:



	5.	The Registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the Registrant’s auditors and the audit committee of the Registrant’s board of directors (or persons performing the equivalent functions):

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the Registrant’s internal control over financial reporting.

Date: November 14, 2018

/s/ John Ayanoglou

John Ayanoglou

(Principal Financial Officer and Principal Accounting Officer)

EX-32.1 4 exhibit32_1.htm EXHIBIT 32.1 Converted by EDGARwiz

Exhibit 32.1

BIOTRICITY INC.

CERTIFICATION PURSUANT TO

18 U.S.C. §1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report on Form 10-Q of Biotricity Inc. (the “Company”) for the quarterly period ended September 30, 2018, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Waqaas Al-Siddiq, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. §1350, as adopted pursuant to §906 of the Sarbanes-Oxley Act of 2002, that:

(1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: November 14, 2018

/s/ Waqaas Al-Siddiq

Waqaas Al-Siddiq

Chief Executive Officer

(principal executive officer)

EX-32.2 5 exhibit32_2.htm EXHIBIT 32.2 Converted by EDGARwiz

Exhibit 32.2

BIOTRICITY INC.

CERTIFICATION PURSUANT TO

18 U.S.C. §1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report on Form 10-Q of Biotricity Inc. (the “Company”) for the quarterly period ended September 30, 2018, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, John Ayanoglou, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. §1350, as adopted pursuant to §906 of the Sarbanes-Oxley Act of 2002, that:

(1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: November 14, 2018

/s/ John Ayanoglou

John Ayanoglou

(Principal Financial Officer and

Principal Accounting Officer)

EX-101.INS 6 btcy-20180930.xml XBRL INSTANCE DOCUMENT 10-Q 2018-09-30 false BIOTRICITY INC. 0001630113 btcy --03-31 27605567 Non-accelerated Filer Yes No No 2019 Q2

83254

843643

43436

179430

51316 35737

28984

17046

386420

896426

33000

419420

929426

1047896

756179

1047896

756179

33331

31858

80216 69963

30935575

27161984

-632912

-643129

-31044687

-26447430

-628476

173247

419420

929426

0.001

10000000

0.001

125000000

27605567

23713602

27605567

23713602

84760

102420

47118

56918

37642

45502

2026523

1041275

4154829

2129474

187859

413624

487930

728734

2214382

1454899

4642759

2858208

-2176740

-1454899

-4597257

-3758212

-2176740

-1454899

112866

-83858

10217

-170348

-2063874

-1538757

-4587040

-3928560

-0.066

-0.048

-0.142

-0.127

32819848

30590667

32377274

29529534

-4597257

-3758212

728162

442155

898025 419217 368352 174976

879416

20588

-43436

-179430

-15580 -19602

-11939

7983

182465

-374650

-2670638

-2208129

1739943 2340409

50835

1790778

2340409

119471 50001

-879860

132280

843643

424868

83254

607149

7. STOCKHOLDERS EQUITY (DEFICIENCY) <p style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:107%;margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:.25in;margin-bottom:.0001pt;text-align:justify;text-justify:inter-ideograph;text-indent:-.25in;line-height:normal'>  <p style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:107%;margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:21.3pt;margin-bottom:.0001pt;text-indent:-.25in;line-height:normal;text-autospace:none'>a)       Authorized stock   As at September 30, 2018, the Company is authorized to issue 125,000,000 (March 31, 2018 125,000,000) shares of common stock ($0.001 par value) and 10,000,000 (March 31, 2018 10,000,000) shares of preferred stock ($0.001 par value).   At September 30, 2018, there were 27,605,567 (March 31, 2018 23,713,602) shares of common stock issued and outstanding. Additionally, at September 30, 2018, there were 5,725,041 (March 31, 2018 8,143,937) outstanding exchangeable shares. There is currently one share of the Special Voting Preferred Stock issued and outstanding held by one holder of record, which is the Trustee in accordance with the terms of the Trust Agreement.   <p style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:107%;margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:21.3pt;margin-bottom:.0001pt;text-indent:-.25in;line-height:normal;text-autospace:none'>b)       Exchange Agreement   <p style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:107%;margin-bottom:0in;margin-bottom:.0001pt;text-align:justify;text-justify:inter-ideograph;line-height:normal;text-autospace:none'>As initially described in Note 1 above, on February 2, 2016: <p style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:107%;margin-bottom:0in;margin-bottom:.0001pt;text-align:justify;text-justify:inter-ideograph;line-height:normal;text-autospace:none'>  <ul type="disc" style='margin-top:0in'> <li style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:107%;margin-bottom:0in;margin-bottom:.0001pt;text-align:justify;text-justify:inter-ideograph;line-height:normal;text-autospace:none'>The Company issued approximately 1.197 shares of its common stock in exchange for each common share of iMedical held by the iMedical shareholders who in general terms, are not residents of Canada (for the purposes of the Income Tax Act (Canada). Accordingly, the Company issued 13,376,947 shares; </li> <li style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:107%;margin-bottom:0in;margin-bottom:.0001pt;text-align:justify;text-justify:inter-ideograph;line-height:normal;text-autospace:none'>Shareholders of iMedical who in general terms, are Canadian residents (for the purposes of the Income Tax Act (Canada)) received approximately 1.197 Exchangeable Shares in the capital of Exchangeco in exchange for each common share of iMedical held. Accordingly, the Company issued 9,123,031 Exchangeable Shares; </li> <li style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:107%;margin-bottom:0in;margin-bottom:.0001pt;text-align:justify;text-justify:inter-ideograph;line-height:normal;text-autospace:none'>Each outstanding option to purchase common shares in iMedical (whether vested or unvested) was exchanged, without any further action or consideration on the part of the holder of such option, for approximately 1.197 economically equivalent replacement options with an inverse adjustment to the exercise price of the replacement option to reflect the exchange ratio of approximately 1.197:1; </li> <li style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:107%;margin-bottom:0in;margin-bottom:.0001pt;text-align:justify;text-justify:inter-ideograph;line-height:normal;text-autospace:none'>Each outstanding warrant to purchase common shares in iMedical was adjusted, in accordance with the terms thereof, such that it entitles the holder to receive approximately 1.197 shares of the common stock of the Company for each warrant, with an inverse adjustment to the exercise price of the warrants to reflect the exchange ratio of approximately 1.197:1 </li> <li style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:107%;margin-bottom:0in;margin-bottom:.0001pt;text-align:justify;text-justify:inter-ideograph;line-height:normal;text-autospace:none'>Each outstanding advisor warrant to purchase common shares in iMedical was adjusted, in accordance with the terms thereof, such that it entitles the holder to receive approximately 1.197 shares of the common stock of the Company for each advisor warrant, with an inverse adjustment to the exercise price of the Advisor Warrants to reflect the exchange ratio of approximately 1.197:1; and </li> <li style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:107%;margin-bottom:0in;margin-bottom:.0001pt;text-align:justify;text-justify:inter-ideograph;line-height:normal;text-autospace:none'>The outstanding 11% secured convertible promissory notes of iMedical were adjusted, in accordance with the adjustment provisions thereof, as and from closing, so as to permit the holders to convert (and in some circumstances permit the Company to force the conversion of) the convertible promissory notes into shares of the common stock of the Company at a 25% discount to purchase price per share in Biotricitys next offering. </li> </ul> <p style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:107%;margin-bottom:0in;margin-bottom:.0001pt;text-align:justify;text-justify:inter-ideograph;line-height:normal;text-autospace:none'>  <p style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:107%;margin-bottom:0in;margin-bottom:.0001pt;text-align:justify;text-justify:inter-ideograph;line-height:normal;text-autospace:none'>Issuance of common stock, exchangeable shares and cancellation of shares in connection with the reverse takeover transaction as explained above represents recapitalization of capital retroactively adjusting the accounting acquirers legal capital to reflect the legal capital of the accounting acquiree. <p style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:107%;margin-bottom:0in;margin-bottom:.0001pt;text-align:justify;text-justify:inter-ideograph;line-height:normal;text-autospace:none'>  During the six months ended September 30, 2018, shareholders holding 2,418,900 exchangeable shares with voting rights and other attributes corresponding to the Companys common stock (but with the additional right to cashlessly exchange on a one-for-one basis into common stock) retracted and exchanged their exchangeable shares for the corresponding number of shares of common stock.   <p style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:107%;margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:.5in;margin-bottom:.0001pt;text-align:justify;text-justify:inter-ideograph;text-indent:-.25in;line-height:normal'>c)       Share issuances   Share issuances during the year ended March 31, 2018   During the year ended March 31, 2018, the Company sold to accredited investors a further total of 1,282,767 Units, (each Unit consisting of one share of common stock one-half of one warrant to purchase a share of common stock) for gross proceeds of $2,244,845 (net proceeds of $1,926,780).   During the year ended March 31, 2018, prior to closing its private placement offering on or about July 31, 2017, the Company sold to accredited investors a further total of 263,188 Units for gross proceeds of $460,579 (net proceeds of $413,629).  Cash issuance costs of $46,950 have been adjusted against additional paid in capital. In connection with this private placement, the Company also issued 21,055 broker warrants and 131,594 warrants to investors (refer to warrant issuances).   During the year ended March 31, 2018, the Company completed a registered offering, which raised net proceeds of $2,520,561 million through the issuance of 450,164 common shares.   Cash issuance costs of $320,355 relating to the above private placements have been adjusted against additional paid in capital. In connection with the above private placements and conversion of notes as detailed in Note 5, the Company issued broker warrants and warrants to investors having fair values of $385,635 and $3,183,614, respectively, which were initially classified as derivative liabilities with corresponding debit to additional paid in capital.   The raising of a total of $3,000,000 in aggregate proceeds from the common share offering would qualify that offering as a Qualified Financing that would allow the Company, at its discretion, to convert the principal amount of the Bridge Notes (discussed in Note 5), along with accrued interest thereon, into units of the common share offering. Conversion would be based upon the price that is the lesser of: (i) $1.60 per share and (ii) the quotient obtained by dividing (x) the Outstanding Balance on the conversion date multiplied by 1.20 by (y) the actual price per share in the Qualified Financing. The notes and the warrants were further subject to a most-favored nation clause in the event the Company, prior to maturity of the notes, consummates a financing that is not a Qualified Financing.  Upon completion of a Qualified Financing, in connection with the conversion of the Bridge Notes, the Company would also pay the Placement Agent up to 8% in cashless broker warrants with an exercise price of $3.00 and an expiry date of two years from the date of issuance. Based on achieving this milestone, on May 31, 2017, the Company converted Bridge Notes with the aggregate principal amount of $2,455,000 plus accrued interest thereon, into a further 1,823,020 Units of its common share offering (each of which corresponded to one share and half of one warrant).   During the year ended March 31, 2018, the Company issued an aggregate of 527,941 shares of common stock and has recognized its obligation to issue a further 20,250 shares of common stock (see paragraph d, below), to various consultants. The fair value of these shares amounted to $1,908,481 were recognized as general and administrative and research and development expenses, as applicable, in the statement of operations, with a corresponding credit to additional paid-in-capital.   During the year ended March 31, 2018, the Company also issued an aggregate of 252,798 shares of its common stock upon exercise of warrants and received $428,311 of exercise cash proceeds. In addition, during this year, the Company issued 58,795 shares of common stock to brokers who opted to perform cashless exercise of their 108,799 warrants. See paragraph e, below <p style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:107%;margin-bottom:0in;margin-bottom:.0001pt;text-align:justify;text-justify:inter-ideograph;line-height:normal;text-autospace:none'>  Share issuances during the six months ended September 30, 2018 <p style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:107%;margin-bottom:0in;margin-bottom:.0001pt;text-align:justify;text-justify:inter-ideograph;line-height:normal;text-autospace:none'>  During the six months ended September 30, 2018, the Company entered into an agreement with a private equity investment fund (the Investor) to establish a committed equity purchase facility, which allows the Company, at its sole option, subject to certain conditions, to direct the Investor to make multiple common share purchases that in aggregate can be up to $25 million (the Aggregate Amount) during the term of the facility, which will be up to 36 months. As part of the initial closing of this transaction, the Investor purchased 128,750 shares of common stock of the Company, at a price of $4.00 per share, for gross proceeds of $515,000 and paid the Investor $15,000 in issuance costs. As compensation for providing this equity purchase facility, the Company also issued to the Investor an additional 121,344 shares (representing a dollar value equal to 1.6% of the aggregate amount, or $400,000, at a price per share that was equal to the average of the closing sale prices of the common shares for the ten (10) consecutive business days prior to the closing date of the transaction). The size and purchase price for each future drawdown under this agreement is governed by the purchase facilities agreement and is predicated on trading volumes as well as the average trading and closing prices of the common stock on the day of drawdown and the prior ten (10) trading days, such that the purchase price is always fixed and know at the time the Company elects to sell shares to the Investor. During the six months ended September 30, 2018, the Company sold a further 669,226 shares under this facility and raised aggregate gross proceeds of $1,819,943.   During the six months ended September 30, 2018, the Company issued an aggregate of 326,333 shares of common stock to various advisors, contractors and consultants, including 62,500 shares of common stock to non-executive directors of its Board as part of their annual compensation program. Not including 14,000 shares, that were accounted for as common shares to be issued in relation to issuance obligations as at March 31, 2018, the fair value of the remaining 312,333 shares amounted to $840,546 and has been expensed to general and administrative expenses in the condensed consolidated statement of operations, with a corresponding credit to additional paid-in-capital.   <p style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:107%;margin-bottom:0in;margin-bottom:.0001pt;text-align:justify;text-justify:inter-ideograph;line-height:normal;text-autospace:none'>During the six months ended September 30, 2018, the Company issued 164,574 shares of common stock upon the exercise of options of its legacy 2015 equity incentive plan; during the same period the Company also issued 62,838 shares of its common stock upon exercise of warrants and received $50,835 of exercise cash proceeds. <p style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:107%;margin-bottom:0in;margin-bottom:.0001pt;text-align:justify;text-justify:inter-ideograph;line-height:normal;text-autospace:none'>  <p style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:107%;margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:.5in;margin-bottom:.0001pt;text-align:justify;text-justify:inter-ideograph;text-indent:-.25in;line-height:normal;text-autospace:none'>d)       Shares to be issued <p style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:107%;margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:.5in;margin-bottom:.0001pt;text-align:justify;text-justify:inter-ideograph;line-height:normal;text-autospace:none'>  <p style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:107%;margin-bottom:0in;margin-bottom:.0001pt;text-align:justify;text-justify:inter-ideograph;line-height:normal;text-autospace:none'>Common stock to be issued of 32,083 shares ($80,216) is comprised of: <p style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:107%;margin-bottom:0in;margin-bottom:.0001pt;text-align:justify;text-justify:inter-ideograph;line-height:normal;text-autospace:none'>  <ul type="disc" style='margin-top:0in'> <li style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:107%;margin-bottom:0in;margin-bottom:.0001pt;text-align:justify;text-justify:inter-ideograph;line-height:normal;text-autospace:none'>19,583 shares of common stock issued to consultants in connection with services rendered during the quarter with a fair value of $37,404; and</li> <li style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:107%;margin-bottom:0in;margin-bottom:.0001pt;text-align:justify;text-justify:inter-ideograph;line-height:normal;text-autospace:none'>12,500 shares of common stock to be issued to a consultant, which represents an obligation recognized in prior periods, with a fair value of $42,812.</li> </ul> <p style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:107%;margin-bottom:0in;margin-bottom:.0001pt;text-align:justify;text-justify:inter-ideograph;line-height:normal;text-autospace:none'>  The fair value of these shares was determined by using the market price of the common stock as at the date of issuance obligation.   <p style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:107%;margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:.5in;margin-bottom:.0001pt;text-align:justify;text-justify:inter-ideograph;text-indent:-.25in;line-height:normal'>e)       Warrant issuances <p style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:107%;margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:.25in;margin-bottom:.0001pt;text-align:justify;text-justify:inter-ideograph;text-indent:-.25in;line-height:normal'>  Warrant issuances during the year ended March 31, 2018   During December 2017, 112,798 broker warrants were exercised at exercises price of between $1.04 and $1.49, such that the Company received cash proceeds of $124,718. Also during December 2017, 140,000 consultant warrants were exercised at exercise prices between $2.00 and 2.58, for cash proceeds to the Company of $303,200.   <p style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:107%;margin-bottom:0in;margin-bottom:.0001pt;text-align:justify;text-justify:inter-ideograph;line-height:normal;text-autospace:none'>During March 2018, 108,799 broker warrants were exercised into 58,795 common shares through the cashless exercise. The holder may, in its sole discretion, exercise all or any part of this warrant in a cashless or net-issue (or cashless) exercise  and receive a number of shares calculated by using the following formula: X = Y (A - B)/A with: X = the number of shares to be issued to the holder  Y = the number of shares with respect to which the warrant is being exercised A = the fair value per share of common stock on the date of exercise of the warrant B = the then-current exercise price of the warrant.   Warrant issuances during the six months ended September 30, 2018 <p style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:107%;margin-bottom:0in;margin-bottom:.0001pt;text-align:justify;text-justify:inter-ideograph;line-height:normal;text-autospace:none'>  <p style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:107%;margin-bottom:0in;margin-bottom:.0001pt;text-align:justify;text-justify:inter-ideograph;line-height:normal;text-autospace:none'>During the six months ended September 30, 2018, the Company issued 458,333 warrants as compensation for advisor and consultant services, which were fair valued at $368.352 and expensed in general and administrative expenses, with a corresponding credit to additional paid in capital. Their fair value has been estimated using a multi-nomial lattice model with an expected life of 3 years, a risk free rate ranging from 2.13% to 2.81%, stock price of $1.24 to $4.15 and expected volatility of 97.8% to 138.27%.   Warrant issuances, exercises and expirations or cancellations during the three months ended September 30, 2018 and preceding periods resulted in warrants outstanding at the end of those respective periods as follows:   <div align="center"> <table border="0" cellspacing="0" cellpadding="0" width="635" style='width:476.4pt;border-collapse:collapse'> <tr style='height:73.5pt'> <td width="152" valign="bottom" style='width:113.7pt;border-top:solid windowtext 1.0pt;border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;padding:0in 5.4pt 0in 5.4pt;height:73.5pt'>   </td> <td width="106" valign="bottom" style='width:79.5pt;border-top:solid windowtext 1.0pt;border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;padding:0in 5.4pt 0in 5.4pt;height:73.5pt'> Broker Warrants </td> <td width="114" valign="bottom" style='width:85.5pt;border-top:solid windowtext 1.0pt;border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;padding:0in 5.4pt 0in 5.4pt;height:73.5pt'> Consultant Warrants </td> <td width="96" valign="bottom" style='width:1.0in;border-top:solid windowtext 1.0pt;border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;padding:0in 5.4pt 0in 5.4pt;height:73.5pt'> Warrants Issued on Conversion of Convertible Notes </td> <td width="84" valign="bottom" style='width:63.0pt;border-top:solid windowtext 1.0pt;border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;padding:0in 5.4pt 0in 5.4pt;height:73.5pt'> Private Placement Warrants </td> <td width="84" valign="bottom" style='width:62.7pt;border-top:solid windowtext 1.0pt;border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;padding:0in 5.4pt 0in 5.4pt;height:73.5pt'> Total </td> </tr> <tr style='height:10.1pt'> <td width="152" valign="bottom" style='width:113.7pt;border:none;background:#CCEEFF;padding:0in 5.4pt 0in 5.4pt;height:10.1pt'> As at March 31, 2017 </td> <td width="106" valign="bottom" style='width:79.5pt;border:none;background:#CCEEFF;padding:0in 5.4pt 0in 5.4pt;height:10.1pt'>    380,682  </td> <td width="114" valign="bottom" style='width:85.5pt;border:none;background:#CCEEFF;padding:0in 5.4pt 0in 5.4pt;height:10.1pt'>      916,466  </td> <td width="96" valign="bottom" style='width:1.0in;border:none;background:#CCEEFF;padding:0in 5.4pt 0in 5.4pt;height:10.1pt'>                     - </td> <td width="84" valign="bottom" style='width:63.0pt;border:none;background:#CCEEFF;padding:0in 5.4pt 0in 5.4pt;height:10.1pt'> 390,744 </td> <td width="84" valign="bottom" style='width:62.7pt;border:none;background:#CCEEFF;padding:0in 5.4pt 0in 5.4pt;height:10.1pt'> 1,687,892  </td> </tr> <tr style='height:10.1pt'> <td width="152" valign="bottom" style='width:113.7pt;padding:0in 5.4pt 0in 5.4pt;height:10.1pt'> Less: Exercised </td> <td width="106" valign="bottom" style='width:79.5pt;padding:0in 5.4pt 0in 5.4pt;height:10.1pt'> (222,690) </td> <td width="114" valign="bottom" style='width:85.5pt;padding:0in 5.4pt 0in 5.4pt;height:10.1pt'>    (140,000) </td> <td width="96" valign="bottom" style='width:1.0in;padding:0in 5.4pt 0in 5.4pt;height:10.1pt'>                     - </td> <td width="84" valign="bottom" style='width:63.0pt;padding:0in 5.4pt 0in 5.4pt;height:10.1pt'> - </td> <td width="84" valign="bottom" style='width:62.7pt;padding:0in 5.4pt 0in 5.4pt;height:10.1pt'> (362,690) </td> </tr> <tr style='height:10.1pt'> <td width="152" valign="bottom" style='width:113.7pt;background:#CCEEFF;padding:0in 5.4pt 0in 5.4pt;height:10.1pt'> Less: Expired/cancelled </td> <td width="106" valign="bottom" style='width:79.5pt;background:#CCEEFF;padding:0in 5.4pt 0in 5.4pt;height:10.1pt'>    (19,935) </td> <td width="114" valign="bottom" style='width:85.5pt;background:#CCEEFF;padding:0in 5.4pt 0in 5.4pt;height:10.1pt'>    (380,300) </td> <td width="96" valign="bottom" style='width:1.0in;background:#CCEEFF;padding:0in 5.4pt 0in 5.4pt;height:10.1pt'>                     - </td> <td width="84" valign="bottom" style='width:63.0pt;background:#CCEEFF;padding:0in 5.4pt 0in 5.4pt;height:10.1pt'> - </td> <td width="84" valign="bottom" style='width:62.7pt;background:#CCEEFF;padding:0in 5.4pt 0in 5.4pt;height:10.1pt'> (400,235) </td> </tr> <tr style='height:10.1pt'> <td width="152" valign="bottom" style='width:113.7pt;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:10.1pt'> Add: Issued </td> <td width="106" valign="bottom" style='width:79.5pt;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:10.1pt'>    246,095  </td> <td width="114" valign="bottom" style='width:85.5pt;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:10.1pt'>      273,806  </td> <td width="96" valign="bottom" style='width:1.0in;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:10.1pt'>    2,734,530 </td> <td width="84" valign="bottom" style='width:63.0pt;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:10.1pt'> 772,978 </td> <td width="84" valign="bottom" style='width:62.7pt;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:10.1pt'> 4,027,409  </td> </tr> <tr style='height:10.1pt'> <td width="152" valign="bottom" style='width:113.7pt;border:none;border-bottom:solid windowtext 1.0pt;background:#CCEEFF;padding:0in 5.4pt 0in 5.4pt;height:10.1pt'> As at March 31, 2018 </td> <td width="106" valign="bottom" style='width:79.5pt;border:none;border-bottom:solid windowtext 1.0pt;background:#CCEEFF;padding:0in 5.4pt 0in 5.4pt;height:10.1pt'>    384,152  </td> <td width="114" valign="bottom" style='width:85.5pt;border:none;border-bottom:solid windowtext 1.0pt;background:#CCEEFF;padding:0in 5.4pt 0in 5.4pt;height:10.1pt'>     669,972* </td> <td width="96" valign="bottom" style='width:1.0in;border:none;border-bottom:solid windowtext 1.0pt;background:#CCEEFF;padding:0in 5.4pt 0in 5.4pt;height:10.1pt'>    2,734,530 </td> <td width="84" valign="bottom" style='width:63.0pt;border:none;border-bottom:solid windowtext 1.0pt;background:#CCEEFF;padding:0in 5.4pt 0in 5.4pt;height:10.1pt'> 1,163,722 </td> <td width="84" valign="bottom" style='width:62.7pt;border:none;border-bottom:solid windowtext 1.0pt;background:#CCEEFF;padding:0in 5.4pt 0in 5.4pt;height:10.1pt'> 4,952,376  </td> </tr> <tr style='height:10.1pt'> <td width="152" valign="bottom" style='width:113.7pt;border:none;padding:0in 5.4pt 0in 5.4pt;height:10.1pt'>   </td> <td width="106" valign="bottom" style='width:79.5pt;border:none;padding:0in 5.4pt 0in 5.4pt;height:10.1pt'>   </td> <td width="114" valign="bottom" style='width:85.5pt;border:none;padding:0in 5.4pt 0in 5.4pt;height:10.1pt'>   </td> <td width="96" valign="bottom" style='width:1.0in;border:none;padding:0in 5.4pt 0in 5.4pt;height:10.1pt'>   </td> <td width="84" valign="bottom" style='width:63.0pt;border:none;padding:0in 5.4pt 0in 5.4pt;height:10.1pt'>   </td> <td width="84" valign="bottom" style='width:62.7pt;border:none;padding:0in 5.4pt 0in 5.4pt;height:10.1pt'>   </td> </tr> <tr style='height:10.1pt'> <td width="152" valign="bottom" style='width:113.7pt;padding:0in 5.4pt 0in 5.4pt;height:10.1pt'> Less: Exercised </td> <td width="106" valign="bottom" style='width:79.5pt;padding:0in 5.4pt 0in 5.4pt;height:10.1pt'>    (62,838) </td> <td width="114" valign="bottom" style='width:85.5pt;padding:0in 5.4pt 0in 5.4pt;height:10.1pt'>                   -  </td> <td width="96" valign="bottom" style='width:1.0in;padding:0in 5.4pt 0in 5.4pt;height:10.1pt'>                     - </td> <td width="84" valign="bottom" style='width:63.0pt;padding:0in 5.4pt 0in 5.4pt;height:10.1pt'> - </td> <td width="84" valign="bottom" style='width:62.7pt;padding:0in 5.4pt 0in 5.4pt;height:10.1pt'> (62,838) </td> </tr> <tr style='height:10.1pt'> <td width="152" valign="bottom" style='width:113.7pt;background:#CCEEFF;padding:0in 5.4pt 0in 5.4pt;height:10.1pt'> Less: Expired/cancelled </td> <td width="106" valign="bottom" style='width:79.5pt;background:#CCEEFF;padding:0in 5.4pt 0in 5.4pt;height:10.1pt'>                 -  </td> <td width="114" valign="bottom" style='width:85.5pt;background:#CCEEFF;padding:0in 5.4pt 0in 5.4pt;height:10.1pt'>       (31,250) </td> <td width="96" valign="bottom" style='width:1.0in;background:#CCEEFF;padding:0in 5.4pt 0in 5.4pt;height:10.1pt'>                     - </td> <td width="84" valign="bottom" style='width:63.0pt;background:#CCEEFF;padding:0in 5.4pt 0in 5.4pt;height:10.1pt'> - </td> <td width="84" valign="bottom" style='width:62.7pt;background:#CCEEFF;padding:0in 5.4pt 0in 5.4pt;height:10.1pt'> (31,250) </td> </tr> <tr style='height:10.1pt'> <td width="152" valign="bottom" style='width:113.7pt;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:10.1pt'> Add: Issued </td> <td width="106" valign="bottom" style='width:79.5pt;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:10.1pt'>                 -  </td> <td width="114" valign="bottom" style='width:85.5pt;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:10.1pt'>         65,000  </td> <td width="96" valign="bottom" style='width:1.0in;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:10.1pt'>                    -  </td> <td width="84" valign="bottom" style='width:63.0pt;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:10.1pt'>                 -  </td> <td width="84" valign="bottom" style='width:62.7pt;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:10.1pt'> 65,000  </td> </tr> <tr style='height:10.1pt'> <td width="152" valign="bottom" style='width:113.7pt;border:none;border-bottom:solid windowtext 1.0pt;background:#CCEEFF;padding:0in 5.4pt 0in 5.4pt;height:10.1pt'> As at June 30, 2018 </td> <td width="106" valign="bottom" style='width:79.5pt;border:none;border-bottom:solid windowtext 1.0pt;background:#CCEEFF;padding:0in 5.4pt 0in 5.4pt;height:10.1pt'>    321,314  </td> <td width="114" valign="bottom" style='width:85.5pt;border:none;border-bottom:solid windowtext 1.0pt;background:#CCEEFF;padding:0in 5.4pt 0in 5.4pt;height:10.1pt'>     703,722* </td> <td width="96" valign="bottom" style='width:1.0in;border:none;border-bottom:solid windowtext 1.0pt;background:#CCEEFF;padding:0in 5.4pt 0in 5.4pt;height:10.1pt'>    2,734,530 </td> <td width="84" valign="bottom" style='width:63.0pt;border:none;border-bottom:solid windowtext 1.0pt;background:#CCEEFF;padding:0in 5.4pt 0in 5.4pt;height:10.1pt'> 1,163,722 </td> <td width="84" valign="bottom" style='width:62.7pt;border:none;border-bottom:solid windowtext 1.0pt;background:#CCEEFF;padding:0in 5.4pt 0in 5.4pt;height:10.1pt'> 4,923,288  </td> </tr> <tr style='height:10.1pt'> <td width="152" valign="bottom" style='width:113.7pt;border:none;padding:0in 5.4pt 0in 5.4pt;height:10.1pt'>   </td> <td width="106" valign="bottom" style='width:79.5pt;border:none;padding:0in 5.4pt 0in 5.4pt;height:10.1pt'>   </td> <td width="114" valign="bottom" style='width:85.5pt;border:none;padding:0in 5.4pt 0in 5.4pt;height:10.1pt'>   </td> <td width="96" valign="bottom" style='width:1.0in;border:none;padding:0in 5.4pt 0in 5.4pt;height:10.1pt'>   </td> <td width="84" valign="bottom" style='width:63.0pt;border:none;padding:0in 5.4pt 0in 5.4pt;height:10.1pt'>   </td> <td width="84" valign="bottom" style='width:62.7pt;border:none;padding:0in 5.4pt 0in 5.4pt;height:10.1pt'>   </td> </tr> <tr style='height:10.1pt'> <td width="152" valign="bottom" style='width:113.7pt;padding:0in 5.4pt 0in 5.4pt;height:10.1pt'> Less: Exercised </td> <td width="106" valign="bottom" style='width:79.5pt;padding:0in 5.4pt 0in 5.4pt;height:10.1pt'>                 -  </td> <td width="114" valign="bottom" style='width:85.5pt;padding:0in 5.4pt 0in 5.4pt;height:10.1pt'>                   -  </td> <td width="96" valign="bottom" style='width:1.0in;padding:0in 5.4pt 0in 5.4pt;height:10.1pt'>                     - </td> <td width="84" valign="bottom" style='width:63.0pt;padding:0in 5.4pt 0in 5.4pt;height:10.1pt'> - </td> <td width="84" valign="bottom" style='width:62.7pt;padding:0in 5.4pt 0in 5.4pt;height:10.1pt'> - </td> </tr> <tr style='height:10.1pt'> <td width="152" valign="bottom" style='width:113.7pt;background:#CCEEFF;padding:0in 5.4pt 0in 5.4pt;height:10.1pt'> Less: Expired/cancelled </td> <td width="106" valign="bottom" style='width:79.5pt;background:#CCEEFF;padding:0in 5.4pt 0in 5.4pt;height:10.1pt'>                 -  </td> <td width="114" valign="bottom" style='width:85.5pt;background:#CCEEFF;padding:0in 5.4pt 0in 5.4pt;height:10.1pt'>                -   ** </td> <td width="96" valign="bottom" style='width:1.0in;background:#CCEEFF;padding:0in 5.4pt 0in 5.4pt;height:10.1pt'>                     - </td> <td width="84" valign="bottom" style='width:63.0pt;background:#CCEEFF;padding:0in 5.4pt 0in 5.4pt;height:10.1pt'> - </td> <td width="84" valign="bottom" style='width:62.7pt;background:#CCEEFF;padding:0in 5.4pt 0in 5.4pt;height:10.1pt'></td> </tr> <tr style='height:10.1pt'> <td width="152" valign="bottom" style='width:113.7pt;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:10.1pt'> Add: Issued </td> <td width="106" valign="bottom" style='width:79.5pt;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:10.1pt'>                 -  </td> <td width="114" valign="bottom" style='width:85.5pt;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:10.1pt'>      393,333  </td> <td width="96" valign="bottom" style='width:1.0in;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:10.1pt'>                    -  </td> <td width="84" valign="bottom" style='width:63.0pt;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:10.1pt'>                 -  </td> <td width="84" valign="bottom" style='width:62.7pt;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:10.1pt'> 393,333  </td> </tr> <tr style='height:10.1pt'> <td width="152" valign="bottom" style='width:113.7pt;border:none;border-bottom:solid windowtext 1.0pt;background:#CCEEFF;padding:0in 5.4pt 0in 5.4pt;height:10.1pt'> As at September 30, 2018 </td> <td width="106" valign="bottom" style='width:79.5pt;border:none;border-bottom:solid windowtext 1.0pt;background:#CCEEFF;padding:0in 5.4pt 0in 5.4pt;height:10.1pt'>    321,314  </td> <td width="114" valign="bottom" style='width:85.5pt;border:none;border-bottom:solid windowtext 1.0pt;background:#CCEEFF;padding:0in 5.4pt 0in 5.4pt;height:10.1pt'> 1,097,055* </td> <td width="96" valign="bottom" style='width:1.0in;border:none;border-bottom:solid windowtext 1.0pt;background:#CCEEFF;padding:0in 5.4pt 0in 5.4pt;height:10.1pt'>    2,734,530 </td> <td width="84" valign="bottom" style='width:63.0pt;border:none;border-bottom:solid windowtext 1.0pt;background:#CCEEFF;padding:0in 5.4pt 0in 5.4pt;height:10.1pt'> 1,163,722 </td> <td width="84" valign="bottom" style='width:62.7pt;border:none;border-bottom:solid windowtext 1.0pt;background:#CCEEFF;padding:0in 5.4pt 0in 5.4pt;height:10.1pt'> 5,316,621  </td> </tr> <tr style='height:15.0pt'> <td width="152" valign="bottom" style='width:113.7pt;border:none;padding:0in 5.4pt 0in 5.4pt;height:15.0pt'></td> <td width="106" valign="bottom" style='width:79.5pt;border:none;padding:0in 5.4pt 0in 5.4pt;height:15.0pt'></td> <td width="114" valign="bottom" style='width:85.5pt;border:none;padding:0in 5.4pt 0in 5.4pt;height:15.0pt'></td> <td width="96" valign="bottom" style='width:1.0in;border:none;padding:0in 5.4pt 0in 5.4pt;height:15.0pt'></td> <td width="84" valign="bottom" style='width:63.0pt;border:none;padding:0in 5.4pt 0in 5.4pt;height:15.0pt'></td> <td width="84" valign="bottom" style='width:62.7pt;border:none;padding:0in 5.4pt 0in 5.4pt;height:15.0pt'></td> </tr> <tr style='height:15.0pt'> <td width="152" style='width:113.7pt;background:#CCEEFF;padding:0in 5.4pt 0in 5.4pt;height:15.0pt'> Exercise Price </td> <td width="106" style='width:79.5pt;background:#CCEEFF;padding:0in 5.4pt 0in 5.4pt;height:15.0pt'> $    0.78-$3.00  </td> <td width="114" style='width:85.5pt;background:#CCEEFF;padding:0in 5.4pt 0in 5.4pt;height:15.0pt'> $     1.24-$7.59  </td> <td width="96" style='width:1.0in;background:#CCEEFF;padding:0in 5.4pt 0in 5.4pt;height:15.0pt'>               2.00 </td> <td width="84" style='width:63.0pt;background:#CCEEFF;padding:0in 5.4pt 0in 5.4pt;height:15.0pt'> 3.00 </td> <td width="84" style='width:62.7pt;background:#CCEEFF;padding:0in 5.4pt 0in 5.4pt;height:15.0pt'></td> </tr> <tr style='height:48.75pt'> <td width="152" style='width:113.7pt;padding:0in 5.4pt 0in 5.4pt;height:48.75pt'> Expiration Date </td> <td width="106" style='width:79.5pt;padding:0in 5.4pt 0in 5.4pt;height:48.75pt'>  October 2019 to July 2022 </td> <td width="114" style='width:85.5pt;padding:0in 5.4pt 0in 5.4pt;height:48.75pt'> October 2018 to September 2021 </td> <td width="96" style='width:1.0in;padding:0in 5.4pt 0in 5.4pt;height:48.75pt'>  March 2020 to November 2022 </td> <td width="84" style='width:63.0pt;padding:0in 5.4pt 0in 5.4pt;height:48.75pt'>  April 2020 to July 2020 </td> <td width="84" style='width:62.7pt;padding:0in 5.4pt 0in 5.4pt;height:48.75pt'></td> </tr> </table> </div>   *Consultant Warrants as at September 30, 2018 include an aggregate of 188,806 warrants provided to an officer of the Company as compensation while he was not a member of any Company options plan.   ** Subsequent to September 30, 2018, 210,416 warrants expired unexercised.   <p style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:107%;margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:.5in;margin-bottom:.0001pt;text-align:justify;text-justify:inter-ideograph;text-indent:-.25in;line-height:normal;text-autospace:none'>f)        Warrant exercises <p style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:107%;margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:.25in;margin-bottom:.0001pt;text-align:justify;text-justify:inter-ideograph;line-height:normal;text-autospace:none'>  <p style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:107%;margin-bottom:0in;margin-bottom:.0001pt;text-align:justify;text-justify:inter-ideograph;line-height:normal;text-autospace:none'>During the six months ended September 30, 2018, 62,838 warrants were exercised at an average exercise price of approximately $0.7839. The Company received $50,835 of cash proceeds. <p style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:107%;margin-bottom:0in;margin-bottom:.0001pt;text-align:justify;text-justify:inter-ideograph;line-height:normal;text-autospace:none'>  <p style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:107%;margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:.5in;margin-bottom:.0001pt;text-align:justify;text-justify:inter-ideograph;text-indent:-.25in;line-height:normal;text-autospace:none'>g)       Stock-based compensation   <p style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:107%;margin-bottom:0in;margin-bottom:.0001pt;text-align:justify;text-justify:inter-ideograph;line-height:normal;text-autospace:none'>2015 Equity Incentive Plan <p style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:107%;margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:1.0in;margin-bottom:.0001pt;text-align:justify;text-justify:inter-ideograph;line-height:normal;text-autospace:none'>  <p style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:107%;margin-bottom:0in;margin-bottom:.0001pt;text-align:justify;text-justify:inter-ideograph;line-height:normal;text-autospace:none'>On March 30, 2015, iMedical approved its Directors, Officers and Employees Stock Option Plan, under which it authorized and issued 3,000,000 options. This plan was established to enable the iMedical to attract and retain the services of highly qualified and experience directors, officers, employees and consultants and to give such person an interest in the success of the Company. This is a legacy option plan established and utilized prior to the Companys reorganization (see note 7b) Exchange Agreement, above). No other grants will be made under this plan. As of March 31, 2018, there were no outstanding vested options and 137,500 unvested options at an exercise price of $.0001 under this plan.  These legacy options represented the right to purchase shares of the Companys common stock using the same exchange ratio of approximately 1.1969:1; thus there were 164,590 (35,907 had been cancelled) adjusted unvested options as at March 31, 2018. During the six-month period ended September 30, 2018 the remaining 164,590 outstanding options vested and were exercised. <p style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:107%;margin-bottom:0in;margin-bottom:.0001pt;text-align:justify;text-justify:inter-ideograph;line-height:normal;text-autospace:none'>  The following table summarizes the stock option activities of the Company:   <div align="center"> <table border="0" cellspacing="0" cellpadding="0"> <tr align="left"> <td width="395" valign="bottom" style='width:296.15pt;padding:0in .1in 0in .1in'>   </td> <td width="116" valign="bottom" style='width:87.05pt;padding:0in .1in 0in .1in'>   </td> <td width="113" valign="bottom" style='width:84.8pt;padding:0in .1in 0in .1in'>   </td> </tr> <tr align="left"> <td width="395" valign="bottom" style='width:296.15pt;border-top:solid black 1.0pt;border-left:none;border-bottom:solid black 1.0pt;border-right:none;padding:0in .1in 0in .1in'>   </td> <td width="116" valign="bottom" style='width:87.05pt;border-top:solid black 1.0pt;border-left:none;border-bottom:solid black 1.0pt;border-right:none;padding:0in .1in 0in .1in'> Number of options </td> <td width="113" valign="bottom" style='width:84.8pt;border-top:solid black 1.0pt;border-left:none;border-bottom:solid black 1.0pt;border-right:none;padding:0in .1in 0in .1in'> Weighted average exercise price ($) </td> </tr> <tr align="left"> <td width="395" valign="bottom" style='width:296.15pt;border:none;border-top:solid black 1.0pt;background:#CCEEFF;padding:0in .1in 0in .1in'> Granted </td> <td width="116" valign="bottom" style='width:87.05pt;border:none;border-top:solid black 1.0pt;background:#CCEEFF;padding:0in .1in 0in .1in'>           3,591,000  </td> <td width="113" valign="bottom" style='width:84.8pt;border:none;border-top:solid black 1.0pt;background:#CCEEFF;padding:0in .1in 0in .1in'>                0.0001 </td> </tr> <tr align="left"> <td width="395" valign="bottom" style='width:296.15pt;padding:0in .1in 0in .1in'> Exercised </td> <td width="116" valign="bottom" style='width:87.05pt;padding:0in .1in 0in .1in'>         (3,390,503) </td> <td width="113" valign="bottom" style='width:84.8pt;padding:0in .1in 0in .1in'>                0.0001 </td> </tr> <tr align="left"> <td width="395" valign="bottom" style='width:296.15pt;border:none;border-top:solid black 1.0pt;background:#CCEEFF;padding:0in .1in 0in .1in'> Outstanding as of December 31, 2015 </td> <td width="116" valign="bottom" style='width:87.05pt;border:none;border-top:solid black 1.0pt;background:#CCEEFF;padding:0in .1in 0in .1in'>               200,497  </td> <td width="113" valign="bottom" style='width:84.8pt;border:none;border-top:solid black 1.0pt;background:#CCEEFF;padding:0in .1in 0in .1in'>                0.0001 </td> </tr> <tr style='height:3.85pt'> <td width="395" valign="bottom" style='width:296.15pt;border:none;border-bottom:solid windowtext 1.0pt;padding:0in .1in 0in .1in;height:3.85pt'> Cancelled during 2016 </td> <td width="116" valign="bottom" style='width:87.05pt;border:none;border-bottom:solid windowtext 1.0pt;padding:0in .1in 0in .1in;height:3.85pt'>               (35,907) </td> <td width="113" valign="bottom" style='width:84.8pt;border:none;border-bottom:solid windowtext 1.0pt;padding:0in .1in 0in .1in;height:3.85pt'>                0.0001 </td> </tr> <tr align="left"> <td width="395" valign="bottom" style='width:296.15pt;background:#CCEEFF;padding:0in .1in 0in .1in'> Outstanding as of March 31, 2018 </td> <td width="116" valign="bottom" style='width:87.05pt;background:#CCEEFF;padding:0in .1in 0in .1in'>               164,590  </td> <td width="113" valign="bottom" style='width:84.8pt;background:#CCEEFF;padding:0in .1in 0in .1in'>                0.0001 </td> </tr> <tr align="left"> <td width="395" valign="bottom" style='width:296.15pt;padding:0in .1in 0in .1in'> Exercised </td> <td width="116" valign="bottom" style='width:87.05pt;padding:0in .1in 0in .1in'>             (164,590) </td> <td width="113" valign="bottom" style='width:84.8pt;padding:0in .1in 0in .1in'>                0.0001 </td> </tr> <tr align="left"> <td width="395" valign="bottom" style='width:296.15pt;border:none;border-top:solid black 1.0pt;background:#CCEEFF;padding:0in .1in 0in .1in'> Outstanding as of September 30, 2018 </td> <td width="116" valign="bottom" style='width:87.05pt;border:none;border-top:solid black 1.0pt;background:#CCEEFF;padding:0in .1in 0in .1in'>                            -  </td> <td width="113" valign="bottom" style='width:84.8pt;border:none;border-top:solid black 1.0pt;background:#CCEEFF;padding:0in .1in 0in .1in'></td> </tr> </table> </div>   The fair value of options at the issuance date were determined at $2,257,953 which were fully expensed during the twelve months ended December 31, 2015 based on vesting period and were included in general and administrative expenses with corresponding credit to additional paid-in-capital. During the twelve months ended December 31, 2015, 3,390,503 (2,832,500 Pre-exchange Agreement) options were exercised by those employees who met the vesting conditions; 50% of the grants either vest immediately or at the time of U.S. Food and Drug Administration (FDA) filing date and 50% will vest upon Liquidity Trigger.  Liquidity Trigger means the day on which the board of directors resolve in favor of i) the Company is able to raise a certain level of financing; ii) a reverse takeover transaction that results in the Company being a reporting issuer, and iii) initial public offering that results in the Company being a reporting issuer. <p style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:107%;margin-bottom:0in;margin-bottom:.0001pt;text-align:justify;text-justify:inter-ideograph;line-height:normal;text-autospace:none'>  <p style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:107%;margin-bottom:0in;margin-bottom:.0001pt;text-align:justify;text-justify:inter-ideograph;line-height:normal;text-autospace:none'>2016 Equity Incentive Plan   On February 2, 2016, the Board of Directors of the Company approved 2016 Equity Incentive Plan (the Plan). The purpose of the Plan is to advance the interests of the Company and its stockholders by providing an incentive to attract, retain and reward persons performing services for the Company and by motivating such persons to contribute to the growth and profitability of the Company. The Plan seeks to achieve this purpose by providing for awards in the form of options, stock appreciation rights, restricted stock purchase rights, restricted stock bonuses, restricted stock units, performance shares, performance units and other stock-based awards.   <p style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:107%;margin-bottom:0in;margin-bottom:.0001pt;text-align:justify;text-justify:inter-ideograph;line-height:normal;text-autospace:none'>The Plan shall continue in effect until its termination by the board of directors or committee formed by the board; provided, however, that all awards shall be granted, if at all, on or before the day immediately preceding the tenth (10th) anniversary of the effective date. The maximum number of shares of stock that may be issued under the Plan pursuant to awards shall be equal to 3,750,000 shares; provided that the maximum number of shares of stock that may be issued under the Plan shall automatically and without any further Company or shareholder approval, increase on January 1 of each year for not more than 10 years from the effective date, so the number of shares that may be issued is an amount no greater than 15% of the Companys outstanding shares of stock and shares of stock underlying any outstanding exchangeable shares as of such January 1; provided further that no such increase shall be effective if it would violate any applicable law or stock exchange rule or regulation, or result in adverse tax consequences to the Company or any participant that would not otherwise result but for the increase.   <p style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:107%;margin-bottom:0in;margin-bottom:.0001pt;text-align:justify;text-justify:inter-ideograph;line-height:normal;text-autospace:none'>During July 2016, the Company granted an officer options to purchase an aggregate of 2,499,998 shares of common stock at an exercise price of $2.20 subject to a 3 year vesting period, with the fair value of the options being expensed over a 3 year period. Two additional employees were also granted 175,000 options to purchase shares of common stock at an exercise price of $2.24 with a 1 year vesting period, with the fair value of the options being expensed over a 1 year period. One additional employee was also granted 35,000 options to purchase shares of common stock at an exercise price of $2.24 with a 2 year vesting period, with the fair value of the options expensed over a 2 year period. <p style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:107%;margin-bottom:0in;margin-bottom:.0001pt;text-align:justify;text-justify:inter-ideograph;line-height:normal;text-autospace:none'>  <p style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:107%;margin-bottom:0in;margin-bottom:.0001pt;text-align:justify;text-justify:inter-ideograph;line-height:normal;text-autospace:none'>During the year ended March 31, 2018, an additional 1,437,500 stock options were granted with a weighted average remaining contractual life from 2.76 to 9.51 years. <p style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:107%;margin-bottom:0in;margin-bottom:.0001pt;text-align:justify;text-justify:inter-ideograph;line-height:normal;text-autospace:none'>  <p style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:107%;margin-bottom:0in;margin-bottom:.0001pt;text-align:justify;text-justify:inter-ideograph;line-height:normal;text-autospace:none'>During the six months ended September 30, 2018, as part of their approved compensation, the Company granted its non-executive directors options to purchase an aggregate of 62,500 shares of common stock at an exercise price of $2.00, with an aggregate fair value of $31,959, subject to a 1-year vesting period. Six employees were also granted 95,000 options to purchase shares of common stock at exercise prices ranging from $1.40 to $1.84 per share, subject to a 3 year graded vesting period, with fair value of the options of $41,845 being expensed over that respective period. <p style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:107%;margin-bottom:0in;margin-bottom:.0001pt;text-align:justify;text-justify:inter-ideograph;line-height:normal;text-autospace:none'>  <p style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:107%;margin-bottom:0in;margin-bottom:.0001pt;text-align:justify;text-justify:inter-ideograph;line-height:normal;text-autospace:none'>As of September 30, 2018, the cumulative grant-date fair value of the options granted under the Plan was $3,863,813 (September 30, 2017 - $2,372,108). The following table summarizes the stock option activities of the Company: <p style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:107%;margin-bottom:0in;margin-bottom:.0001pt;text-align:justify;text-justify:inter-ideograph;line-height:normal;text-autospace:none'>  <div align="center"> <table border="0" cellspacing="0" cellpadding="0"> <tr align="left"> <td width="395" valign="bottom" style='width:296.15pt;padding:0in .1in 0in .1in'>   </td> <td width="116" valign="bottom" style='width:87.05pt;padding:0in .1in 0in .1in'>   </td> <td width="113" valign="bottom" style='width:84.8pt;padding:0in .1in 0in .1in'>   </td> </tr> <tr align="left"> <td width="395" valign="bottom" style='width:296.15pt;border-top:solid black 1.0pt;border-left:none;border-bottom:solid black 1.0pt;border-right:none;padding:0in .1in 0in .1in'>   </td> <td width="116" valign="bottom" style='width:87.05pt;border-top:solid black 1.0pt;border-left:none;border-bottom:solid black 1.0pt;border-right:none;padding:0in .1in 0in .1in'> Number of options </td> <td width="113" valign="bottom" style='width:84.8pt;border-top:solid black 1.0pt;border-left:none;border-bottom:solid black 1.0pt;border-right:none;padding:0in .1in 0in .1in'> Weighted average exercise price ($) </td> </tr> <tr style='height:8.25pt'> <td width="395" valign="bottom" style='width:296.15pt;border:none;border-top:solid black 1.0pt;background:#CCEEFF;padding:0in .1in 0in .1in;height:8.25pt'> Granted </td> <td width="116" valign="bottom" style='width:87.05pt;border:none;border-top:solid black 1.0pt;background:#CCEEFF;padding:0in .1in 0in .1in;height:8.25pt'>            4,147,498 </td> <td width="113" valign="bottom" style='width:84.8pt;border:none;border-top:solid black 1.0pt;background:#CCEEFF;padding:0in .1in 0in .1in;height:8.25pt'>                3.2306 </td> </tr> <tr align="left"> <td width="395" valign="bottom" style='width:296.15pt;padding:0in .1in 0in .1in'> Exercised </td> <td width="116" valign="bottom" style='width:87.05pt;padding:0in .1in 0in .1in'>                             - </td> <td width="113" valign="bottom" style='width:84.8pt;padding:0in .1in 0in .1in'>                            - </td> </tr> <tr align="left"> <td width="395" valign="bottom" style='width:296.15pt;border-top:solid black 1.0pt;border-left:none;border-bottom:solid black 1.0pt;border-right:none;background:#CCEEFF;padding:0in .1in 0in .1in'> Outstanding as of June 30 and March 31, 2018 </td> <td width="116" valign="bottom" style='width:87.05pt;border-top:solid black 1.0pt;border-left:none;border-bottom:solid black 1.0pt;border-right:none;background:#CCEEFF;padding:0in .1in 0in .1in'>            4,147,498 </td> <td width="113" valign="bottom" style='width:84.8pt;border-top:solid black 1.0pt;border-left:none;border-bottom:solid black 1.0pt;border-right:none;background:#CCEEFF;padding:0in .1in 0in .1in'>                1.8337 </td> </tr> <tr align="left"> <td width="395" valign="bottom" style='width:296.15pt;border:none;border-top:solid black 1.0pt;background:#CCEEFF;padding:0in .1in 0in .1in'> Granted </td> <td width="116" valign="bottom" style='width:87.05pt;border:none;border-top:solid black 1.0pt;background:#CCEEFF;padding:0in .1in 0in .1in'>               157,500 </td> <td width="113" valign="bottom" style='width:84.8pt;border:none;border-top:solid black 1.0pt;background:#CCEEFF;padding:0in .1in 0in .1in'>                3.2306 </td> </tr> <tr align="left"> <td width="395" valign="bottom" style='width:296.15pt;padding:0in .1in 0in .1in'> Exercised </td> <td width="116" valign="bottom" style='width:87.05pt;padding:0in .1in 0in .1in'>                             - </td> <td width="113" valign="bottom" style='width:84.8pt;padding:0in .1in 0in .1in'>                            - </td> </tr> <tr align="left"> <td width="395" valign="bottom" style='width:296.15pt;border-top:solid black 1.0pt;border-left:none;border-bottom:solid black 1.0pt;border-right:none;background:#CCEEFF;padding:0in .1in 0in .1in'> Outstanding as of September 30, 2018 </td> <td width="116" valign="bottom" style='width:87.05pt;border-top:solid black 1.0pt;border-left:none;border-bottom:solid black 1.0pt;border-right:none;background:#CCEEFF;padding:0in .1in 0in .1in'>            4,304,998 </td> <td width="113" valign="bottom" style='width:84.8pt;border-top:solid black 1.0pt;border-left:none;border-bottom:solid black 1.0pt;border-right:none;background:#CCEEFF;padding:0in .1in 0in .1in'>                3.1795 </td> </tr> </table> </div>     <p style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:107%;margin-bottom:0in;margin-bottom:.0001pt;text-align:justify;text-justify:inter-ideograph;line-height:normal;text-autospace:none'>During the six months ended September 30, 2018, the Company recorded stock based compensation of $728,163 in connection with the 2016 equity incentive plan (September 30, 2017 $442,155) under general and administrative expenses with a corresponding credit to additional paid in capital. <p style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:107%;margin-bottom:0in;margin-bottom:.0001pt;text-align:justify;text-justify:inter-ideograph;line-height:normal;text-autospace:none'>  The fair value of each option granted is estimated at the time of grant using multi-nomial lattice model using the following assumptions:   <div align="center"> <table border="0" cellspacing="0" cellpadding="0" width="635" style='width:476.1pt;border-collapse:collapse'> <tr style='height:13.5pt'> <td width="236" valign="bottom" style='width:176.75pt;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:13.5pt'>   </td> <td width="134" valign="top" style='width:100.35pt;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:13.5pt'> 2017-2018 </td> <td width="134" valign="bottom" style='width:100.35pt;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:13.5pt'> 2016-2017 </td> <td width="132" valign="bottom" style='width:98.65pt;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:13.5pt'> 2015-2016 </td> </tr> <tr style='height:13.5pt'> <td width="236" valign="bottom" style='width:176.75pt;border:none;background:#CCEEFF;padding:0in 5.4pt 0in 5.4pt;height:13.5pt'> Exercise price ($) </td> <td width="134" valign="top" style='width:100.35pt;border:none;background:#CCEEFF;padding:0in 5.4pt 0in 5.4pt;height:13.5pt'> 1.24-7.59 </td> <td width="134" valign="bottom" style='width:100.35pt;border:none;background:#CCEEFF;padding:0in 5.4pt 0in 5.4pt;height:13.5pt'> 2.00 2.58 </td> <td width="132" valign="bottom" style='width:98.65pt;border:none;background:#CCEEFF;padding:0in 5.4pt 0in 5.4pt;height:13.5pt'> 0.0001   </td> </tr> <tr style='height:13.5pt'> <td width="236" valign="bottom" style='width:176.75pt;padding:0in 5.4pt 0in 5.4pt;height:13.5pt'> Risk free interest rate (%) </td> <td width="134" valign="top" style='width:100.35pt;padding:0in 5.4pt 0in 5.4pt;height:13.5pt'> 1.98-2.81 </td> <td width="134" valign="bottom" style='width:100.35pt;padding:0in 5.4pt 0in 5.4pt;height:13.5pt'> 0.45 - 1.47 </td> <td width="132" valign="bottom" style='width:98.65pt;padding:0in 5.4pt 0in 5.4pt;height:13.5pt'> 0.04 - 1.07 </td> </tr> <tr style='height:13.5pt'> <td width="236" valign="bottom" style='width:176.75pt;background:#CCEEFF;padding:0in 5.4pt 0in 5.4pt;height:13.5pt'> Expected term (Years) </td> <td width="134" valign="top" style='width:100.35pt;background:#CCEEFF;padding:0in 5.4pt 0in 5.4pt;height:13.5pt'> 3.0 </td> <td width="134" valign="bottom" style='width:100.35pt;background:#CCEEFF;padding:0in 5.4pt 0in 5.4pt;height:13.5pt'> 1.0 - 3.0 </td> <td width="132" valign="bottom" style='width:98.65pt;background:#CCEEFF;padding:0in 5.4pt 0in 5.4pt;height:13.5pt'> 10.0 </td> </tr> <tr style='height:13.5pt'> <td width="236" valign="bottom" style='width:176.75pt;padding:0in 5.4pt 0in 5.4pt;height:13.5pt'> Expected volatility (%) </td> <td width="134" valign="top" style='width:100.35pt;padding:0in 5.4pt 0in 5.4pt;height:13.5pt'> 97.8-145.99 </td> <td width="134" valign="bottom" style='width:100.35pt;padding:0in 5.4pt 0in 5.4pt;height:13.5pt'> 101 105 </td> <td width="132" valign="bottom" style='width:98.65pt;padding:0in 5.4pt 0in 5.4pt;height:13.5pt'> 94 </td> </tr> <tr style='height:13.5pt'> <td width="236" valign="bottom" style='width:176.75pt;background:#CCEEFF;padding:0in 5.4pt 0in 5.4pt;height:13.5pt'> Expected dividend yield (%) </td> <td width="134" valign="top" style='width:100.35pt;background:#CCEEFF;padding:0in 5.4pt 0in 5.4pt;height:13.5pt'> 0.00 </td> <td width="134" valign="bottom" style='width:100.35pt;background:#CCEEFF;padding:0in 5.4pt 0in 5.4pt;height:13.5pt'> 0.00 </td> <td width="132" valign="bottom" style='width:98.65pt;background:#CCEEFF;padding:0in 5.4pt 0in 5.4pt;height:13.5pt'> 0.00 </td> </tr> <tr style='height:13.5pt'> <td width="236" valign="bottom" style='width:176.75pt;padding:0in 5.4pt 0in 5.4pt;height:13.5pt'> Fair value of option ($) </td> <td width="134" valign="top" style='width:100.35pt;padding:0in 5.4pt 0in 5.4pt;height:13.5pt'> 1.032 </td> <td width="134" valign="bottom" style='width:100.35pt;padding:0in 5.4pt 0in 5.4pt;height:13.5pt'> 0.88 </td> <td width="132" valign="bottom" style='width:98.65pt;padding:0in 5.4pt 0in 5.4pt;height:13.5pt'> 0.74 </td> </tr> <tr style='height:13.5pt'> <td width="236" valign="bottom" style='width:176.75pt;background:#CCEEFF;padding:0in 5.4pt 0in 5.4pt;height:13.5pt'> Expected forfeiture (attrition) rate (%) </td> <td width="134" valign="top" style='width:100.35pt;background:#CCEEFF;padding:0in 5.4pt 0in 5.4pt;height:13.5pt'> 0.00 </td> <td width="134" valign="bottom" style='width:100.35pt;background:#CCEEFF;padding:0in 5.4pt 0in 5.4pt;height:13.5pt'> 0.00 5.00 </td> <td width="132" valign="bottom" style='width:98.65pt;background:#CCEEFF;padding:0in 5.4pt 0in 5.4pt;height:13.5pt'> 5.00 - 20.00 </td> </tr> </table> </div>

<p style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:107%;margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:.25in;margin-bottom:.0001pt;text-align:justify;text-justify:inter-ideograph;text-indent:-.25in;line-height:normal'>8. RELATED PARTY TRANSACTIONS AND BALANCES <p style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:107%;margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:.25in;margin-bottom:.0001pt;text-align:justify;text-justify:inter-ideograph;text-indent:-.25in;line-height:normal'>  The Companys transactions with related parties were carried out on normal commercial terms and in the course of the Companys business. Other than those disclosed elsewhere in the financial statements, related party transactions are as follows: <div align="center"> <table border="0" cellspacing="0" cellpadding="0" width="622" style='width:466.35pt;border-collapse:collapse'> <tr style='height:12.05pt'> <td width="387" valign="bottom" style='width:290.6pt;padding:0in 5.4pt 0in 5.4pt;height:12.05pt'></td> <td width="123" valign="bottom" style='width:92.15pt;padding:0in 5.4pt 0in 5.4pt;height:12.05pt'></td> <td width="111" valign="bottom" style='width:83.6pt;padding:0in 5.4pt 0in 5.4pt;height:12.05pt'></td> </tr> </table> </div>   <div align="center"> <table border="0" cellspacing="0" cellpadding="0" width="651" style='width:488.2pt;border-collapse:collapse'> <tr style='height:9.1pt'> <td width="258" valign="bottom" style='width:193.55pt;padding:0in 5.4pt 0in 5.4pt;height:9.1pt'></td> <td width="164" colspan="2" valign="bottom" style='width:123.35pt;padding:0in 5.4pt 0in 5.4pt;height:9.1pt'></td> <td width="68" colspan="2" valign="bottom" style='width:51.0pt;padding:0in 5.4pt 0in 5.4pt;height:9.1pt'></td> <td width="160" colspan="2" style='border:none;border-bottom:solid windowtext 1.0pt'> </td> </tr> <tr style='height:27.5pt'> <td width="258" valign="bottom" style='width:193.55pt;border:none;border-top:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:27.5pt'>   </td> <td width="113" valign="bottom" style='width:84.8pt;border:none;border-top:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:27.5pt'> Three Months Ended September 30, 2018 </td> <td width="111" colspan="2" valign="bottom" style='width:82.9pt;border:none;border-top:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:27.5pt'> Three Months Ended September 30, 2017 </td> <td width="81" colspan="2" valign="bottom" style='width:60.7pt;border:none;border-top:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:27.5pt'> Six Months Ended September 30, 2018 </td> <td width="88" valign="bottom" style='width:66.25pt;border:none;padding:0in 5.4pt 0in 5.4pt;height:27.5pt'> Six Months Ended September 30, 2017 </td> </tr> <tr style='height:8.7pt'> <td width="258" valign="bottom" style='width:193.55pt;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:8.7pt'>   </td> <td width="113" valign="bottom" style='width:84.8pt;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:8.7pt'>  $ </td> <td width="111" colspan="2" valign="bottom" style='width:82.9pt;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:8.7pt'>  $ </td> <td width="81" colspan="2" valign="bottom" style='width:60.7pt;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:8.7pt'> $ </td> <td width="88" valign="bottom" style='width:66.25pt;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:8.7pt'> $ </td> </tr> <tr style='height:8.7pt'> <td width="258" valign="bottom" style='width:193.55pt;border:none;border-bottom:solid windowtext 1.0pt;background:#CCEEFF;padding:0in 5.4pt 0in 5.4pt;height:8.7pt'> Salary and allowance** </td> <td width="113" valign="bottom" style='width:84.8pt;border:none;border-bottom:solid windowtext 1.0pt;background:#CCEEFF;padding:0in 5.4pt 0in 5.4pt;height:8.7pt'> 181,887 </td> <td width="111" colspan="2" valign="bottom" style='width:82.9pt;border:none;border-bottom:solid windowtext 1.0pt;background:#CCEEFF;padding:0in 5.4pt 0in 5.4pt;height:8.7pt'>               120,052 </td> <td width="81" colspan="2" valign="bottom" style='width:60.7pt;border:none;border-bottom:solid windowtext 1.0pt;background:#CCEEFF;padding:0in 5.4pt 0in 5.4pt;height:8.7pt'> 363,773 </td> <td width="88" valign="bottom" style='width:66.25pt;border:none;border-bottom:solid windowtext 1.0pt;background:#CCEEFF;padding:0in 5.4pt 0in 5.4pt;height:8.7pt'> 270,104 </td> </tr> <tr style='height:8.7pt'> <td width="258" valign="bottom" style='width:193.55pt;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:8.7pt'> Stock based compensation*** </td> <td width="113" valign="bottom" style='width:84.8pt;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:8.7pt'> 421,028 </td> <td width="111" colspan="2" valign="bottom" style='width:82.9pt;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:8.7pt'>               183,981 </td> <td width="81" colspan="2" valign="bottom" style='width:60.7pt;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:8.7pt'> 744,168 </td> <td width="88" valign="bottom" style='width:66.25pt;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:8.7pt'> 374,472 </td> </tr> <tr style='height:9.1pt'> <td width="258" valign="bottom" style='width:193.55pt;border:none;border-bottom:solid windowtext 1.0pt;background:#CCEEFF;padding:0in 5.4pt 0in 5.4pt;height:9.1pt'> Total </td> <td width="113" valign="bottom" style='width:84.8pt;border:none;border-bottom:solid windowtext 1.0pt;background:#CCEEFF;padding:0in 5.4pt 0in 5.4pt;height:9.1pt'> 602,915 </td> <td width="111" colspan="2" valign="bottom" style='width:82.9pt;border:none;border-bottom:solid windowtext 1.0pt;background:#CCEEFF;padding:0in 5.4pt 0in 5.4pt;height:9.1pt'>               304,033 </td> <td width="81" colspan="2" valign="bottom" style='width:60.7pt;border:none;border-bottom:solid windowtext 1.0pt;background:#CCEEFF;padding:0in 5.4pt 0in 5.4pt;height:9.1pt'> 1,107,941 </td> <td width="88" valign="bottom" style='width:66.25pt;border:none;border-bottom:solid windowtext 1.0pt;background:#CCEEFF;padding:0in 5.4pt 0in 5.4pt;height:9.1pt'> 644,576 </td> </tr> <tr align="left"> <td width="258" style='border:none'></td> <td width="113" style='border:none'></td> <td width="51" style='border:none'></td> <td width="59" style='border:none'></td> <td width="9" style='border:none'></td> <td width="72" style='border:none'></td> <td width="88" style='border:none'></td> </tr> </table> </div>   The above expenses were recorded under general and administrative expenses.   * Salary and allowance include salary, car allowance, vacation pay, bonus and other allowances paid or payable to key management of the Company. ** Stock based compensation represent the fair value of the options, warrants and equity incentive plan for directors and key management of the Company.

<p style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:107%;margin-bottom:0in;margin-bottom:.0001pt;text-align:justify;text-justify:inter-ideograph;line-height:normal;text-autospace:none'>10. SUBSEQUENT EVENTS <p style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:107%;margin-bottom:0in;margin-bottom:.0001pt;text-align:justify;text-justify:inter-ideograph;line-height:normal;text-autospace:none'>  <p style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:107%;margin-bottom:0in;margin-bottom:.0001pt;text-align:justify;text-justify:inter-ideograph;line-height:normal;text-autospace:none'>The Companys management has evaluated subsequent events up to November 14, 2018, the date the condensed consolidated financial statements were issued, pursuant to the requirements of ASC 855 and has determined the following material subsequent events: <p style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:107%;margin-bottom:0in;margin-bottom:.0001pt;text-align:justify;text-justify:inter-ideograph;line-height:normal;text-autospace:none'>  <p style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:107%;margin-bottom:0in;margin-bottom:.0001pt;text-align:justify;text-justify:inter-ideograph;line-height:normal;text-autospace:none'>During the period of October 1, 2018 through November 13, 2018, the Company issued an aggregate of 534,894 common shares under its common share finance facility with a private equity firm (the Investor). The size and purchase price for each drawdown is governed by the purchase facilities agreement and is predicated on trading volumes as well as the average trading and closing prices of the common stock on the day of drawdown and the prior ten (10) trading days, such that the purchase price is always fixed and known at the time the Company elects to sell shares to the Investor. <p style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:107%;margin-bottom:0in;margin-bottom:.0001pt;text-align:justify;text-justify:inter-ideograph;line-height:normal;text-autospace:none'>  During this same period, shareholders holding 856,576 exchangeable shares with voting rights and other attributes corresponding to the Companys common stock (but with the additional right to cashlessly exchange on a one-for-one basis into common stock) retracted and exchanged their exchangeable shares for the corresponding number of shares of common stock.   During July 2018, the Board of Directors of the company adopted a new compensation program for directors which includes cash compensation for the current fiscal year of $24,000, equity compensation for the current fiscal year to include 31,250 shares of the Companys common stock and 31,250 options to purchase shares of the Companys common stock at $2.00 per share, such options to vest and be fully exercisable upon the first anniversary from the date upon which a director was named to the Board. On November 4, 2018, the Company increased the size of its Board to 4 Directors and immediately filled the vacancy by appointing a new Director, , who will be compensated using this same compensation program.

Revenue Recognition   The Company has adopted the Financial Accounting Standards Boards (FASB) Accounting Standards Codification (ASC) Topic 606.   The Bioflux mobile cardiac telemetry device, a wearable device, is worn by patients for a monitoring period up to 30 days. The cardiac data that the device monitors and collects is curated and analyzed by the Companys proprietary algorithms and then securely communicated to a remote monitoring facility for electronic reporting and conveyance to the patients prescribing physician or other certified cardiac medical professional. The device, together with its licensed software, is available for sale to the medical center or physician, who is responsible for the delivery of clinical diagnosis and therapy. The remote monitoring, data collection and reporting services performed by the technology culminate in a patient study that is generally billable when it is complete and is issued to the physician. In order to recognize revenue, management considers whether or not the following criteria are met: persuasive evidence of a commercial arrangement exists, and delivery has occurred or services have been rendered. For sales of devices, which are invoiced directly, additional revenue recognition criteria include that the price is fixed and determinable and collectability is reasonably assured; for revenue that is earned based on customer usage of the proprietary software to render a patients cardiac study, the Company recognizes revenue when the study ends based on a fixed billing rate. Costs associated with providing the services are recorded as the service is provided regardless of whether or when revenue is recognized.

Use of Estimates   The preparation of the condensed consolidated financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Areas involving significant estimates and assumptions include: allowance for doubtful accounts, valuation of inventory, deferred income tax assets and related valuation allowance, accruals and valuation of derivatives, convertible promissory notes, stock options and warrants, as well as assumptions used by management in its assessment of liquidity. Actual results could differ from those estimates. These estimates are reviewed periodically, and, as adjustments become necessary, they are reported in earnings in the period in which they become known.

Earnings (Loss) Per Share   The Company has adopted the Financial Accounting Standards Boards (FASB) Accounting Standards Codification (ASC) Topic 260-10 which provides for calculation of basic and diluted earnings per share. Basic earnings per share includes no dilution and is computed by dividing net income or loss available to common stockholders by the weighted average number of common shares outstanding for the period. Diluted earnings per share reflect the potential dilution of securities that could share in the earnings of an entity. Diluted earnings per share exclude all potentially dilutive shares if their effect is anti-dilutive. There were no potentially dilutive shares outstanding as at September 30, 2018 and 2017.

Accounts Receivable   Accounts receivable consists of amounts due to the Company from medical facilities, which receive reimbursement from institutions and third-party government and commercial payors and their related patients, as a result of the Companys normal business activities. Accounts receivable is reported on the balance sheets net of an estimated allowance for doubtful accounts. The Company establishes an allowance for doubtful accounts for estimated uncollectible receivables based on historical experience, assessment of specific risk, review of outstanding invoices, and various assumptions and estimates that are believed to be reasonable under the circumstances, and recognizes the provision as a component of selling, general and administrative expenses. Uncollectible accounts are written off against the allowance after appropriate collection efforts have been exhausted and when it is deemed that a balance is uncollectible.

Research and Development   Research and development costs, which relate primarily to product and software development, are charged to operations as incurred. Under certain research and development arrangements with third parties, the Company may be required to make payments that are contingent on the achievement of specific developmental, regulatory and/or commercial milestones. Before a product receives regulatory approval, milestone payments made to third parties are expensed when the milestone is achieved. Milestone payments made to third parties after regulatory approval is received are capitalized and amortized over the estimated useful life of the approved product.

Convertible Notes Payable and Derivative Instruments <p style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:107%;margin-bottom:0in;margin-bottom:.0001pt;text-align:justify;text-justify:inter-ideograph;text-indent:.5in;line-height:normal'>  The Company has adopted the provisions of ASU 2017-11, which addresses the accounting for (I) certain financial instruments with down round features and (II) replacement of the indefinite deferral for mandatorily redeemable financial instruments of certain nonpublic entities and certain mandatorily redeemable non-controlling interests with a scope exception. The main provisions of Part I of ASU 2017-11 change the classification analysis of certain equity-linked financial instruments (or embedded features) with down round features. When determining whether certain financial instruments should be classified as liabilities or equity instruments, a down round feature no longer precludes equity classification when assessing whether the instrument is indexed to an entitys own stock. The amendments also clarify existing disclosure requirements for equity-classified instruments. As a result, a freestanding equity-linked financial instrument (or embedded conversion option) no longer would be accounted for as a derivative liability at fair value as a result of the existence of a down round feature. For freestanding equity classified financial instruments, the amendments require entities that present earnings per share (EPS) to recognize the effect of the down round feature when it is triggered. That effect is treated as a dividend and as a reduction of income available to common shareholders in basic EPS. Under previous US GAAP, warrants with a down round feature are not being considered indexed to the entitys own stock, which results in classification of the warrant as a derivative liability. Under ASU 2017-11, the down round feature qualifies for a scope exception from derivative treatment. ASU 2017-11 is effective for public companies as of December 15, 2018 and interim periods within that fiscal year. Early adoption is permitted, including adoption in an interim period, with adjustments reflected as of the beginning of the fiscal year. The Company has issued financial instruments with down round features. The Company opted to adopt ASU 2017-11 in its three-month interim period ended September 30, 2017, which is effective from April 1, 2017, with adjustments reflected in the accumulated deficit of stockholders deficiency as of April 1, 2017. Please refer to Note 6. <p style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:107%;margin-bottom:0in;margin-bottom:.0001pt;text-align:justify;text-justify:inter-ideograph;text-indent:.5in;line-height:normal'>

Recently Issued Accounting Pronouncements   In June 2018, the FASB issued an accounting pronouncement (FASB ASU 2018-07) to expand the scope of ASC Topic 718, Compensation - Stock Compensation, to include share-based payment transactions for acquiring goods and services from nonemployees. The pronouncement is effective for fiscal years, and for interim periods within those fiscal years, beginning after December 15, 2018, with early adoption permitted. We are currently in the process of evaluating the effects of this pronouncement on our consolidated financial statements, including potential early adoption.   On April 1, 2018, the Company adopted the accounting pronouncement issued by the Financial Accounting Standards Board (FASB) to clarify existing guidance on revenue recognition. This guidance includes the required steps to achieve the core principle that a company should recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. The Company adopted this pronouncement on a modified retrospective basis.   On January 1, 2018, the Company adopted the accounting pronouncement issued by the FASB to clarify how entities should present restricted cash and restricted cash equivalents in the statement of cash flows. This guidance requires entities to show changes in the total of cash, cash equivalents and restricted cash in the combined statement of cash flows. This guidance was adopted on a retrospective basis, and such adoption did not have a material impact on combined financial position and/or results of operations.

<div align="center"> <table border="0" cellspacing="0" cellpadding="0" width="376" style='width:282.0pt;border-collapse:collapse'> <tr style='height:24.75pt'> <td width="175" valign="top" style='width:131.5pt;border:none;border-top:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:24.75pt'>   </td> <td width="94" valign="top" style='width:70.25pt;border:none;border-top:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:24.75pt'>  As at September 30, 2018 </td> <td width="107" valign="top" style='width:80.25pt;border:none;border-top:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:24.75pt'>  As at March 31, 2018 </td> </tr> <tr style='height:12.75pt'> <td width="175" valign="top" style='width:131.5pt;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.75pt'></td> <td width="94" valign="top" style='width:70.25pt;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.75pt'>  $ </td> <td width="107" valign="top" style='width:80.25pt;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.75pt'>  $ </td> </tr> <tr style='height:10.3pt'> <td width="175" style='width:131.5pt;border:none;background:#CCEEFF;padding:0in 5.4pt 0in 5.4pt;height:10.3pt'> Accounts payable </td> <td width="94" valign="bottom" style='width:70.25pt;border:none;background:#CCEEFF;padding:0in 5.4pt 0in 5.4pt;height:10.3pt'>         817,171 </td> <td width="107" valign="bottom" style='width:80.25pt;border:none;background:#CCEEFF;padding:0in 5.4pt 0in 5.4pt;height:10.3pt'>              547,858 </td> </tr> <tr style='height:3.85pt'> <td width="175" style='width:131.5pt;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:3.85pt'> Accrued liabilities </td> <td width="94" valign="bottom" style='width:70.25pt;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:3.85pt'>         230,725 </td> <td width="107" valign="bottom" style='width:80.25pt;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:3.85pt'>              208,321 </td> </tr> <tr style='height:13.5pt'> <td width="175" style='width:131.5pt;border:none;border-bottom:solid windowtext 1.0pt;background:#CCEEFF;padding:0in 5.4pt 0in 5.4pt;height:13.5pt'>   </td> <td width="94" style='width:70.25pt;border:none;border-bottom:solid windowtext 1.0pt;background:#CCEEFF;padding:0in 5.4pt 0in 5.4pt;height:13.5pt'>      1,047,896 </td> <td width="107" style='width:80.25pt;border:none;border-bottom:solid windowtext 1.0pt;background:#CCEEFF;padding:0in 5.4pt 0in 5.4pt;height:13.5pt'>              756,179 </td> </tr> </table> </div>

<p style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:107%;margin-bottom:0in;margin-bottom:.0001pt;text-align:justify;text-justify:inter-ideograph;line-height:normal;text-autospace:none'>  <div align="center"> <table border="0" cellspacing="0" cellpadding="0" width="621" style='width:466.05pt;border-collapse:collapse'> <tr style='height:10.5pt'> <td width="507" style='width:380.55pt;border-top:solid windowtext 1.0pt;border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;padding:0in 5.4pt 0in 5.4pt;height:10.5pt'>   </td> <td width="114" style='width:85.5pt;border-top:solid windowtext 1.0pt;border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;padding:0in 5.4pt 0in 5.4pt;height:10.5pt'> $ </td> </tr> <tr style='height:10.5pt'> <td width="507" style='width:380.55pt;border:none;background:#CCEEFF;padding:0in 5.4pt 0in 5.4pt;height:10.5pt'> Accreted value of convertible promissory notes as at December 31, 2015 </td> <td width="114" style='width:85.5pt;border:none;background:#CCEEFF;padding:0in 5.4pt 0in 5.4pt;height:10.5pt'>           783,778  </td> </tr> <tr style='height:10.5pt'> <td width="507" style='width:380.55pt;padding:0in 5.4pt 0in 5.4pt;height:10.5pt'> Face value of convertible promissory notes issued during March 2016 </td> <td width="114" style='width:85.5pt;padding:0in 5.4pt 0in 5.4pt;height:10.5pt'>            175,000  </td> </tr> <tr style='height:10.5pt'> <td width="507" style='width:380.55pt;background:#CCEEFF;padding:0in 5.4pt 0in 5.4pt;height:10.5pt'> Discount recognized at issuance due to embedded derivatives </td> <td width="114" style='width:85.5pt;background:#CCEEFF;padding:0in 5.4pt 0in 5.4pt;height:10.5pt'>            (74,855) </td> </tr> <tr style='height:10.5pt'> <td width="507" style='width:380.55pt;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:10.5pt'> Accretion expense for three months March 31, 2016 </td> <td width="114" style='width:85.5pt;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:10.5pt'>              73,572  </td> </tr> <tr style='height:10.5pt'> <td width="507" style='width:380.55pt;border:none;background:#CCEEFF;padding:0in 5.4pt 0in 5.4pt;height:10.5pt'> Accreted value of convertible promissory notes as at March 31, 2016 </td> <td width="114" style='width:85.5pt;border:none;background:#CCEEFF;padding:0in 5.4pt 0in 5.4pt;height:10.5pt'>            957,495  </td> </tr> <tr style='height:10.5pt'> <td width="507" valign="bottom" style='width:380.55pt;padding:0in 5.4pt 0in 5.4pt;height:10.5pt'> Accretion expense - including loss on conversion of $88,530 </td> <td width="114" valign="bottom" style='width:85.5pt;padding:0in 5.4pt 0in 5.4pt;height:10.5pt'>            411,483  </td> </tr> <tr style='height:10.5pt'> <td width="507" valign="bottom" style='width:380.55pt;border:none;border-bottom:solid windowtext 1.0pt;background:#CCEEFF;padding:0in 5.4pt 0in 5.4pt;height:10.5pt'> Conversion of the notes transferred to equity </td> <td width="114" valign="bottom" style='width:85.5pt;border:none;border-bottom:solid windowtext 1.0pt;background:#CCEEFF;padding:0in 5.4pt 0in 5.4pt;height:10.5pt'>     (1,368,978) </td> </tr> <tr style='height:10.5pt'> <td width="507" style='width:380.55pt;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:10.5pt'> Accreted value of convertible promissory notes at September 30, 2018 and March 31, 2018 </td> <td width="114" valign="bottom" style='width:85.5pt;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:10.5pt'>                         -  </td> </tr> </table> </div>

<p style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:107%;margin-bottom:0in;margin-bottom:.0001pt;text-align:justify;text-justify:inter-ideograph;line-height:normal;text-autospace:none'>  <div align="center"> <table border="0" cellspacing="0" cellpadding="0" width="348" style='width:261.0pt;border-collapse:collapse'> <tr style='height:10.1pt'> <td width="256" style='width:192.2pt;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:10.1pt'> As at March 31, 2017 </td> <td width="92" style='width:68.8pt;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:10.1pt'> $ </td> </tr> <tr style='height:10.1pt'> <td width="256" style='width:192.2pt;border:none;background:#CCEEFF;padding:0in 5.4pt 0in 5.4pt;height:10.1pt'> Face value of Bridge Notes issued </td> <td width="92" style='width:68.8pt;border:none;background:#CCEEFF;padding:0in 5.4pt 0in 5.4pt;height:10.1pt'>       2,455,000  </td> </tr> <tr style='height:10.1pt'> <td width="256" style='width:192.2pt;padding:0in 5.4pt 0in 5.4pt;height:10.1pt'> Day one derivative loss recognized during the year </td> <td width="92" style='width:68.8pt;padding:0in 5.4pt 0in 5.4pt;height:10.1pt'>             35,249  </td> </tr> <tr style='height:10.1pt'> <td width="256" style='width:192.2pt;background:#CCEEFF;padding:0in 5.4pt 0in 5.4pt;height:10.1pt'> Discount recognized at issuance due to embedded derivatives </td> <td width="92" style='width:68.8pt;background:#CCEEFF;padding:0in 5.4pt 0in 5.4pt;height:10.1pt'>      (1,389,256) </td> </tr> <tr style='height:10.1pt'> <td width="256" style='width:192.2pt;padding:0in 5.4pt 0in 5.4pt;height:10.1pt'> Cash financing costs </td> <td width="92" style='width:68.8pt;padding:0in 5.4pt 0in 5.4pt;height:10.1pt'>         (174,800) </td> </tr> <tr style='height:10.1pt'> <td width="256" style='width:192.2pt;border:none;border-bottom:solid windowtext 1.0pt;background:#CCEEFF;padding:0in 5.4pt 0in 5.4pt;height:10.1pt'> Accretion expense </td> <td width="92" style='width:68.8pt;border:none;border-bottom:solid windowtext 1.0pt;background:#CCEEFF;padding:0in 5.4pt 0in 5.4pt;height:10.1pt'>           630,797  </td> </tr> <tr style='height:10.1pt'> <td width="256" style='width:192.2pt;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:10.1pt'> Accreted value of Bridge Notes </td> <td width="92" style='width:68.8pt;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:10.1pt'>        1,556,990  </td> </tr> </table> </div>

<p style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:107%;margin-bottom:0in;margin-bottom:.0001pt;text-align:justify;text-justify:inter-ideograph;line-height:normal;text-autospace:none'>  <div align="center"> <table border="0" cellspacing="0" cellpadding="0" width="437" style='width:327.95pt;border-collapse:collapse'> <tr style='height:10.1pt'> <td width="364" valign="bottom" style='width:273.3pt;border-top:solid windowtext 1.0pt;border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;padding:0in 5.4pt 0in 5.4pt;height:10.1pt'> <p style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:107%;margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:9.75pt;margin-bottom:.0001pt;line-height:normal'>  </td> <td width="73" valign="bottom" style='width:54.65pt;border-top:solid windowtext 1.0pt;border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;padding:0in 5.4pt 0in 5.4pt;height:10.1pt'> $ </td> </tr> <tr style='height:10.1pt'> <td width="364" valign="bottom" style='width:273.3pt;border:none;background:#CCEEFF;padding:0in 5.4pt 0in 5.4pt;height:10.1pt'> <p style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:107%;margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:1.5pt;margin-bottom:.0001pt;line-height:normal'>Accreted value of Bridge Note as of March 31, 2017 </td> <td width="73" valign="bottom" style='width:54.65pt;border:none;background:#CCEEFF;padding:0in 5.4pt 0in 5.4pt;height:10.1pt'>   1,556,990  </td> </tr> <tr style='height:10.1pt'> <td width="364" valign="bottom" style='width:273.3pt;padding:0in 5.4pt 0in 5.4pt;height:10.1pt'> <p style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:107%;margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:1.5pt;margin-bottom:.0001pt;line-height:normal'>Accretion expense </td> <td width="73" valign="bottom" style='width:54.65pt;padding:0in 5.4pt 0in 5.4pt;height:10.1pt'>      879,416  </td> </tr> <tr style='height:10.1pt'> <td width="364" valign="bottom" style='width:273.3pt;border:none;border-bottom:solid windowtext 1.0pt;background:#CCEEFF;padding:0in 5.4pt 0in 5.4pt;height:10.1pt'> <p style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:107%;margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:1.5pt;margin-bottom:.0001pt;line-height:normal'>Conversion of Bridge Notes transferred to equity (Note 7, c) </td> <td width="73" valign="bottom" style='width:54.65pt;border:none;border-bottom:solid windowtext 1.0pt;background:#CCEEFF;padding:0in 5.4pt 0in 5.4pt;height:10.1pt'> (2,436,406) </td> </tr> <tr style='height:10.1pt'> <td width="364" valign="bottom" style='width:273.3pt;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:10.1pt'> <p style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:107%;margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:1.5pt;margin-bottom:.0001pt;line-height:normal'>Face value of Bridge Notes as of September 30, 2018 and March 31, 2018 </td> <td width="73" valign="bottom" style='width:54.65pt;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:10.1pt'>                   -  </td> </tr> </table> </div>

<div align="center"> <table border="0" cellspacing="0" cellpadding="0" width="613" style='width:459.9pt;border-collapse:collapse'> <tr style='height:10.1pt'> <td width="452" style='width:339.25pt;border:none;border-top:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:10.1pt'>   </td> <td width="161" style='width:120.65pt;border:none;border-top:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:10.1pt'> Total </td> </tr> <tr style='height:10.1pt'> <td width="452" style='width:339.25pt;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:10.1pt'></td> <td width="161" style='width:120.65pt;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:10.1pt'> $ </td> </tr> <tr style='height:10.1pt'> <td width="452" style='width:339.25pt;border:none;background:#CCEEFF;padding:0in 5.4pt 0in 5.4pt;height:10.1pt'> Derivative liabilities as at March 31, 2017 </td> <td width="161" style='width:120.65pt;border:none;background:#CCEEFF;padding:0in 5.4pt 0in 5.4pt;height:10.1pt'>                           2,163,884  </td> </tr> <tr style='height:10.1pt'> <td width="452" style='width:339.25pt;padding:0in 5.4pt 0in 5.4pt;height:10.1pt'> Derivative fair value at issuance </td> <td width="161" style='width:120.65pt;padding:0in 5.4pt 0in 5.4pt;height:10.1pt'>                            3,569,249  </td> </tr> <tr style='height:10.1pt'> <td width="452" style='width:339.25pt;background:#CCEEFF;padding:0in 5.4pt 0in 5.4pt;height:10.1pt'> Transferred to equity upon conversion of notes (Notes 5 and 7) </td> <td width="161" style='width:120.65pt;background:#CCEEFF;padding:0in 5.4pt 0in 5.4pt;height:10.1pt'>                          (1,700,949) </td> </tr> <tr style='height:10.1pt'> <td width="452" style='width:339.25pt;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:10.1pt'> Change in fair value of derivatives </td> <td width="161" style='width:120.65pt;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:10.1pt'>                                 42,128  </td> </tr> <tr style='height:10.1pt'> <td width="452" style='width:339.25pt;border:none;background:#CCEEFF;padding:0in 5.4pt 0in 5.4pt;height:10.1pt'> Derivative liabilities as at June 30, 2017 (pre-adoption) </td> <td width="161" style='width:120.65pt;border:none;background:#CCEEFF;padding:0in 5.4pt 0in 5.4pt;height:10.1pt'>                            4,074,312  </td> </tr> <tr style='height:10.1pt'> <td width="452" style='width:339.25pt;padding:0in 5.4pt 0in 5.4pt;height:10.1pt'>   Adjustments relating to adoption of ASU 2017-11 </td> <td width="161" style='width:120.65pt;padding:0in 5.4pt 0in 5.4pt;height:10.1pt'>   </td> </tr> <tr style='height:10.1pt'> <td width="452" style='width:339.25pt;background:#CCEEFF;padding:0in 5.4pt 0in 5.4pt;height:10.1pt'> Reversal of fair value </td> <td width="161" style='width:120.65pt;background:#CCEEFF;padding:0in 5.4pt 0in 5.4pt;height:10.1pt'>                               (21,540) </td> </tr> <tr style='height:10.1pt'> <td width="452" style='width:339.25pt;padding:0in 5.4pt 0in 5.4pt;height:10.1pt'> Transferred to accumulated deficit </td> <td width="161" style='width:120.65pt;padding:0in 5.4pt 0in 5.4pt;height:10.1pt'>                             (483,524) </td> </tr> <tr style='height:10.1pt'> <td width="452" style='width:339.25pt;border:none;border-bottom:solid windowtext 1.0pt;background:#CCEEFF;padding:0in 5.4pt 0in 5.4pt;height:10.1pt'> Transferred to additional paid-in-capital </td> <td width="161" style='width:120.65pt;border:none;border-bottom:solid windowtext 1.0pt;background:#CCEEFF;padding:0in 5.4pt 0in 5.4pt;height:10.1pt'>                          (3,569,248) </td> </tr> <tr style='height:10.1pt'> <td width="452" style='width:339.25pt;border:none;border-bottom:solid windowtext 1.5pt;padding:0in 5.4pt 0in 5.4pt;height:10.1pt'> Derivative liabilities as at September 30, 2018 and March 31, 2018 (post adoption) </td> <td width="161" style='width:120.65pt;border:none;border-bottom:solid windowtext 1.5pt;padding:0in 5.4pt 0in 5.4pt;height:10.1pt'>                                            -  </td> </tr> </table> </div>

<div align="center"> <table border="0" cellspacing="0" cellpadding="0" width="270" style='width:202.65pt;border-collapse:collapse'> <tr style='height:38.25pt'> <td width="162" style='width:121.5pt;border-top:solid windowtext 1.0pt;border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;padding:0in 5.4pt 0in 5.4pt;height:38.25pt'></td> <td width="108" style='width:81.15pt;border-top:solid windowtext 1.0pt;border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;padding:0in 5.4pt 0in 5.4pt;height:38.25pt'> Assumptions </td> </tr> <tr style='height:12.75pt'> <td width="162" style='width:121.5pt;border:none;background:#CCEEFF;padding:0in 5.4pt 0in 5.4pt;height:12.75pt'> Dividend yield </td> <td width="108" style='width:81.15pt;border:none;background:#CCEEFF;padding:0in 5.4pt 0in 5.4pt;height:12.75pt'> 0.00% </td> </tr> <tr style='height:15.0pt'> <td width="162" style='width:121.5pt;padding:0in 5.4pt 0in 5.4pt;height:15.0pt'> Risk-free rate for term </td> <td width="108" style='width:81.15pt;padding:0in 5.4pt 0in 5.4pt;height:15.0pt'> 0.62% 1.14% </td> </tr> <tr style='height:51.75pt'> <td width="162" style='width:121.5pt;background:#CCEEFF;padding:0in 5.4pt 0in 5.4pt;height:51.75pt'> Volatility </td> <td width="108" style='width:81.15pt;background:#CCEEFF;padding:0in 5.4pt 0in 5.4pt;height:51.75pt'> 103% 118% </td> </tr> <tr style='height:12.75pt'> <td width="162" style='width:121.5pt;padding:0in 5.4pt 0in 5.4pt;height:12.75pt'> Remaining terms (Years) </td> <td width="108" style='width:81.15pt;padding:0in 5.4pt 0in 5.4pt;height:12.75pt'> 0.01 1.0 </td> </tr> <tr style='height:13.5pt'> <td width="162" style='width:121.5pt;border:none;border-bottom:solid windowtext 1.0pt;background:#CCEEFF;padding:0in 5.4pt 0in 5.4pt;height:13.5pt'> Stock price ($ per share) </td> <td width="108" style='width:81.15pt;border:none;border-bottom:solid windowtext 1.0pt;background:#CCEEFF;padding:0in 5.4pt 0in 5.4pt;height:13.5pt'> $2.50 and $2.70 </td> </tr> </table> </div>

<div align="center"> <table border="0" cellspacing="0" cellpadding="0" width="635" style='width:476.4pt;border-collapse:collapse'> <tr style='height:73.5pt'> <td width="152" valign="bottom" style='width:113.7pt;border-top:solid windowtext 1.0pt;border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;padding:0in 5.4pt 0in 5.4pt;height:73.5pt'>   </td> <td width="106" valign="bottom" style='width:79.5pt;border-top:solid windowtext 1.0pt;border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;padding:0in 5.4pt 0in 5.4pt;height:73.5pt'> Broker Warrants </td> <td width="114" valign="bottom" style='width:85.5pt;border-top:solid windowtext 1.0pt;border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;padding:0in 5.4pt 0in 5.4pt;height:73.5pt'> Consultant Warrants </td> <td width="96" valign="bottom" style='width:1.0in;border-top:solid windowtext 1.0pt;border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;padding:0in 5.4pt 0in 5.4pt;height:73.5pt'> Warrants Issued on Conversion of Convertible Notes </td> <td width="84" valign="bottom" style='width:63.0pt;border-top:solid windowtext 1.0pt;border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;padding:0in 5.4pt 0in 5.4pt;height:73.5pt'> Private Placement Warrants </td> <td width="84" valign="bottom" style='width:62.7pt;border-top:solid windowtext 1.0pt;border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;padding:0in 5.4pt 0in 5.4pt;height:73.5pt'> Total </td> </tr> <tr style='height:10.1pt'> <td width="152" valign="bottom" style='width:113.7pt;border:none;background:#CCEEFF;padding:0in 5.4pt 0in 5.4pt;height:10.1pt'> As at March 31, 2017 </td> <td width="106" valign="bottom" style='width:79.5pt;border:none;background:#CCEEFF;padding:0in 5.4pt 0in 5.4pt;height:10.1pt'>    380,682  </td> <td width="114" valign="bottom" style='width:85.5pt;border:none;background:#CCEEFF;padding:0in 5.4pt 0in 5.4pt;height:10.1pt'>      916,466  </td> <td width="96" valign="bottom" style='width:1.0in;border:none;background:#CCEEFF;padding:0in 5.4pt 0in 5.4pt;height:10.1pt'>                     - </td> <td width="84" valign="bottom" style='width:63.0pt;border:none;background:#CCEEFF;padding:0in 5.4pt 0in 5.4pt;height:10.1pt'> 390,744 </td> <td width="84" valign="bottom" style='width:62.7pt;border:none;background:#CCEEFF;padding:0in 5.4pt 0in 5.4pt;height:10.1pt'> 1,687,892  </td> </tr> <tr style='height:10.1pt'> <td width="152" valign="bottom" style='width:113.7pt;padding:0in 5.4pt 0in 5.4pt;height:10.1pt'> Less: Exercised </td> <td width="106" valign="bottom" style='width:79.5pt;padding:0in 5.4pt 0in 5.4pt;height:10.1pt'> (222,690) </td> <td width="114" valign="bottom" style='width:85.5pt;padding:0in 5.4pt 0in 5.4pt;height:10.1pt'>    (140,000) </td> <td width="96" valign="bottom" style='width:1.0in;padding:0in 5.4pt 0in 5.4pt;height:10.1pt'>                     - </td> <td width="84" valign="bottom" style='width:63.0pt;padding:0in 5.4pt 0in 5.4pt;height:10.1pt'> - </td> <td width="84" valign="bottom" style='width:62.7pt;padding:0in 5.4pt 0in 5.4pt;height:10.1pt'> (362,690) </td> </tr> <tr style='height:10.1pt'> <td width="152" valign="bottom" style='width:113.7pt;background:#CCEEFF;padding:0in 5.4pt 0in 5.4pt;height:10.1pt'> Less: Expired/cancelled </td> <td width="106" valign="bottom" style='width:79.5pt;background:#CCEEFF;padding:0in 5.4pt 0in 5.4pt;height:10.1pt'>    (19,935) </td> <td width="114" valign="bottom" style='width:85.5pt;background:#CCEEFF;padding:0in 5.4pt 0in 5.4pt;height:10.1pt'>    (380,300) </td> <td width="96" valign="bottom" style='width:1.0in;background:#CCEEFF;padding:0in 5.4pt 0in 5.4pt;height:10.1pt'>                     - </td> <td width="84" valign="bottom" style='width:63.0pt;background:#CCEEFF;padding:0in 5.4pt 0in 5.4pt;height:10.1pt'> - </td> <td width="84" valign="bottom" style='width:62.7pt;background:#CCEEFF;padding:0in 5.4pt 0in 5.4pt;height:10.1pt'> (400,235) </td> </tr> <tr style='height:10.1pt'> <td width="152" valign="bottom" style='width:113.7pt;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:10.1pt'> Add: Issued </td> <td width="106" valign="bottom" style='width:79.5pt;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:10.1pt'>    246,095  </td> <td width="114" valign="bottom" style='width:85.5pt;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:10.1pt'>      273,806  </td> <td width="96" valign="bottom" style='width:1.0in;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:10.1pt'>    2,734,530 </td> <td width="84" valign="bottom" style='width:63.0pt;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:10.1pt'> 772,978 </td> <td width="84" valign="bottom" style='width:62.7pt;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:10.1pt'> 4,027,409  </td> </tr> <tr style='height:10.1pt'> <td width="152" valign="bottom" style='width:113.7pt;border:none;border-bottom:solid windowtext 1.0pt;background:#CCEEFF;padding:0in 5.4pt 0in 5.4pt;height:10.1pt'> As at March 31, 2018 </td> <td width="106" valign="bottom" style='width:79.5pt;border:none;border-bottom:solid windowtext 1.0pt;background:#CCEEFF;padding:0in 5.4pt 0in 5.4pt;height:10.1pt'>    384,152  </td> <td width="114" valign="bottom" style='width:85.5pt;border:none;border-bottom:solid windowtext 1.0pt;background:#CCEEFF;padding:0in 5.4pt 0in 5.4pt;height:10.1pt'>     669,972* </td> <td width="96" valign="bottom" style='width:1.0in;border:none;border-bottom:solid windowtext 1.0pt;background:#CCEEFF;padding:0in 5.4pt 0in 5.4pt;height:10.1pt'>    2,734,530 </td> <td width="84" valign="bottom" style='width:63.0pt;border:none;border-bottom:solid windowtext 1.0pt;background:#CCEEFF;padding:0in 5.4pt 0in 5.4pt;height:10.1pt'> 1,163,722 </td> <td width="84" valign="bottom" style='width:62.7pt;border:none;border-bottom:solid windowtext 1.0pt;background:#CCEEFF;padding:0in 5.4pt 0in 5.4pt;height:10.1pt'> 4,952,376  </td> </tr> <tr style='height:10.1pt'> <td width="152" valign="bottom" style='width:113.7pt;border:none;padding:0in 5.4pt 0in 5.4pt;height:10.1pt'>   </td> <td width="106" valign="bottom" style='width:79.5pt;border:none;padding:0in 5.4pt 0in 5.4pt;height:10.1pt'>   </td> <td width="114" valign="bottom" style='width:85.5pt;border:none;padding:0in 5.4pt 0in 5.4pt;height:10.1pt'>   </td> <td width="96" valign="bottom" style='width:1.0in;border:none;padding:0in 5.4pt 0in 5.4pt;height:10.1pt'>   </td> <td width="84" valign="bottom" style='width:63.0pt;border:none;padding:0in 5.4pt 0in 5.4pt;height:10.1pt'>   </td> <td width="84" valign="bottom" style='width:62.7pt;border:none;padding:0in 5.4pt 0in 5.4pt;height:10.1pt'>   </td> </tr> <tr style='height:10.1pt'> <td width="152" valign="bottom" style='width:113.7pt;padding:0in 5.4pt 0in 5.4pt;height:10.1pt'> Less: Exercised </td> <td width="106" valign="bottom" style='width:79.5pt;padding:0in 5.4pt 0in 5.4pt;height:10.1pt'>    (62,838) </td> <td width="114" valign="bottom" style='width:85.5pt;padding:0in 5.4pt 0in 5.4pt;height:10.1pt'>                   -  </td> <td width="96" valign="bottom" style='width:1.0in;padding:0in 5.4pt 0in 5.4pt;height:10.1pt'>                     - </td> <td width="84" valign="bottom" style='width:63.0pt;padding:0in 5.4pt 0in 5.4pt;height:10.1pt'> - </td> <td width="84" valign="bottom" style='width:62.7pt;padding:0in 5.4pt 0in 5.4pt;height:10.1pt'> (62,838) </td> </tr> <tr style='height:10.1pt'> <td width="152" valign="bottom" style='width:113.7pt;background:#CCEEFF;padding:0in 5.4pt 0in 5.4pt;height:10.1pt'> Less: Expired/cancelled </td> <td width="106" valign="bottom" style='width:79.5pt;background:#CCEEFF;padding:0in 5.4pt 0in 5.4pt;height:10.1pt'>                 -  </td> <td width="114" valign="bottom" style='width:85.5pt;background:#CCEEFF;padding:0in 5.4pt 0in 5.4pt;height:10.1pt'>       (31,250) </td> <td width="96" valign="bottom" style='width:1.0in;background:#CCEEFF;padding:0in 5.4pt 0in 5.4pt;height:10.1pt'>                     - </td> <td width="84" valign="bottom" style='width:63.0pt;background:#CCEEFF;padding:0in 5.4pt 0in 5.4pt;height:10.1pt'> - </td> <td width="84" valign="bottom" style='width:62.7pt;background:#CCEEFF;padding:0in 5.4pt 0in 5.4pt;height:10.1pt'> (31,250) </td> </tr> <tr style='height:10.1pt'> <td width="152" valign="bottom" style='width:113.7pt;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:10.1pt'> Add: Issued </td> <td width="106" valign="bottom" style='width:79.5pt;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:10.1pt'>                 -  </td> <td width="114" valign="bottom" style='width:85.5pt;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:10.1pt'>         65,000  </td> <td width="96" valign="bottom" style='width:1.0in;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:10.1pt'>                    -  </td> <td width="84" valign="bottom" style='width:63.0pt;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:10.1pt'>                 -  </td> <td width="84" valign="bottom" style='width:62.7pt;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:10.1pt'> 65,000  </td> </tr> <tr style='height:10.1pt'> <td width="152" valign="bottom" style='width:113.7pt;border:none;border-bottom:solid windowtext 1.0pt;background:#CCEEFF;padding:0in 5.4pt 0in 5.4pt;height:10.1pt'> As at June 30, 2018 </td> <td width="106" valign="bottom" style='width:79.5pt;border:none;border-bottom:solid windowtext 1.0pt;background:#CCEEFF;padding:0in 5.4pt 0in 5.4pt;height:10.1pt'>    321,314  </td> <td width="114" valign="bottom" style='width:85.5pt;border:none;border-bottom:solid windowtext 1.0pt;background:#CCEEFF;padding:0in 5.4pt 0in 5.4pt;height:10.1pt'>     703,722* </td> <td width="96" valign="bottom" style='width:1.0in;border:none;border-bottom:solid windowtext 1.0pt;background:#CCEEFF;padding:0in 5.4pt 0in 5.4pt;height:10.1pt'>    2,734,530 </td> <td width="84" valign="bottom" style='width:63.0pt;border:none;border-bottom:solid windowtext 1.0pt;background:#CCEEFF;padding:0in 5.4pt 0in 5.4pt;height:10.1pt'> 1,163,722 </td> <td width="84" valign="bottom" style='width:62.7pt;border:none;border-bottom:solid windowtext 1.0pt;background:#CCEEFF;padding:0in 5.4pt 0in 5.4pt;height:10.1pt'> 4,923,288  </td> </tr> <tr style='height:10.1pt'> <td width="152" valign="bottom" style='width:113.7pt;border:none;padding:0in 5.4pt 0in 5.4pt;height:10.1pt'>   </td> <td width="106" valign="bottom" style='width:79.5pt;border:none;padding:0in 5.4pt 0in 5.4pt;height:10.1pt'>   </td> <td width="114" valign="bottom" style='width:85.5pt;border:none;padding:0in 5.4pt 0in 5.4pt;height:10.1pt'>   </td> <td width="96" valign="bottom" style='width:1.0in;border:none;padding:0in 5.4pt 0in 5.4pt;height:10.1pt'>   </td> <td width="84" valign="bottom" style='width:63.0pt;border:none;padding:0in 5.4pt 0in 5.4pt;height:10.1pt'>   </td> <td width="84" valign="bottom" style='width:62.7pt;border:none;padding:0in 5.4pt 0in 5.4pt;height:10.1pt'>   </td> </tr> <tr style='height:10.1pt'> <td width="152" valign="bottom" style='width:113.7pt;padding:0in 5.4pt 0in 5.4pt;height:10.1pt'> Less: Exercised </td> <td width="106" valign="bottom" style='width:79.5pt;padding:0in 5.4pt 0in 5.4pt;height:10.1pt'>                 -  </td> <td width="114" valign="bottom" style='width:85.5pt;padding:0in 5.4pt 0in 5.4pt;height:10.1pt'>                   -  </td> <td width="96" valign="bottom" style='width:1.0in;padding:0in 5.4pt 0in 5.4pt;height:10.1pt'>                     - </td> <td width="84" valign="bottom" style='width:63.0pt;padding:0in 5.4pt 0in 5.4pt;height:10.1pt'> - </td> <td width="84" valign="bottom" style='width:62.7pt;padding:0in 5.4pt 0in 5.4pt;height:10.1pt'> - </td> </tr> <tr style='height:10.1pt'> <td width="152" valign="bottom" style='width:113.7pt;background:#CCEEFF;padding:0in 5.4pt 0in 5.4pt;height:10.1pt'> Less: Expired/cancelled </td> <td width="106" valign="bottom" style='width:79.5pt;background:#CCEEFF;padding:0in 5.4pt 0in 5.4pt;height:10.1pt'>                 -  </td> <td width="114" valign="bottom" style='width:85.5pt;background:#CCEEFF;padding:0in 5.4pt 0in 5.4pt;height:10.1pt'>                -   ** </td> <td width="96" valign="bottom" style='width:1.0in;background:#CCEEFF;padding:0in 5.4pt 0in 5.4pt;height:10.1pt'>                     - </td> <td width="84" valign="bottom" style='width:63.0pt;background:#CCEEFF;padding:0in 5.4pt 0in 5.4pt;height:10.1pt'> - </td> <td width="84" valign="bottom" style='width:62.7pt;background:#CCEEFF;padding:0in 5.4pt 0in 5.4pt;height:10.1pt'></td> </tr> <tr style='height:10.1pt'> <td width="152" valign="bottom" style='width:113.7pt;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:10.1pt'> Add: Issued </td> <td width="106" valign="bottom" style='width:79.5pt;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:10.1pt'>                 -  </td> <td width="114" valign="bottom" style='width:85.5pt;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:10.1pt'>      393,333  </td> <td width="96" valign="bottom" style='width:1.0in;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:10.1pt'>                    -  </td> <td width="84" valign="bottom" style='width:63.0pt;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:10.1pt'>                 -  </td> <td width="84" valign="bottom" style='width:62.7pt;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:10.1pt'> 393,333  </td> </tr> <tr style='height:10.1pt'> <td width="152" valign="bottom" style='width:113.7pt;border:none;border-bottom:solid windowtext 1.0pt;background:#CCEEFF;padding:0in 5.4pt 0in 5.4pt;height:10.1pt'> As at September 30, 2018 </td> <td width="106" valign="bottom" style='width:79.5pt;border:none;border-bottom:solid windowtext 1.0pt;background:#CCEEFF;padding:0in 5.4pt 0in 5.4pt;height:10.1pt'>    321,314  </td> <td width="114" valign="bottom" style='width:85.5pt;border:none;border-bottom:solid windowtext 1.0pt;background:#CCEEFF;padding:0in 5.4pt 0in 5.4pt;height:10.1pt'> 1,097,055* </td> <td width="96" valign="bottom" style='width:1.0in;border:none;border-bottom:solid windowtext 1.0pt;background:#CCEEFF;padding:0in 5.4pt 0in 5.4pt;height:10.1pt'>    2,734,530 </td> <td width="84" valign="bottom" style='width:63.0pt;border:none;border-bottom:solid windowtext 1.0pt;background:#CCEEFF;padding:0in 5.4pt 0in 5.4pt;height:10.1pt'> 1,163,722 </td> <td width="84" valign="bottom" style='width:62.7pt;border:none;border-bottom:solid windowtext 1.0pt;background:#CCEEFF;padding:0in 5.4pt 0in 5.4pt;height:10.1pt'> 5,316,621  </td> </tr> <tr style='height:15.0pt'> <td width="152" valign="bottom" style='width:113.7pt;border:none;padding:0in 5.4pt 0in 5.4pt;height:15.0pt'></td> <td width="106" valign="bottom" style='width:79.5pt;border:none;padding:0in 5.4pt 0in 5.4pt;height:15.0pt'></td> <td width="114" valign="bottom" style='width:85.5pt;border:none;padding:0in 5.4pt 0in 5.4pt;height:15.0pt'></td> <td width="96" valign="bottom" style='width:1.0in;border:none;padding:0in 5.4pt 0in 5.4pt;height:15.0pt'></td> <td width="84" valign="bottom" style='width:63.0pt;border:none;padding:0in 5.4pt 0in 5.4pt;height:15.0pt'></td> <td width="84" valign="bottom" style='width:62.7pt;border:none;padding:0in 5.4pt 0in 5.4pt;height:15.0pt'></td> </tr> <tr style='height:15.0pt'> <td width="152" style='width:113.7pt;background:#CCEEFF;padding:0in 5.4pt 0in 5.4pt;height:15.0pt'> Exercise Price </td> <td width="106" style='width:79.5pt;background:#CCEEFF;padding:0in 5.4pt 0in 5.4pt;height:15.0pt'> $    0.78-$3.00  </td> <td width="114" style='width:85.5pt;background:#CCEEFF;padding:0in 5.4pt 0in 5.4pt;height:15.0pt'> $     1.24-$7.59  </td> <td width="96" style='width:1.0in;background:#CCEEFF;padding:0in 5.4pt 0in 5.4pt;height:15.0pt'>               2.00 </td> <td width="84" style='width:63.0pt;background:#CCEEFF;padding:0in 5.4pt 0in 5.4pt;height:15.0pt'> 3.00 </td> <td width="84" style='width:62.7pt;background:#CCEEFF;padding:0in 5.4pt 0in 5.4pt;height:15.0pt'></td> </tr> <tr style='height:48.75pt'> <td width="152" style='width:113.7pt;padding:0in 5.4pt 0in 5.4pt;height:48.75pt'> Expiration Date </td> <td width="106" style='width:79.5pt;padding:0in 5.4pt 0in 5.4pt;height:48.75pt'>  October 2019 to July 2022 </td> <td width="114" style='width:85.5pt;padding:0in 5.4pt 0in 5.4pt;height:48.75pt'> October 2018 to September 2021 </td> <td width="96" style='width:1.0in;padding:0in 5.4pt 0in 5.4pt;height:48.75pt'>  March 2020 to November 2022 </td> <td width="84" style='width:63.0pt;padding:0in 5.4pt 0in 5.4pt;height:48.75pt'>  April 2020 to July 2020 </td> <td width="84" style='width:62.7pt;padding:0in 5.4pt 0in 5.4pt;height:48.75pt'></td> </tr> </table> </div>

<div align="center"> <table border="0" cellspacing="0" cellpadding="0"> <tr align="left"> <td width="395" valign="bottom" style='width:296.15pt;padding:0in .1in 0in .1in'>   </td> <td width="116" valign="bottom" style='width:87.05pt;padding:0in .1in 0in .1in'>   </td> <td width="113" valign="bottom" style='width:84.8pt;padding:0in .1in 0in .1in'>   </td> </tr> <tr align="left"> <td width="395" valign="bottom" style='width:296.15pt;border-top:solid black 1.0pt;border-left:none;border-bottom:solid black 1.0pt;border-right:none;padding:0in .1in 0in .1in'>   </td> <td width="116" valign="bottom" style='width:87.05pt;border-top:solid black 1.0pt;border-left:none;border-bottom:solid black 1.0pt;border-right:none;padding:0in .1in 0in .1in'> Number of options </td> <td width="113" valign="bottom" style='width:84.8pt;border-top:solid black 1.0pt;border-left:none;border-bottom:solid black 1.0pt;border-right:none;padding:0in .1in 0in .1in'> Weighted average exercise price ($) </td> </tr> <tr align="left"> <td width="395" valign="bottom" style='width:296.15pt;border:none;border-top:solid black 1.0pt;background:#CCEEFF;padding:0in .1in 0in .1in'> Granted </td> <td width="116" valign="bottom" style='width:87.05pt;border:none;border-top:solid black 1.0pt;background:#CCEEFF;padding:0in .1in 0in .1in'>           3,591,000  </td> <td width="113" valign="bottom" style='width:84.8pt;border:none;border-top:solid black 1.0pt;background:#CCEEFF;padding:0in .1in 0in .1in'>                0.0001 </td> </tr> <tr align="left"> <td width="395" valign="bottom" style='width:296.15pt;padding:0in .1in 0in .1in'> Exercised </td> <td width="116" valign="bottom" style='width:87.05pt;padding:0in .1in 0in .1in'>         (3,390,503) </td> <td width="113" valign="bottom" style='width:84.8pt;padding:0in .1in 0in .1in'>                0.0001 </td> </tr> <tr align="left"> <td width="395" valign="bottom" style='width:296.15pt;border:none;border-top:solid black 1.0pt;background:#CCEEFF;padding:0in .1in 0in .1in'> Outstanding as of December 31, 2015 </td> <td width="116" valign="bottom" style='width:87.05pt;border:none;border-top:solid black 1.0pt;background:#CCEEFF;padding:0in .1in 0in .1in'>               200,497  </td> <td width="113" valign="bottom" style='width:84.8pt;border:none;border-top:solid black 1.0pt;background:#CCEEFF;padding:0in .1in 0in .1in'>                0.0001 </td> </tr> <tr style='height:3.85pt'> <td width="395" valign="bottom" style='width:296.15pt;border:none;border-bottom:solid windowtext 1.0pt;padding:0in .1in 0in .1in;height:3.85pt'> Cancelled during 2016 </td> <td width="116" valign="bottom" style='width:87.05pt;border:none;border-bottom:solid windowtext 1.0pt;padding:0in .1in 0in .1in;height:3.85pt'>               (35,907) </td> <td width="113" valign="bottom" style='width:84.8pt;border:none;border-bottom:solid windowtext 1.0pt;padding:0in .1in 0in .1in;height:3.85pt'>                0.0001 </td> </tr> <tr align="left"> <td width="395" valign="bottom" style='width:296.15pt;background:#CCEEFF;padding:0in .1in 0in .1in'> Outstanding as of March 31, 2018 </td> <td width="116" valign="bottom" style='width:87.05pt;background:#CCEEFF;padding:0in .1in 0in .1in'>               164,590  </td> <td width="113" valign="bottom" style='width:84.8pt;background:#CCEEFF;padding:0in .1in 0in .1in'>                0.0001 </td> </tr> <tr align="left"> <td width="395" valign="bottom" style='width:296.15pt;padding:0in .1in 0in .1in'> Exercised </td> <td width="116" valign="bottom" style='width:87.05pt;padding:0in .1in 0in .1in'>             (164,590) </td> <td width="113" valign="bottom" style='width:84.8pt;padding:0in .1in 0in .1in'>                0.0001 </td> </tr> <tr align="left"> <td width="395" valign="bottom" style='width:296.15pt;border:none;border-top:solid black 1.0pt;background:#CCEEFF;padding:0in .1in 0in .1in'> Outstanding as of September 30, 2018 </td> <td width="116" valign="bottom" style='width:87.05pt;border:none;border-top:solid black 1.0pt;background:#CCEEFF;padding:0in .1in 0in .1in'>                            -  </td> <td width="113" valign="bottom" style='width:84.8pt;border:none;border-top:solid black 1.0pt;background:#CCEEFF;padding:0in .1in 0in .1in'></td> </tr> </table> </div>

<p style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:107%;margin-bottom:0in;margin-bottom:.0001pt;text-align:justify;text-justify:inter-ideograph;line-height:normal;text-autospace:none'>  <div align="center"> <table border="0" cellspacing="0" cellpadding="0"> <tr align="left"> <td width="395" valign="bottom" style='width:296.15pt;padding:0in .1in 0in .1in'>   </td> <td width="116" valign="bottom" style='width:87.05pt;padding:0in .1in 0in .1in'>   </td> <td width="113" valign="bottom" style='width:84.8pt;padding:0in .1in 0in .1in'>   </td> </tr> <tr align="left"> <td width="395" valign="bottom" style='width:296.15pt;border-top:solid black 1.0pt;border-left:none;border-bottom:solid black 1.0pt;border-right:none;padding:0in .1in 0in .1in'>   </td> <td width="116" valign="bottom" style='width:87.05pt;border-top:solid black 1.0pt;border-left:none;border-bottom:solid black 1.0pt;border-right:none;padding:0in .1in 0in .1in'> Number of options </td> <td width="113" valign="bottom" style='width:84.8pt;border-top:solid black 1.0pt;border-left:none;border-bottom:solid black 1.0pt;border-right:none;padding:0in .1in 0in .1in'> Weighted average exercise price ($) </td> </tr> <tr style='height:8.25pt'> <td width="395" valign="bottom" style='width:296.15pt;border:none;border-top:solid black 1.0pt;background:#CCEEFF;padding:0in .1in 0in .1in;height:8.25pt'> Granted </td> <td width="116" valign="bottom" style='width:87.05pt;border:none;border-top:solid black 1.0pt;background:#CCEEFF;padding:0in .1in 0in .1in;height:8.25pt'>            4,147,498 </td> <td width="113" valign="bottom" style='width:84.8pt;border:none;border-top:solid black 1.0pt;background:#CCEEFF;padding:0in .1in 0in .1in;height:8.25pt'>                3.2306 </td> </tr> <tr align="left"> <td width="395" valign="bottom" style='width:296.15pt;padding:0in .1in 0in .1in'> Exercised </td> <td width="116" valign="bottom" style='width:87.05pt;padding:0in .1in 0in .1in'>                             - </td> <td width="113" valign="bottom" style='width:84.8pt;padding:0in .1in 0in .1in'>                            - </td> </tr> <tr align="left"> <td width="395" valign="bottom" style='width:296.15pt;border-top:solid black 1.0pt;border-left:none;border-bottom:solid black 1.0pt;border-right:none;background:#CCEEFF;padding:0in .1in 0in .1in'> Outstanding as of June 30 and March 31, 2018 </td> <td width="116" valign="bottom" style='width:87.05pt;border-top:solid black 1.0pt;border-left:none;border-bottom:solid black 1.0pt;border-right:none;background:#CCEEFF;padding:0in .1in 0in .1in'>            4,147,498 </td> <td width="113" valign="bottom" style='width:84.8pt;border-top:solid black 1.0pt;border-left:none;border-bottom:solid black 1.0pt;border-right:none;background:#CCEEFF;padding:0in .1in 0in .1in'>                1.8337 </td> </tr> <tr align="left"> <td width="395" valign="bottom" style='width:296.15pt;border:none;border-top:solid black 1.0pt;background:#CCEEFF;padding:0in .1in 0in .1in'> Granted </td> <td width="116" valign="bottom" style='width:87.05pt;border:none;border-top:solid black 1.0pt;background:#CCEEFF;padding:0in .1in 0in .1in'>               157,500 </td> <td width="113" valign="bottom" style='width:84.8pt;border:none;border-top:solid black 1.0pt;background:#CCEEFF;padding:0in .1in 0in .1in'>                3.2306 </td> </tr> <tr align="left"> <td width="395" valign="bottom" style='width:296.15pt;padding:0in .1in 0in .1in'> Exercised </td> <td width="116" valign="bottom" style='width:87.05pt;padding:0in .1in 0in .1in'>                             - </td> <td width="113" valign="bottom" style='width:84.8pt;padding:0in .1in 0in .1in'>                            - </td> </tr> <tr align="left"> <td width="395" valign="bottom" style='width:296.15pt;border-top:solid black 1.0pt;border-left:none;border-bottom:solid black 1.0pt;border-right:none;background:#CCEEFF;padding:0in .1in 0in .1in'> Outstanding as of September 30, 2018 </td> <td width="116" valign="bottom" style='width:87.05pt;border-top:solid black 1.0pt;border-left:none;border-bottom:solid black 1.0pt;border-right:none;background:#CCEEFF;padding:0in .1in 0in .1in'>            4,304,998 </td> <td width="113" valign="bottom" style='width:84.8pt;border-top:solid black 1.0pt;border-left:none;border-bottom:solid black 1.0pt;border-right:none;background:#CCEEFF;padding:0in .1in 0in .1in'>                3.1795 </td> </tr> </table> </div>

<div align="center"> <table border="0" cellspacing="0" cellpadding="0" width="635" style='width:476.1pt;border-collapse:collapse'> <tr style='height:13.5pt'> <td width="236" valign="bottom" style='width:176.75pt;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:13.5pt'>   </td> <td width="134" valign="top" style='width:100.35pt;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:13.5pt'> 2017-2018 </td> <td width="134" valign="bottom" style='width:100.35pt;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:13.5pt'> 2016-2017 </td> <td width="132" valign="bottom" style='width:98.65pt;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:13.5pt'> 2015-2016 </td> </tr> <tr style='height:13.5pt'> <td width="236" valign="bottom" style='width:176.75pt;border:none;background:#CCEEFF;padding:0in 5.4pt 0in 5.4pt;height:13.5pt'> Exercise price ($) </td> <td width="134" valign="top" style='width:100.35pt;border:none;background:#CCEEFF;padding:0in 5.4pt 0in 5.4pt;height:13.5pt'> 1.24-7.59 </td> <td width="134" valign="bottom" style='width:100.35pt;border:none;background:#CCEEFF;padding:0in 5.4pt 0in 5.4pt;height:13.5pt'> 2.00 2.58 </td> <td width="132" valign="bottom" style='width:98.65pt;border:none;background:#CCEEFF;padding:0in 5.4pt 0in 5.4pt;height:13.5pt'> 0.0001   </td> </tr> <tr style='height:13.5pt'> <td width="236" valign="bottom" style='width:176.75pt;padding:0in 5.4pt 0in 5.4pt;height:13.5pt'> Risk free interest rate (%) </td> <td width="134" valign="top" style='width:100.35pt;padding:0in 5.4pt 0in 5.4pt;height:13.5pt'> 1.98-2.81 </td> <td width="134" valign="bottom" style='width:100.35pt;padding:0in 5.4pt 0in 5.4pt;height:13.5pt'> 0.45 - 1.47 </td> <td width="132" valign="bottom" style='width:98.65pt;padding:0in 5.4pt 0in 5.4pt;height:13.5pt'> 0.04 - 1.07 </td> </tr> <tr style='height:13.5pt'> <td width="236" valign="bottom" style='width:176.75pt;background:#CCEEFF;padding:0in 5.4pt 0in 5.4pt;height:13.5pt'> Expected term (Years) </td> <td width="134" valign="top" style='width:100.35pt;background:#CCEEFF;padding:0in 5.4pt 0in 5.4pt;height:13.5pt'> 3.0 </td> <td width="134" valign="bottom" style='width:100.35pt;background:#CCEEFF;padding:0in 5.4pt 0in 5.4pt;height:13.5pt'> 1.0 - 3.0 </td> <td width="132" valign="bottom" style='width:98.65pt;background:#CCEEFF;padding:0in 5.4pt 0in 5.4pt;height:13.5pt'> 10.0 </td> </tr> <tr style='height:13.5pt'> <td width="236" valign="bottom" style='width:176.75pt;padding:0in 5.4pt 0in 5.4pt;height:13.5pt'> Expected volatility (%) </td> <td width="134" valign="top" style='width:100.35pt;padding:0in 5.4pt 0in 5.4pt;height:13.5pt'> 97.8-145.99 </td> <td width="134" valign="bottom" style='width:100.35pt;padding:0in 5.4pt 0in 5.4pt;height:13.5pt'> 101 105 </td> <td width="132" valign="bottom" style='width:98.65pt;padding:0in 5.4pt 0in 5.4pt;height:13.5pt'> 94 </td> </tr> <tr style='height:13.5pt'> <td width="236" valign="bottom" style='width:176.75pt;background:#CCEEFF;padding:0in 5.4pt 0in 5.4pt;height:13.5pt'> Expected dividend yield (%) </td> <td width="134" valign="top" style='width:100.35pt;background:#CCEEFF;padding:0in 5.4pt 0in 5.4pt;height:13.5pt'> 0.00 </td> <td width="134" valign="bottom" style='width:100.35pt;background:#CCEEFF;padding:0in 5.4pt 0in 5.4pt;height:13.5pt'> 0.00 </td> <td width="132" valign="bottom" style='width:98.65pt;background:#CCEEFF;padding:0in 5.4pt 0in 5.4pt;height:13.5pt'> 0.00 </td> </tr> <tr style='height:13.5pt'> <td width="236" valign="bottom" style='width:176.75pt;padding:0in 5.4pt 0in 5.4pt;height:13.5pt'> Fair value of option ($) </td> <td width="134" valign="top" style='width:100.35pt;padding:0in 5.4pt 0in 5.4pt;height:13.5pt'> 1.032 </td> <td width="134" valign="bottom" style='width:100.35pt;padding:0in 5.4pt 0in 5.4pt;height:13.5pt'> 0.88 </td> <td width="132" valign="bottom" style='width:98.65pt;padding:0in 5.4pt 0in 5.4pt;height:13.5pt'> 0.74 </td> </tr> <tr style='height:13.5pt'> <td width="236" valign="bottom" style='width:176.75pt;background:#CCEEFF;padding:0in 5.4pt 0in 5.4pt;height:13.5pt'> Expected forfeiture (attrition) rate (%) </td> <td width="134" valign="top" style='width:100.35pt;background:#CCEEFF;padding:0in 5.4pt 0in 5.4pt;height:13.5pt'> 0.00 </td> <td width="134" valign="bottom" style='width:100.35pt;background:#CCEEFF;padding:0in 5.4pt 0in 5.4pt;height:13.5pt'> 0.00 5.00 </td> <td width="132" valign="bottom" style='width:98.65pt;background:#CCEEFF;padding:0in 5.4pt 0in 5.4pt;height:13.5pt'> 5.00 - 20.00 </td> </tr> </table> </div>

<div align="center"> <table border="0" cellspacing="0" cellpadding="0" width="651" style='width:488.2pt;border-collapse:collapse'> <tr style='height:9.1pt'> <td width="258" valign="bottom" style='width:193.55pt;padding:0in 5.4pt 0in 5.4pt;height:9.1pt'></td> <td width="164" colspan="2" valign="bottom" style='width:123.35pt;padding:0in 5.4pt 0in 5.4pt;height:9.1pt'></td> <td width="68" colspan="2" valign="bottom" style='width:51.0pt;padding:0in 5.4pt 0in 5.4pt;height:9.1pt'></td> <td width="160" colspan="2" style='border:none;border-bottom:solid windowtext 1.0pt'> </td> </tr> <tr style='height:27.5pt'> <td width="258" valign="bottom" style='width:193.55pt;border:none;border-top:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:27.5pt'>   </td> <td width="113" valign="bottom" style='width:84.8pt;border:none;border-top:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:27.5pt'> Three Months Ended September 30, 2018 </td> <td width="111" colspan="2" valign="bottom" style='width:82.9pt;border:none;border-top:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:27.5pt'> Three Months Ended September 30, 2017 </td> <td width="81" colspan="2" valign="bottom" style='width:60.7pt;border:none;border-top:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:27.5pt'> Six Months Ended September 30, 2018 </td> <td width="88" valign="bottom" style='width:66.25pt;border:none;padding:0in 5.4pt 0in 5.4pt;height:27.5pt'> Six Months Ended September 30, 2017 </td> </tr> <tr style='height:8.7pt'> <td width="258" valign="bottom" style='width:193.55pt;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:8.7pt'>   </td> <td width="113" valign="bottom" style='width:84.8pt;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:8.7pt'>  $ </td> <td width="111" colspan="2" valign="bottom" style='width:82.9pt;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:8.7pt'>  $ </td> <td width="81" colspan="2" valign="bottom" style='width:60.7pt;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:8.7pt'> $ </td> <td width="88" valign="bottom" style='width:66.25pt;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:8.7pt'> $ </td> </tr> <tr style='height:8.7pt'> <td width="258" valign="bottom" style='width:193.55pt;border:none;border-bottom:solid windowtext 1.0pt;background:#CCEEFF;padding:0in 5.4pt 0in 5.4pt;height:8.7pt'> Salary and allowance** </td> <td width="113" valign="bottom" style='width:84.8pt;border:none;border-bottom:solid windowtext 1.0pt;background:#CCEEFF;padding:0in 5.4pt 0in 5.4pt;height:8.7pt'> 181,887 </td> <td width="111" colspan="2" valign="bottom" style='width:82.9pt;border:none;border-bottom:solid windowtext 1.0pt;background:#CCEEFF;padding:0in 5.4pt 0in 5.4pt;height:8.7pt'>               120,052 </td> <td width="81" colspan="2" valign="bottom" style='width:60.7pt;border:none;border-bottom:solid windowtext 1.0pt;background:#CCEEFF;padding:0in 5.4pt 0in 5.4pt;height:8.7pt'> 363,773 </td> <td width="88" valign="bottom" style='width:66.25pt;border:none;border-bottom:solid windowtext 1.0pt;background:#CCEEFF;padding:0in 5.4pt 0in 5.4pt;height:8.7pt'> 270,104 </td> </tr> <tr style='height:8.7pt'> <td width="258" valign="bottom" style='width:193.55pt;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:8.7pt'> Stock based compensation*** </td> <td width="113" valign="bottom" style='width:84.8pt;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:8.7pt'> 421,028 </td> <td width="111" colspan="2" valign="bottom" style='width:82.9pt;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:8.7pt'>               183,981 </td> <td width="81" colspan="2" valign="bottom" style='width:60.7pt;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:8.7pt'> 744,168 </td> <td width="88" valign="bottom" style='width:66.25pt;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:8.7pt'> 374,472 </td> </tr> <tr style='height:9.1pt'> <td width="258" valign="bottom" style='width:193.55pt;border:none;border-bottom:solid windowtext 1.0pt;background:#CCEEFF;padding:0in 5.4pt 0in 5.4pt;height:9.1pt'> Total </td> <td width="113" valign="bottom" style='width:84.8pt;border:none;border-bottom:solid windowtext 1.0pt;background:#CCEEFF;padding:0in 5.4pt 0in 5.4pt;height:9.1pt'> 602,915 </td> <td width="111" colspan="2" valign="bottom" style='width:82.9pt;border:none;border-bottom:solid windowtext 1.0pt;background:#CCEEFF;padding:0in 5.4pt 0in 5.4pt;height:9.1pt'>               304,033 </td> <td width="81" colspan="2" valign="bottom" style='width:60.7pt;border:none;border-bottom:solid windowtext 1.0pt;background:#CCEEFF;padding:0in 5.4pt 0in 5.4pt;height:9.1pt'> 1,107,941 </td> <td width="88" valign="bottom" style='width:66.25pt;border:none;border-bottom:solid windowtext 1.0pt;background:#CCEEFF;padding:0in 5.4pt 0in 5.4pt;height:9.1pt'> 644,576 </td> </tr> <tr align="left"> <td width="258" style='border:none'></td> <td width="113" style='border:none'></td> <td width="51" style='border:none'></td> <td width="59" style='border:none'></td> <td width="9" style='border:none'></td> <td width="72" style='border:none'></td> <td width="88" style='border:none'></td> </tr> </table> </div>

Nevada 2012-08-29

817171

547858

230725

208321

783778 175000 -74855 73572 957495 411483 -1368978 2455000 35249 -1389256 -174800 630797 1556990 1556990 879416

2163884

3569249

-1700949 42128

4074312

-21540 -483524 -3569248 0.0000

0.0062

0.0114

1.0300

1.1800

0.01 1.0 2.50 2.70

380682

916466

390744

1687892

-222690

-140000

-362690

-19935

-380300

-400235

246095

273806

2734530

772978

4027409

384152

669972

2734530

1163722

4952376

-62838

-31250

65000

321314

703722

2734530

1163722

4923288

393333

321314

1097055

2734530

1163722

5316621

3591000

0.0001

-3390503

0.0001

200497

0.0001

-35907

0.0001

164590

0.0001

-164590

0.0001

4147498 3.2306 4147498 1.8337 157500 3.2306 4304998 3.1795 1.24 7.59 2.00 2.58 0.0001

0.0198

0.0281

0.0045

0.0147

0.0004

0.0107

3.0 1.0 3.0 10.0

0.9780

1.4599

1.0100

1.0500

0.9400

0.0000 0.0000 0.0000 1.032 0.88 0.74 0.0000 0.0000 0.0500 0.0500 0.2000

181887

120052

363773

270104

421028

183981

744168

374472

602915

304033

1107941

644576

16530 17026 17536 18062 0001630113 2017-03-31 0001630113 2018-03-31 0001630113 2018-06-30 0001630113 2015-12-31 0001630113 2016-01-01 2016-03-31 0001630113 2016-03-31 0001630113 fil:TotalMember 2017-03-31 0001630113 fil:TotalMember 2017-06-30 0001630113 fil:BrokerWarrantsMember 2017-03-31 0001630113 fil:ConsultantWarrantsMember 2017-03-31 0001630113 fil:PrivatePlacementCommonShareIssuanceWarrantsMember 2017-03-31 0001630113 fil:TotalMember 2017-03-31 0001630113 fil:LessExercisedMemberfil:BrokerWarrantsMember 2017-03-31 0001630113 fil:LessExercisedMemberfil:ConsultantWarrantsMember 2017-03-31 0001630113 fil:LessExercisedMemberfil:TotalMember 2017-03-31 0001630113 fil:LessExpiredMemberfil:BrokerWarrantsMember 2017-03-31 0001630113 fil:LessExpiredMemberfil:ConsultantWarrantsMember 2017-03-31 0001630113 fil:LessExpiredMemberfil:TotalMember 2017-03-31 0001630113 fil:AddIssuedMemberfil:BrokerWarrantsMember 2017-03-31 0001630113 fil:AddIssuedMemberfil:ConsultantWarrantsMember 2017-03-31 0001630113 fil:AddIssuedMemberfil:WarrantsWithConvertibleNotesMember 2017-03-31 0001630113 fil:AddIssuedMemberfil:PrivatePlacementCommonShareIssuanceWarrantsMember 2017-03-31 0001630113 fil:AddIssuedMemberfil:TotalMember 2017-03-31 0001630113 fil:BrokerWarrantsMember 2018-03-31 0001630113 fil:ConsultantWarrantsMember 2018-03-31 0001630113 fil:WarrantsWithConvertibleNotesMember 2018-03-31 0001630113 fil:PrivatePlacementCommonShareIssuanceWarrantsMember 2018-03-31 0001630113 fil:TotalMember 2018-03-31 0001630113 fil:LessExercisedMemberfil:BrokerWarrantsMember 2018-03-31 0001630113 fil:LessExercisedMemberfil:TotalMember 2018-03-31 0001630113 fil:LessExpiredMemberfil:ConsultantWarrantsMember 2018-03-31 0001630113 fil:LessExpiredMemberfil:TotalMember 2018-03-31 0001630113 fil:AddIssuedMemberfil:ConsultantWarrantsMember 2018-03-31 0001630113 fil:AddIssuedMemberfil:TotalMember 2018-03-31 0001630113 fil:BrokerWarrantsMember 2018-06-30 0001630113 fil:ConsultantWarrantsMember 2018-06-30 0001630113 fil:WarrantsWithConvertibleNotesMember 2018-06-30 0001630113 fil:TotalMember 2018-06-30 0001630113 2015-01-01 2015-12-31 0001630113 2017-04-01 2018-06-30 0001630113 fil:StockOptionsGrantedMultiNomialLatticeMember 2016-01-01 2017-12-31 0001630113 fil:StockOptionsGrantedMultiNomialLatticeMember 2015-01-01 2016-12-31 0001630113 2016-01-01 2016-01-31 0001630113 2017-01-01 2017-12-31 0001630113 2018-01-01 2018-12-31 0001630113 2018-04-01 2018-09-30 0001630113 2018-09-30 0001630113 2012-08-29 2018-09-30 0001630113 2016-04-01 2018-09-30 0001630113 fil:TotalMember 2018-09-30 0001630113 2018-07-01 2018-09-30 0001630113 fil:AssumptionsMember 2018-07-01 2018-09-30 0001630113 fil:PrivatePlacementCommonShareIssuanceWarrantsMember 2018-06-30 0001630113 fil:AddIssuedMemberfil:ConsultantWarrantsMember 2018-06-30 0001630113 fil:AddIssuedMemberfil:TotalMember 2018-06-30 0001630113 fil:BrokerWarrantsMember 2018-09-30 0001630113 fil:ConsultantWarrantsMember 2018-09-30 0001630113 fil:WarrantsWithConvertibleNotesMember 2018-09-30 0001630113 fil:PrivatePlacementCommonShareIssuanceWarrantsMember 2018-09-30 0001630113 fil:TotalMember 2018-09-30 0001630113 2016-01-01 2018-09-30 0001630113 2017-07-01 2018-09-30 0001630113 fil:StockOptionsGrantedMultiNomialLatticeMember 2018-01-01 2018-09-30 0001630113 2017-07-01 2017-09-30 0001630113 2017-04-01 2017-09-30 0001630113 2019-01-01 2019-03-31 0001630113 2017-09-30 shares iso4217:USD iso4217:USD shares pure See Note 4 See Note 7 See Note 9 See Note 10 See Notes 7, 8 and 9 See Note 5 See Note 6

EX-101.SCH 7 btcy-20180930.xsd XBRL TAXONOMY EXTENSION SCHEMA 000100 - Disclosure - 5. Convertible Promissory Notes link:presentationLink link:definitionLink link:calculationLink 000090 - Disclosure - 4. Accounts Payable and Accrued Liabilities link:presentationLink link:definitionLink link:calculationLink 000480 - Disclosure - 7. Stockholders' Equity (deficiency): Share-based Compensation, Stock Options, Activity (Details) link:presentationLink link:definitionLink link:calculationLink 000130 - Disclosure - 8. Related Party Transactions and Balances link:presentationLink link:definitionLink link:calculationLink 000260 - Disclosure - 3. Summary of Significant Accounting Policies: Stock Based Compensation (Policies) link:presentationLink link:definitionLink link:calculationLink 000360 - Disclosure - 7. Stockholders' Equity (deficiency): Share-based Compensation, Stock Options, Activity (Tables) link:presentationLink link:definitionLink link:calculationLink 000230 - Disclosure - 3. Summary of Significant Accounting Policies: Operating Leases (Policies) link:presentationLink link:definitionLink link:calculationLink 000520 - Disclosure - 9. Commitments and Contingencies (Details) link:presentationLink link:definitionLink link:calculationLink 000320 - Disclosure - 5. Convertible Promissory Notes: Schedule of Debt (Tables) link:presentationLink link:definitionLink link:calculationLink 000160 - Disclosure - 3. Summary of Significant Accounting Policies: Revenue Recognition (Policies) link:presentationLink link:definitionLink link:calculationLink 000490 - Disclosure - 7. Stockholders' Equity (deficiency): Schedule of Stock Option Activities Table Text Block (Details) link:presentationLink link:definitionLink link:calculationLink 000140 - Disclosure - 9. Commitments and Contingencies link:presentationLink link:definitionLink link:calculationLink 000210 - Disclosure - 3. Summary of Significant Accounting Policies: Accounts Receivable (Policies) link:presentationLink link:definitionLink link:calculationLink 000510 - Disclosure - 8. Related Party Transactions and Balances: Schedule of Related Party Transactions (Details) link:presentationLink link:definitionLink link:calculationLink 000290 - Disclosure - 4. Accounts Payable and Accrued Liabilities: Schedule of Accounts Payable and Accrued Liabilities (Tables) link:presentationLink link:definitionLink link:calculationLink 000380 - Disclosure - 7. Stockholders' Equity (deficiency): Schedule of Assumptions Used (Tables) link:presentationLink link:definitionLink link:calculationLink 000050 - Statement - Biotricity, Inc. - Condensed Consolidated Statements of Cash Flows link:presentationLink link:definitionLink link:calculationLink 000370 - Disclosure - 7. Stockholders' Equity (deficiency): Schedule of Stock Option Activities Table Text Block (Tables) link:presentationLink link:definitionLink link:calculationLink 000420 - Disclosure - 5. Convertible Promissory Notes: Convertible Debt (Details) link:presentationLink link:definitionLink link:calculationLink 000110 - Disclosure - 6. Derivative Liabilities link:presentationLink link:definitionLink link:calculationLink 000150 - Disclosure - 10. Subsequent Events link:presentationLink link:definitionLink link:calculationLink 000470 - Disclosure - 7. Stockholders' Equity (deficiency): Schedule of Stockholders' Equity Note, Warrants or Rights (Details) link:presentationLink link:definitionLink link:calculationLink 000030 - Statement - Statement of Financial Position - Parenthetical link:presentationLink link:definitionLink link:calculationLink 000040 - Statement - Biotricity, Inc. - Condensed Consolidated Statements of Operations and Comprehensive Loss link:presentationLink link:definitionLink link:calculationLink 000240 - Disclosure - 3. Summary of Significant Accounting Policies: Income Taxes (Policies) link:presentationLink link:definitionLink link:calculationLink 000070 - Disclosure - 2. Basis of Presentation, Measurement and Consolidation link:presentationLink link:definitionLink link:calculationLink 000340 - Disclosure - 6. Derivative Liabilities: Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions (Tables) link:presentationLink link:definitionLink link:calculationLink 000180 - Disclosure - 3. Summary of Significant Accounting Policies: Earnings (loss) Per Share (Policies) link:presentationLink link:definitionLink link:calculationLink 000440 - Disclosure - 5. Convertible Promissory Notes: Schedule of Debt (Details) link:presentationLink link:definitionLink link:calculationLink 000300 - Disclosure - 5. Convertible Promissory Notes: Convertible Debt (Tables) link:presentationLink link:definitionLink link:calculationLink 000270 - Disclosure - 3. Summary of Significant Accounting Policies: Convertible Notes Payable and Derivative Instruments (Policies) link:presentationLink link:definitionLink link:calculationLink 000120 - Disclosure - 7. Stockholders' Equity (deficiency) link:presentationLink link:definitionLink link:calculationLink 000170 - Disclosure - 3. Summary of Significant Accounting Policies: Use of Estimates (Policies) link:presentationLink link:definitionLink link:calculationLink 000060 - Disclosure - 1. Nature of Operations link:presentationLink link:definitionLink link:calculationLink 000080 - Disclosure - 3. Summary of Significant Accounting Policies link:presentationLink link:definitionLink link:calculationLink 000010 - Document - Document and Entity Information link:presentationLink link:definitionLink link:calculationLink 000430 - Disclosure - 5. Convertible Promissory Notes: Schedule of Accreted Value of Bridge Notes Table Text Block (Details) link:presentationLink link:definitionLink link:calculationLink 000500 - Disclosure - 7. Stockholders' Equity (deficiency): Schedule of Assumptions Used (Details) link:presentationLink link:definitionLink link:calculationLink 000350 - Disclosure - 7. Stockholders' Equity (deficiency): Schedule of Stockholders' Equity Note, Warrants or Rights (Tables) link:presentationLink link:definitionLink link:calculationLink 000460 - Disclosure - 6. Derivative Liabilities: Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions (Details) link:presentationLink link:definitionLink link:calculationLink 000390 - Disclosure - 8. Related Party Transactions and Balances: Schedule of Related Party Transactions (Tables) link:presentationLink link:definitionLink link:calculationLink 000310 - Disclosure - 5. Convertible Promissory Notes: Schedule of Accreted Value of Bridge Notes Table Text Block (Tables) link:presentationLink link:definitionLink link:calculationLink 000200 - Disclosure - 3. Summary of Significant Accounting Policies: Foreign Currency Translation (Policies) link:presentationLink link:definitionLink link:calculationLink 000250 - Disclosure - 3. Summary of Significant Accounting Policies: Research and Development (Policies) link:presentationLink link:definitionLink link:calculationLink 000400 - Disclosure - 1. Nature of Operations (Details) link:presentationLink link:definitionLink link:calculationLink 000280 - Disclosure - 3. Summary of Significant Accounting Policies: Recently Issued Accounting Pronouncements (Policies) link:presentationLink link:definitionLink link:calculationLink 000020 - Statement - Biotricity, Inc. - Condensed Consolidated Balance Sheets link:presentationLink link:definitionLink link:calculationLink 000330 - Disclosure - 6. Derivative Liabilities: Schedule of Derivative Assets at Fair Value (Tables) link:presentationLink link:definitionLink link:calculationLink 000190 - Disclosure - 3. Summary of Significant Accounting Policies: Cash (Policies) link:presentationLink link:definitionLink link:calculationLink 000450 - Disclosure - 6. Derivative Liabilities: Schedule of Derivative Assets at Fair Value (Details) link:presentationLink link:definitionLink link:calculationLink 000410 - Disclosure - 4. Accounts Payable and Accrued Liabilities: Schedule of Accounts Payable and Accrued Liabilities (Details) link:presentationLink link:definitionLink link:calculationLink 000220 - Disclosure - 3. Summary of Significant Accounting Policies: Fair Value of Financial Instruments (Policies) link:presentationLink link:definitionLink link:calculationLink EX-101.CAL 8 btcy-20180930_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 9 btcy-20180930_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 10 btcy-20180930_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Lease Operating Expenses Represents the monetary amount of Lease Operating Expenses, during the indicated time period. Expected Forfeiture Rate, Maximum Expected Forfeiture Rate, Maximum. Stock Options Granted - Multi-Nomial Lattice Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number Total Conversion of Notes Traferred to Equity Accreted Value of Convertible Promissory Notes. Fair Value of Financial Instruments 10. Subsequent Events 2. Basis of Presentation, Measurement and Consolidation Cash flows from financing activities: Accounts payable and accrued liabilities {1} Accounts payable and accrued liabilities Common Stock, Par Value Subsequent Events Represents the monetary amount of Subsequent Events, as of the indicated date. TOTAL LIABILITIES AND STOCKHOLDERS' (DEFICIENCY) EQUITY TOTAL LIABILITIES AND STOCKHOLDERS' (DEFICIENCY) EQUITY Common stock Entity Incorporation, Date of Incorporation Document Fiscal Period Focus Entity Central Index Key Fair Value Exercise Price Maximum Represents the per-share monetary value of Fair Value Exercise Price Maximum, during the indicated time period. Stock Options Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum Assumptions Assumptions [Axis] Schedule of Accounts Payable and Accrued Liabilities Cash, beginning of period Cash, beginning of period Cash, end of period Cost of revenue Amendment Flag Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price Face Value of Convertible Promissory Notes Issued Face Value of Convertible Promissory Notes Issued. Net loss Accumulated other comprehensive loss Entity Incorporation, State Country Name Entity Public Float Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Less Expired Derivative Liability, Fair Value, Gross Liability Accretion Expense, Including Loss on Conversion Accretion Expense, Including Loss on Conversion. Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions Convertible Notes Payable and Derivative Instruments Convertible Notes Payable and Derivative Instruments Policy Text Block. Research and Development Net Cash provided by financing activities Net Cash provided by financing activities Inventory Income taxes Common Stock, Shares Authorized Stock Options Exercised Stock Options Exercised. Less Exercised Private Placement Common Share Issuance Warrants Stock Price2 Stock Price. Derivative Liability, Current Derivative Liabilities Accrued Liabilities, Current Earnings (loss) Per Share Policies Net (decrease) increase in cash during the period Net (decrease) increase in cash during the period Accretion expense Expenses: Revenue Preferred Stock, Shares Issued Stock Price Stock Price. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum Assumptions {1} Assumptions Transferred to Equity Upon Conversion of Notes Represents the monetary amount of Transferred to Equity Upon Conversion of Notes, as of the indicated date. Schedule of Assumptions Used Foreign Currency Translation Cash {1} Cash Effect of foreign currency translation Represents the monetary amount of Effect of foreign currency translation, during the indicated time period. Harmonized sales tax recoverable {1} Harmonized sales tax recoverable Represents the monetary amount of Harmonized sales tax recoverable, increase decrease, during the indicated time period. Additional paid-in capital Harmonized sales tax recoverable Represents the monetary amount of Harmonized sales tax recoverable, as of the indicated date. Statement of Financial Position Balance Sheets - Parenthetical Stock Options Exercised - Weighted Average Exercise Price Stock Options Exercised - Weighted Average Exercise Price. Add Issued Accretion Expense {1} Accretion Expense Represents the monetary amount of Accretion Expense, during the indicated time period. Tables/Schedules Income Taxes Accounts Receivable 6. Derivative Liabilities 3. Summary of Significant Accounting Policies 1. Nature of Operations Proceeds from exercise of warrants Fair value of warrants issued Represents the monetary amount of Fair value of warrants issued, during the indicated time period. Weighted average number of common shares outstanding Translation adjustment Commitments and Contingencies TOTAL LIABILITIES TOTAL LIABILITIES Document Fiscal Year Focus Entity Well-known Seasoned Issuer Related Party Tax Expense, Due to Affiliates, Current Employee Benefits and Share-based Compensation Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price Share based compensation arrangement by share based payment award options exercised during period Share based compensation arrangement by share based payment award options exercised during period. Warrants with Convertible Notes Accreted value of convertible promissory note Represents the monetary amount of Accreted value of convertible promissory note, as of the indicated date. Conversion of Notes Transferred to Equity Conversion of Notes Transferred to Equity. Schedule of Debt Convertible Debt {1} Convertible Debt Preferred Stock, Shares Authorized TOTAL STOCKHOLDERS' (DEFICIENCY) EQUITY TOTAL STOCKHOLDERS' (DEFICIENCY) EQUITY Entity Registrant Name Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures Stockholders Equity2 Statement [Line Items] Cash Financing Costs Cash Financing Costs.. Accreted Value of Convertible Promissory Notes Accreted Value of Convertible Promissory Notes. 9. Commitments and Contingencies Issuance of shares for services Represents the monetary amount of Issuance of shares for services, during the indicated time period. Net revenue Income Statement Common Stock, Shares Issued Preferred Stock, Shares Outstanding CURRENT ASSETS Compensation Stockholders Equity2 [Axis] Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum Accounts Payable, Trade, Current Schedule of Stock Option Activities Table Text Block Represents the textual narrative disclosure of Schedule of Stock Option Activities Table Text Block, during the indicated time period. Operating Leases Represents the textual narrative disclosure of Operating Leases, during the indicated time period. Issuance of convertible debentures, net Represents the monetary amount of Issuance of convertible debentures, net, during the indicated time period. Issuance of shares, net Represents the monetary amount of Issuance of shares, net, during the indicated time period. Deposits and other receivables {2} Deposits and other receivables Net loss before income taxes Total Operating Expenses Accumulated deficit Cash Stockholders Equity [Axis] Transferred to Additional Paid In Capital Represents the monetary amount of Transferred to Additional Paid In Capital, as of the indicated date. Statement [Table] Accreted Value of Promissory Notes Accreted Value of Promissory Notes. Use of Estimates Notes Net Cash used in operating activities Net Cash used in operating activities Accounts receivable Comprehensive loss NON-CURRENT ASSETS Class of Warrant or Right, Outstanding Remaining Term 2 Remaining Term, in years. Change in Fair Value of Derivatives Change in Fair Value of Derivatives. Accretion Expense {2} Accretion Expense Accretion Expense. Share-based Compensation, Stock Options, Activity Schedule of Accreted Value of Bridge Notes Table Text Block Represents the textual narrative disclosure of Schedule of Accreted Value of Bridge Notes Table Text Block, during the indicated time period. 8. Related Party Transactions and Balances Cash flow from operating activities: Research and development expenses Accounts payable and accrued liabilities Accounts receivable, no allowance Represents the monetary amount of Accounts receivable, no allowance, as of the indicated date. Entity Voluntary Filers Entity Common Stock, Shares Outstanding Document and Entity Information: Stock Options Outstanding - Weighted Average Exercise Price Stock Options Outstanding - Weighted Average Exercise Price Stock Options Outstanding Stock Options Outstanding. Accretion Expense of Bridge Notes Represents the monetary amount of Accretion Expense of Bridge Notes, as of the indicated date. Discount Recognized at Issuance Due to Embedded Derivatives Discount Recognized at Issuance Due to Embedded Derivatives. Stock Based Compensation Statement of Cash Flows Shares to be issued Represents the monetary amount of Shares to be issued, as of the indicated date. Deposits and other receivables {1} Deposits and other receivables Total Current Assets Total Current Assets Broker Warrants Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum Transferred to Accumulated Deficit Represents the monetary amount of Transferred to Accumulated Deficit, as of the indicated date. Derivative Liabilities [Axis] Discount Recognized due to Embedded Derivatives Discount Recognized due to Embedded Derivatives. Details Schedule of Stockholders' Equity Note, Warrants or Rights Revenue Recognition Changes in operating assets and liabilities: Common Stock, Shares Outstanding Preferred Stock, Par Value Preferred stock Stockholders' (Deficiency) Equity Current Liabilities: Deposits and other receivables Entity Current Reporting Status Stock Options Granted - Weighted Average Exercise Price Stock Options Granted - Weighted Average Exercise Price. Consultant Warrants Dividend Yield Represents the Dividend Yield, during the indicated time period. Reversal of Fair Value Represents the monetary amount of Reversal of Fair Value, as of the indicated date. Convertbile Promissory Note Face Value Convertbile Promissory Note Face Value Schedule of Derivative Assets at Fair Value Recently Issued Accounting Pronouncements 5. Convertible Promissory Notes Change in fair value of derivative liabilities Represents the monetary amount of Change in fair value of derivative liabilities, during the indicated time period. Total Assets Total Assets Entity Filer Category Current Fiscal Year End Date Trading Symbol Document Period End Date Expected Forfeiture Rate, Minimum Expected Forfeiture Rate, Minimum. Stock Options [Axis] Stockholders Equity EX-101.PRE 11 btcy-20180930_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 12 R1.htm IDEA: XBRL DOCUMENT

Document and Entity Information	6 Months Ended	73 Months Ended
Document and Entity Information	Sep. 30, 2018 shares	Sep. 30, 2018 shares
Document and Entity Information:
Entity Registrant Name	BIOTRICITY INC.
Document Type	10-Q
Document Period End Date	Sep. 30, 2018
Trading Symbol	btcy
Amendment Flag	false
Entity Central Index Key	0001630113
Current Fiscal Year End Date	--03-31
Entity Common Stock, Shares Outstanding	27,605,567	27,605,567
Entity Filer Category	Non-accelerated Filer
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Well-known Seasoned Issuer	No
Document Fiscal Year Focus	2019
Document Fiscal Period Focus	Q2
Entity Incorporation, State Country Name		Nevada
Entity Incorporation, Date of Incorporation		Aug. 29, 2012

XML 13 R2.htm IDEA: XBRL DOCUMENT

Biotricity, Inc. - Condensed Consolidated Balance Sheets - USD ($)

Sep. 30, 2018

Mar. 31, 2018

CURRENT ASSETS

Cash

$ 83,254

$ 843,643

Accounts receivable, no allowance

43,436

Inventory, net

179,430

Harmonized sales tax recoverable

51,316

35,737

Deposits and other receivables

28,984

17,046

Total Current Assets

386,420

896,426

NON-CURRENT ASSETS

Deposits and other receivables

33,000

Total Assets

419,420

929,426

Current Liabilities:

Accounts payable and accrued liabilities

^[1]

1,047,896

756,179

TOTAL LIABILITIES

1,047,896

756,179

Stockholders' (Deficiency) Equity

Preferred stock

Common stock

^[2]

33,331

31,858

Shares to be issued

^[2]

80,216

69,963

Additional paid-in capital

30,935,575

27,161,984

Accumulated other comprehensive loss

(632,912)

(643,129)

Accumulated deficit

(31,044,687)

(26,447,430)

TOTAL STOCKHOLDERS' (DEFICIENCY) EQUITY

(628,476)

173,247

TOTAL LIABILITIES AND STOCKHOLDERS' (DEFICIENCY) EQUITY

419,420

929,426

Commitments and Contingencies

^[3]

Subsequent Events

^[4]

[1]	See Note 4
[2]	See Note 7
[3]	See Note 9
[4]	See Note 10

XML 14 R3.htm IDEA: XBRL DOCUMENT

Statement of Financial Position - Parenthetical - $ / shares	Sep. 30, 2018	Mar. 31, 2018
Statement of Financial Position
Preferred Stock, Par Value	$ 0.001	$ 0.001
Preferred Stock, Shares Authorized	10,000,000	10,000,000
Preferred Stock, Shares Issued	1	1
Preferred Stock, Shares Outstanding	1	1
Common Stock, Par Value	$ 0.001	$ 0.001
Common Stock, Shares Authorized	125,000,000	125,000,000
Common Stock, Shares Issued	27,605,567	23,713,602
Common Stock, Shares Outstanding	27,605,567	23,713,602

XML 15 R4.htm IDEA: XBRL DOCUMENT

Biotricity, Inc. - Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($)

3 Months Ended

6 Months Ended

Sep. 30, 2018

Sep. 30, 2017

Sep. 30, 2018

Sep. 30, 2017

Income Statement

Revenue

$ 84,760

$ 102,420

Cost of revenue

47,118

56,918

Net revenue

37,642

45,502

Expenses:

General and administrative expenses

^[1]

2,026,523

$ 1,041,275

4,154,829

$ 2,129,474

Research and development expenses

187,859

413,624

487,930

728,734

Total Operating Expenses

2,214,382

1,454,899

4,642,759

2,858,208

Accretion expense

^[2]

879,416

Change in fair value of derivative liabilities

^[3]

20,588

Net loss before income taxes

(2,176,740)

(1,454,899)

(4,597,257)

(3,758,212)

Income taxes

Net loss

(2,176,740)

(1,454,899)

(4,597,257)

(3,758,212)

Translation adjustment

112,866

(83,858)

10,217

(170,348)

Comprehensive loss

$ (2,063,874)

$ (1,538,757)

$ (4,587,040)

$ (3,928,560)

Loss per share, basic and diluted

$ (0.066)

$ (0.048)

$ (0.142)

$ (0.127)

Weighted average number of common shares outstanding

32,819,848

30,590,667

32,377,274

29,529,534

[1]	See Notes 7, 8 and 9
[2]	See Note 5
[3]	See Note 6

XML 16 R5.htm IDEA: XBRL DOCUMENT

Biotricity, Inc. - Condensed Consolidated Statements of Cash Flows - USD ($)

3 Months Ended

6 Months Ended

Sep. 30, 2018

Sep. 30, 2017

Sep. 30, 2018

Sep. 30, 2017

Cash flow from operating activities:

Net loss

$ (2,176,740)

$ (1,454,899)

$ (4,597,257)

$ (3,758,212)

Adjustments to reconcile net loss to net cash used in operations

Stock based compensation

728,162

442,155

Issuance of shares for services

898,025

419,217

Issuance of warrants for services, at fair value

368,352

174,976

Accretion expense

^[1]

879,416

Change in fair value of derivative liabilities

^[2]

20,588

Fair value of warrants issued

Changes in operating assets and liabilities:

Accounts receivable

(43,436)

Inventory

(179,430)

Harmonized sales tax recoverable

(15,580)

(19,602)

Deposits and other receivables

(11,939)

7,983

Accounts payable and accrued liabilities

182,465

(374,650)

Net Cash used in operating activities

(2,670,638)

(2,208,129)

Cash flows from financing activities:

Issuance of shares, net

1,739,943

2,340,409

Proceeds from exercise of warrants

50,835

Issuance of convertible debentures, net

Due to shareholders

Net Cash provided by financing activities

1,790,778

2,340,409

Effect of foreign currency translation

119,471

50,001

Net (decrease) increase in cash during the period

(879,860)

132,280

Cash, beginning of period

843,643

424,868

Cash, end of period

$ 83,254

$ 607,149

$ 83,254

$ 607,149

[1]	See Note 5
[2]	See Note 6

XML 17 R6.htm IDEA: XBRL DOCUMENT

1. Nature of Operations

6 Months Ended

Sep. 30, 2018

Notes

1. Nature of Operations

1. NATURE OF OPERATIONS

Biotricity Inc. (formerly MetaSolutions, Inc.) (the “Company”) was incorporated under the laws of the State of Nevada on August 29, 2012.

iMedical Innovations Inc. (“iMedical”), a wholly-owned subsidiary of the Company, was incorporated on July 3, 2014 under the laws of the Province of Ontario, Canada.

XML 18 R7.htm IDEA: XBRL DOCUMENT

2. Basis of Presentation, Measurement and Consolidation

6 Months Ended

Sep. 30, 2018

Notes

2. Basis of Presentation, Measurement and Consolidation

2. BASIS OF PRESENTATION, MEASUREMENT AND CONSOLIDATION

Liquidity and Basis of Presentation

XML 19 R8.htm IDEA: XBRL DOCUMENT

3. Summary of Significant Accounting Policies

6 Months Ended

Sep. 30, 2018

Notes

3. Summary of Significant Accounting Policies

3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Revenue Recognition

The Company has adopted the Financial Accounting Standards Board’s (“FASB”) Accounting Standards Codification (“ASC”) Topic 606.

Inventory

Use of Estimates

Earnings (Loss) Per Share

Cash

Cash includes cash on hand and balances with banks.

Foreign Currency Translation

Accounts Receivable

Fair Value of Financial Instruments

		Level 1 – Valuation based on quoted market prices in active markets for identical assets or liabilities.

		Level 2 – Valuation based on quoted market prices for similar assets and liabilities in active markets.

		Level 3 – Valuation based on unobservable inputs that are supported by little or no market activity, therefore requiring management’s best estimate of what market participants would use as fair value.

Operating Leases

Income Taxes

Research and Development

Stock Based Compensation

Convertible Notes Payable and Derivative Instruments

Recently Issued Accounting Pronouncements

XML 20 R9.htm IDEA: XBRL DOCUMENT

4. Accounts Payable and Accrued Liabilities

6 Months Ended

Sep. 30, 2018

Notes

4. Accounts Payable and Accrued Liabilities

4. ACCOUNTS PAYABLE AND ACCRUED LIABILITIES

	As at September 30, 2018	As at March 31, 2018
	$	$
Accounts payable	817,171	547,858
Accrued liabilities	230,725	208,321
	1,047,896	756,179

XML 21 R10.htm IDEA: XBRL DOCUMENT

5. Convertible Promissory Notes

6 Months Ended

Sep. 30, 2018

Notes

5. Convertible Promissory Notes

5. CONVERTIBLE PROMISSORY NOTES

	$
Accreted value of convertible promissory notes as at December 31, 2015	783,778
Face value of convertible promissory notes issued during March 2016	175,000
Discount recognized at issuance due to embedded derivatives	(74,855)
Accretion expense for three months March 31, 2016	73,572
Accreted value of convertible promissory notes as at March 31, 2016	957,495
Accretion expense - including loss on conversion of $88,530	411,483
Conversion of the notes transferred to equity	(1,368,978)
Accreted value of convertible promissory notes at September 30, 2018 and March 31, 2018	-

In connection with the Bridge Notes offering, the accreted value of this offering was as follows as at March 31, 2017:

As at March 31, 2017	$
Face value of Bridge Notes issued	2,455,000
Day one derivative loss recognized during the year	35,249
Discount recognized at issuance due to embedded derivatives	(1,389,256)
Cash financing costs	(174,800)
Accretion expense	630,797
Accreted value of Bridge Notes	1,556,990

On May 31, 2017, all Bridge Notes, having a face value of $2,436,406, were converted into Units of a private placement offering of the Company’s common stock:

	$
Accreted value of Bridge Note as of March 31, 2017	1,556,990
Accretion expense	879,416
Conversion of Bridge Notes transferred to equity (Note 7, c)	(2,436,406)
Face value of Bridge Notes as of September 30, 2018 and March 31, 2018	-

XML 22 R11.htm IDEA: XBRL DOCUMENT

6. Derivative Liabilities

6 Months Ended

Sep. 30, 2018

Notes

6. Derivative Liabilities

6. DERIVATIVE LIABILITIES

Balance Sheet Impacts Under ASU 2017-11	As of April 1, 2017
Accumulated Deficit	$ 483,524
Derivative Liabilities	(483,524)

The impact on the unaudited June 30, 2017 Balance Sheet and Statement of Operations is as follows:

Balance Sheet Impacts Under ASU 2017-11	As of June 30, 2017
Derivative Liabilities	$ (4,074,312)
Additional Paid in Capital	3,569,248
Accumulated Deficit	483,524

Income Statement Impacts Under ASU 2017-11	As of June 30, 2017
Reversal of change in fair value of derivative liabilities	$ 21,540

	Total
	$
Derivative liabilities as at March 31, 2017	2,163,884
Derivative fair value at issuance	3,569,249
Transferred to equity upon conversion of notes (Notes 5 and 7)	(1,700,949)
Change in fair value of derivatives	42,128
Derivative liabilities as at June 30, 2017 (pre-adoption)	4,074,312
Adjustments relating to adoption of ASU 2017-11
Reversal of fair value	(21,540)
Transferred to accumulated deficit	(483,524)
Transferred to additional paid-in-capital	(3,569,248)
Derivative liabilities as at September 30, 2018 and March 31, 2018 (post adoption)	-

The lattice methodology was used to value the derivative components, using the following assumptions:

	Assumptions
Dividend yield	0.00%
Risk-free rate for term	0.62% – 1.14%
Volatility	103% – 118%
Remaining terms (Years)	0.01 – 1.0
Stock price ($ per share)	$2.50 and $2.70

XML 23 R12.htm IDEA: XBRL DOCUMENT

7. Stockholders' Equity (deficiency)

6 Months Ended

Sep. 30, 2018

Notes

7. Stockholders' Equity (deficiency)

7. STOCKHOLDERS’ EQUITY (DEFICIENCY)

a) Authorized stock

b) Exchange Agreement

As initially described in Note 1 above, on February 2, 2016:

The Company issued approximately 1.197 shares of its common stock in exchange for each common share of iMedical held by the iMedical shareholders who in general terms, are not residents of Canada (for the purposes of the Income Tax Act (Canada). Accordingly, the Company issued 13,376,947 shares;
Shareholders of iMedical who in general terms, are Canadian residents (for the purposes of the Income Tax Act (Canada)) received approximately 1.197 Exchangeable Shares in the capital of Exchangeco in exchange for each common share of iMedical held. Accordingly, the Company issued 9,123,031 Exchangeable Shares;
Each outstanding option to purchase common shares in iMedical (whether vested or unvested) was exchanged, without any further action or consideration on the part of the holder of such option, for approximately 1.197 economically equivalent replacement options with an inverse adjustment to the exercise price of the replacement option to reflect the exchange ratio of approximately 1.197:1;
Each outstanding warrant to purchase common shares in iMedical was adjusted, in accordance with the terms thereof, such that it entitles the holder to receive approximately 1.197 shares of the common stock of the Company for each warrant, with an inverse adjustment to the exercise price of the warrants to reflect the exchange ratio of approximately 1.197:1
Each outstanding advisor warrant to purchase common shares in iMedical was adjusted, in accordance with the terms thereof, such that it entitles the holder to receive approximately 1.197 shares of the common stock of the Company for each advisor warrant, with an inverse adjustment to the exercise price of the Advisor Warrants to reflect the exchange ratio of approximately 1.197:1; and
The outstanding 11% secured convertible promissory notes of iMedical were adjusted, in accordance with the adjustment provisions thereof, as and from closing, so as to permit the holders to convert (and in some circumstances permit the Company to force the conversion of) the convertible promissory notes into shares of the common stock of the Company at a 25% discount to purchase price per share in Biotricity’s next offering.

c) Share issuances

Share issuances during the year ended March 31, 2018

During the year ended March 31, 2018, the Company completed a registered offering, which raised net proceeds of $2,520,561 million through the issuance of 450,164 common shares.

Share issuances during the six months ended September 30, 2018

During the six months ended September 30, 2018, the Company entered into an agreement with a private equity investment fund (the “Investor”) to establish a committed equity purchase facility, which allows the Company, at its sole option, subject to certain conditions, to direct the Investor to make multiple common share purchases that in aggregate can be up to $25 million (the “Aggregate Amount”) during the term of the facility, which will be up to 36 months. As part of the initial closing of this transaction, the Investor purchased 128,750 shares of common stock of the Company, at a price of $4.00 per share, for gross proceeds of $515,000 and paid the Investor $15,000 in issuance costs. As compensation for providing this equity purchase facility, the Company also issued to the Investor an additional 121,344 shares (representing a dollar value equal to 1.6% of the aggregate amount, or $400,000, at a price per share that was equal to the average of the closing sale prices of the common shares for the ten (10) consecutive business days prior to the closing date of the transaction). The size and purchase price for each future drawdown under this agreement is governed by the purchase facilities agreement and is predicated on trading volumes as well as the average trading and closing prices of the common stock on the day of drawdown and the prior ten (10) trading days, such that the purchase price is always fixed and know at the time the Company elects to sell shares to the Investor. During the six months ended September 30, 2018, the Company sold a further 669,226 shares under this facility and raised aggregate gross proceeds of $1,819,943.

d) Shares to be issued

Common stock to be issued of 32,083 shares ($80,216) is comprised of:

19,583 shares of common stock issued to consultants in connection with services rendered during the quarter with a fair value of $37,404; and
12,500 shares of common stock to be issued to a consultant, which represents an obligation recognized in prior periods, with a fair value of $42,812.

The fair value of these shares was determined by using the market price of the common stock as at the date of issuance obligation.

e) Warrant issuances

Warrant issuances during the year ended March 31, 2018

Warrant issuances during the six months ended September 30, 2018

During the six months ended September 30, 2018, the Company issued 458,333 warrants as compensation for advisor and consultant services, which were fair valued at $368.352 and expensed in general and administrative expenses, with a corresponding credit to additional paid in capital. Their fair value has been estimated using a multi-nomial lattice model with an expected life of 3 years, a risk free rate ranging from 2.13% to 2.81%, stock price of $1.24 to $4.15 and expected volatility of 97.8% to 138.27%.

	Broker Warrants	Consultant Warrants	Warrants Issued on Conversion of Convertible Notes	Private Placement Warrants	Total
As at March 31, 2017	380,682	916,466	-	390,744	1,687,892
Less: Exercised	(222,690)	(140,000)	-	-	(362,690)
Less: Expired/cancelled	(19,935)	(380,300)	-	-	(400,235)
Add: Issued	246,095	273,806	2,734,530	772,978	4,027,409
As at March 31, 2018	384,152	669,972*	2,734,530	1,163,722	4,952,376

Less: Exercised	(62,838)	-	-	-	(62,838)
Less: Expired/cancelled	-	(31,250)	-	-	(31,250)
Add: Issued	-	65,000	-	-	65,000
As at June 30, 2018	321,314	703,722*	2,734,530	1,163,722	4,923,288

Less: Exercised	-	-	-	-	-
Less: Expired/cancelled	-	- **	-	-
Add: Issued	-	393,333	-	-	393,333
As at September 30, 2018	321,314	1,097,055*	2,734,530	1,163,722	5,316,621

Exercise Price	$ 0.78-$3.00	$ 1.24-$7.59	2.00	3.00
Expiration Date	October 2019 to July 2022	October 2018 to September 2021	March 2020 to November 2022	April 2020 to July 2020

*Consultant Warrants as at September 30, 2018 include an aggregate of 188,806 warrants provided to an officer of the Company as compensation while he was not a member of any Company options plan.

** Subsequent to September 30, 2018, 210,416 warrants expired unexercised.

f) Warrant exercises

During the six months ended September 30, 2018, 62,838 warrants were exercised at an average exercise price of approximately $0.7839. The Company received $50,835 of cash proceeds.

g) Stock-based compensation

2015 Equity Incentive Plan

The following table summarizes the stock option activities of the Company:


	Number of options	Weighted average exercise price ($)
Granted	3,591,000	0.0001
Exercised	(3,390,503)	0.0001
Outstanding as of December 31, 2015	200,497	0.0001
Cancelled during 2016	(35,907)	0.0001
Outstanding as of March 31, 2018	164,590	0.0001
Exercised	(164,590)	0.0001
Outstanding as of September 30, 2018	-

2016 Equity Incentive Plan

The Plan shall continue in effect until its termination by the board of directors or committee formed by the board; provided, however, that all awards shall be granted, if at all, on or before the day immediately preceding the tenth (10th) anniversary of the effective date. The maximum number of shares of stock that may be issued under the Plan pursuant to awards shall be equal to 3,750,000 shares; provided that the maximum number of shares of stock that may be issued under the Plan shall automatically and without any further Company or shareholder approval, increase on January 1 of each year for not more than 10 years from the effective date, so the number of shares that may be issued is an amount no greater than 15% of the Company’s outstanding shares of stock and shares of stock underlying any outstanding exchangeable shares as of such January 1; provided further that no such increase shall be effective if it would violate any applicable law or stock exchange rule or regulation, or result in adverse tax consequences to the Company or any participant that would not otherwise result but for the increase.

During the year ended March 31, 2018, an additional 1,437,500 stock options were granted with a weighted average remaining contractual life from 2.76 to 9.51 years.


	Number of options	Weighted average exercise price ($)
Granted	4,147,498	3.2306
Exercised	-	-
Outstanding as of June 30 and March 31, 2018	4,147,498	1.8337
Granted	157,500	3.2306
Exercised	-	-
Outstanding as of September 30, 2018	4,304,998	3.1795

The fair value of each option granted is estimated at the time of grant using multi-nomial lattice model using the following assumptions:

	2017-2018	2016-2017	2015-2016
Exercise price ($)	1.24-7.59	2.00 – 2.58	0.0001
Risk free interest rate (%)	1.98-2.81	0.45 - 1.47	0.04 - 1.07
Expected term (Years)	3.0	1.0 - 3.0	10.0
Expected volatility (%)	97.8-145.99	101 – 105	94
Expected dividend yield (%)	0.00	0.00	0.00
Fair value of option ($)	1.032	0.88	0.74
Expected forfeiture (attrition) rate (%)	0.00	0.00 – 5.00	5.00 - 20.00

XML 24 R13.htm IDEA: XBRL DOCUMENT

8. Related Party Transactions and Balances

6 Months Ended

Sep. 30, 2018

Notes

8. RELATED PARTY TRANSACTIONS AND BALANCES


	Three Months Ended September 30, 2018	Three Months Ended September 30, 2017	Six Months Ended September 30, 2018	Six Months Ended September 30, 2017
	$	$	$	$
Salary and allowance**	181,887	120,052	363,773	270,104
Stock based compensation***	421,028	183,981	744,168	374,472
Total	602,915	304,033	1,107,941	644,576

The above expenses were recorded under general and administrative expenses.

* Salary and allowance include salary, car allowance, vacation pay, bonus and other allowances paid or payable to key management of the Company.

** Stock based compensation represent the fair value of the options, warrants and equity incentive plan for directors and key management of the Company.

XML 25 R14.htm IDEA: XBRL DOCUMENT

9. Commitments and Contingencies

6 Months Ended

Sep. 30, 2018

Notes

9. Commitments and Contingencies

9. COMMITMENTS AND CONTINGENCIES

XML 26 R15.htm IDEA: XBRL DOCUMENT

10. Subsequent Events

6 Months Ended

Sep. 30, 2018

Notes

10. Subsequent Events

10. SUBSEQUENT EVENTS

During July 2018, the Board of Directors of the company adopted a new compensation program for directors which includes cash compensation for the current fiscal year of $24,000, equity compensation for the current fiscal year to include 31,250 shares of the Company’s common stock and 31,250 options to purchase shares of the Company’s common stock at $2.00 per share, such options to vest and be fully exercisable upon the first anniversary from the date upon which a director was named to the Board. On November 4, 2018, the Company increased the size of its Board to 4 Directors and immediately filled the vacancy by appointing a new Director, , who will be compensated using this same compensation program.

XML 27 R16.htm IDEA: XBRL DOCUMENT

3. Summary of Significant Accounting Policies: Revenue Recognition (Policies)

6 Months Ended

Sep. 30, 2018

Policies

Revenue Recognition

Revenue Recognition

The Company has adopted the Financial Accounting Standards Board’s (“FASB”) Accounting Standards Codification (“ASC”) Topic 606.

XML 28 R17.htm IDEA: XBRL DOCUMENT

3. Summary of Significant Accounting Policies: Use of Estimates (Policies)

6 Months Ended

Sep. 30, 2018

Policies

Use of Estimates

Use of Estimates

XML 29 R18.htm IDEA: XBRL DOCUMENT

3. Summary of Significant Accounting Policies: Earnings (loss) Per Share (Policies)

6 Months Ended

Sep. 30, 2018

Policies

Earnings (loss) Per Share

Earnings (Loss) Per Share

XML 30 R19.htm IDEA: XBRL DOCUMENT

3. Summary of Significant Accounting Policies: Cash (Policies)

6 Months Ended

Sep. 30, 2018

Policies

Cash

Cash

Cash includes cash on hand and balances with banks.

XML 31 R20.htm IDEA: XBRL DOCUMENT

3. Summary of Significant Accounting Policies: Foreign Currency Translation (Policies)

6 Months Ended

Sep. 30, 2018

Policies

Foreign Currency Translation

Foreign Currency Translation

XML 32 R21.htm IDEA: XBRL DOCUMENT

3. Summary of Significant Accounting Policies: Accounts Receivable (Policies)

6 Months Ended

Sep. 30, 2018

Policies

Accounts Receivable

Accounts Receivable

- Definition

Disclosure of accounting policy for trade and other accounts receivables. This disclosure may include the basis at which such receivables are carried in the entity's statements of financial position (for example, net realizable value), how the entity determines the level of its allowance for doubtful accounts, when impairments, charge-offs or recoveries are recognized, and the entity's income recognition policies for such receivables, including its treatment of related fees and costs, its treatment of premiums, discounts or unearned income, when accrual of interest is discontinued, how the entity records payments received on nonaccrual receivables and its policy for resuming accrual of interest on such receivables. If the enterprise holds a large number of similar loans, disclosure may include the accounting policy for the anticipation of prepayments and significant assumptions underlying prepayment estimates for amortization of premiums, discounts, and nonrefundable fees and costs.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section 50
-Paragraph 11B
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=84173941&loc=SL6953423-111524

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(9))
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=84159169&loc=d3e10133-111534

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(3))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(5))
-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(4))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section 50
-Paragraph 15
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=84173941&loc=d3e5212-111524

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=84173941&loc=d3e5093-111524

+ Details

XML 33 R22.htm IDEA: XBRL DOCUMENT

3. Summary of Significant Accounting Policies: Fair Value of Financial Instruments (Policies)

6 Months Ended

Sep. 30, 2018

Policies

Fair Value of Financial Instruments

Fair Value of Financial Instruments

		Level 1 – Valuation based on quoted market prices in active markets for identical assets or liabilities.

		Level 2 – Valuation based on quoted market prices for similar assets and liabilities in active markets.

		Level 3 – Valuation based on unobservable inputs that are supported by little or no market activity, therefore requiring management’s best estimate of what market participants would use as fair value.

XML 34 R23.htm IDEA: XBRL DOCUMENT

3. Summary of Significant Accounting Policies: Operating Leases (Policies)

6 Months Ended

Sep. 30, 2018

Policies

Operating Leases

Operating Leases

XML 35 R24.htm IDEA: XBRL DOCUMENT

3. Summary of Significant Accounting Policies: Income Taxes (Policies)

6 Months Ended

Sep. 30, 2018

Policies

Income Taxes

Income Taxes

- Definition

Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.

+ References + Details

XML 36 R25.htm IDEA: XBRL DOCUMENT

3. Summary of Significant Accounting Policies: Research and Development (Policies)

6 Months Ended

Sep. 30, 2018

Policies

Research and Development

Research and Development

XML 37 R26.htm IDEA: XBRL DOCUMENT

3. Summary of Significant Accounting Policies: Stock Based Compensation (Policies)

6 Months Ended

Sep. 30, 2018

Policies

Stock Based Compensation

Stock Based Compensation

XML 38 R27.htm IDEA: XBRL DOCUMENT

3. Summary of Significant Accounting Policies: Convertible Notes Payable and Derivative Instruments (Policies)

6 Months Ended

Sep. 30, 2018

Policies

Convertible Notes Payable and Derivative Instruments

Convertible Notes Payable and Derivative Instruments

XML 39 R28.htm IDEA: XBRL DOCUMENT

3. Summary of Significant Accounting Policies: Recently Issued Accounting Pronouncements (Policies)

6 Months Ended

Sep. 30, 2018

Policies

Recently Issued Accounting Pronouncements

Recently Issued Accounting Pronouncements

XML 40 R29.htm IDEA: XBRL DOCUMENT

4. Accounts Payable and Accrued Liabilities: Schedule of Accounts Payable and Accrued Liabilities (Tables)

6 Months Ended

Sep. 30, 2018

Tables/Schedules

Schedule of Accounts Payable and Accrued Liabilities

	As at September 30, 2018	As at March 31, 2018
	$	$
Accounts payable	817,171	547,858
Accrued liabilities	230,725	208,321
	1,047,896	756,179

XML 41 R30.htm IDEA: XBRL DOCUMENT

5. Convertible Promissory Notes: Convertible Debt (Tables)

6 Months Ended

Sep. 30, 2018

Tables/Schedules

Convertible Debt

	$
Accreted value of convertible promissory notes as at December 31, 2015	783,778
Face value of convertible promissory notes issued during March 2016	175,000
Discount recognized at issuance due to embedded derivatives	(74,855)
Accretion expense for three months March 31, 2016	73,572
Accreted value of convertible promissory notes as at March 31, 2016	957,495
Accretion expense - including loss on conversion of $88,530	411,483
Conversion of the notes transferred to equity	(1,368,978)
Accreted value of convertible promissory notes at September 30, 2018 and March 31, 2018	-

XML 42 R31.htm IDEA: XBRL DOCUMENT

5. Convertible Promissory Notes: Schedule of Accreted Value of Bridge Notes Table Text Block (Tables)

6 Months Ended

Sep. 30, 2018

Tables/Schedules

Schedule of Accreted Value of Bridge Notes Table Text Block

As at March 31, 2017	$
Face value of Bridge Notes issued	2,455,000
Day one derivative loss recognized during the year	35,249
Discount recognized at issuance due to embedded derivatives	(1,389,256)
Cash financing costs	(174,800)
Accretion expense	630,797
Accreted value of Bridge Notes	1,556,990

XML 43 R32.htm IDEA: XBRL DOCUMENT

5. Convertible Promissory Notes: Schedule of Debt (Tables)

6 Months Ended

Sep. 30, 2018

Tables/Schedules

Schedule of Debt

	$
Accreted value of Bridge Note as of March 31, 2017	1,556,990
Accretion expense	879,416
Conversion of Bridge Notes transferred to equity (Note 7, c)	(2,436,406)
Face value of Bridge Notes as of September 30, 2018 and March 31, 2018	-

XML 44 R33.htm IDEA: XBRL DOCUMENT

6. Derivative Liabilities: Schedule of Derivative Assets at Fair Value (Tables)

6 Months Ended

Sep. 30, 2018

Tables/Schedules

Schedule of Derivative Assets at Fair Value

	Total
	$
Derivative liabilities as at March 31, 2017	2,163,884
Derivative fair value at issuance	3,569,249
Transferred to equity upon conversion of notes (Notes 5 and 7)	(1,700,949)
Change in fair value of derivatives	42,128
Derivative liabilities as at June 30, 2017 (pre-adoption)	4,074,312
Adjustments relating to adoption of ASU 2017-11
Reversal of fair value	(21,540)
Transferred to accumulated deficit	(483,524)
Transferred to additional paid-in-capital	(3,569,248)
Derivative liabilities as at September 30, 2018 and March 31, 2018 (post adoption)	-

XML 45 R34.htm IDEA: XBRL DOCUMENT

6. Derivative Liabilities: Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions (Tables)

6 Months Ended

Sep. 30, 2018

Tables/Schedules

Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions

	Assumptions
Dividend yield	0.00%
Risk-free rate for term	0.62% – 1.14%
Volatility	103% – 118%
Remaining terms (Years)	0.01 – 1.0
Stock price ($ per share)	$2.50 and $2.70

XML 46 R35.htm IDEA: XBRL DOCUMENT

7. Stockholders' Equity (deficiency): Schedule of Stockholders' Equity Note, Warrants or Rights (Tables)

6 Months Ended

Sep. 30, 2018

Tables/Schedules

Schedule of Stockholders' Equity Note, Warrants or Rights

	Broker Warrants	Consultant Warrants	Warrants Issued on Conversion of Convertible Notes	Private Placement Warrants	Total
As at March 31, 2017	380,682	916,466	-	390,744	1,687,892
Less: Exercised	(222,690)	(140,000)	-	-	(362,690)
Less: Expired/cancelled	(19,935)	(380,300)	-	-	(400,235)
Add: Issued	246,095	273,806	2,734,530	772,978	4,027,409
As at March 31, 2018	384,152	669,972*	2,734,530	1,163,722	4,952,376

Less: Exercised	(62,838)	-	-	-	(62,838)
Less: Expired/cancelled	-	(31,250)	-	-	(31,250)
Add: Issued	-	65,000	-	-	65,000
As at June 30, 2018	321,314	703,722*	2,734,530	1,163,722	4,923,288

Less: Exercised	-	-	-	-	-
Less: Expired/cancelled	-	- **	-	-
Add: Issued	-	393,333	-	-	393,333
As at September 30, 2018	321,314	1,097,055*	2,734,530	1,163,722	5,316,621

Exercise Price	$ 0.78-$3.00	$ 1.24-$7.59	2.00	3.00
Expiration Date	October 2019 to July 2022	October 2018 to September 2021	March 2020 to November 2022	April 2020 to July 2020

- Definition

Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.

+ References + Details

XML 47 R36.htm IDEA: XBRL DOCUMENT

7. Stockholders' Equity (deficiency): Share-based Compensation, Stock Options, Activity (Tables)

6 Months Ended

Sep. 30, 2018

Tables/Schedules

Share-based Compensation, Stock Options, Activity


	Number of options	Weighted average exercise price ($)
Granted	3,591,000	0.0001
Exercised	(3,390,503)	0.0001
Outstanding as of December 31, 2015	200,497	0.0001
Cancelled during 2016	(35,907)	0.0001
Outstanding as of March 31, 2018	164,590	0.0001
Exercised	(164,590)	0.0001
Outstanding as of September 30, 2018	-

XML 48 R37.htm IDEA: XBRL DOCUMENT

7. Stockholders' Equity (deficiency): Schedule of Stock Option Activities Table Text Block (Tables)

6 Months Ended

Sep. 30, 2018

Tables/Schedules

Schedule of Stock Option Activities Table Text Block


	Number of options	Weighted average exercise price ($)
Granted	4,147,498	3.2306
Exercised	-	-
Outstanding as of June 30 and March 31, 2018	4,147,498	1.8337
Granted	157,500	3.2306
Exercised	-	-
Outstanding as of September 30, 2018	4,304,998	3.1795

XML 49 R38.htm IDEA: XBRL DOCUMENT

7. Stockholders' Equity (deficiency): Schedule of Assumptions Used (Tables)

6 Months Ended

Sep. 30, 2018

Tables/Schedules

Schedule of Assumptions Used

	2017-2018	2016-2017	2015-2016
Exercise price ($)	1.24-7.59	2.00 – 2.58	0.0001
Risk free interest rate (%)	1.98-2.81	0.45 - 1.47	0.04 - 1.07
Expected term (Years)	3.0	1.0 - 3.0	10.0
Expected volatility (%)	97.8-145.99	101 – 105	94
Expected dividend yield (%)	0.00	0.00	0.00
Fair value of option ($)	1.032	0.88	0.74
Expected forfeiture (attrition) rate (%)	0.00	0.00 – 5.00	5.00 - 20.00

XML 50 R39.htm IDEA: XBRL DOCUMENT

8. Related Party Transactions and Balances: Schedule of Related Party Transactions (Tables)

6 Months Ended

Sep. 30, 2018

Tables/Schedules

Schedule of Related Party Transactions


	Three Months Ended September 30, 2018	Three Months Ended September 30, 2017	Six Months Ended September 30, 2018	Six Months Ended September 30, 2017
	$	$	$	$
Salary and allowance**	181,887	120,052	363,773	270,104
Stock based compensation***	421,028	183,981	744,168	374,472
Total	602,915	304,033	1,107,941	644,576

XML 51 R40.htm IDEA: XBRL DOCUMENT

1. Nature of Operations (Details)	73 Months Ended
1. Nature of Operations (Details)	Sep. 30, 2018
Details
Entity Incorporation, State Country Name	Nevada
Entity Incorporation, Date of Incorporation	Aug. 29, 2012

XML 52 R41.htm IDEA: XBRL DOCUMENT

4. Accounts Payable and Accrued Liabilities: Schedule of Accounts Payable and Accrued Liabilities (Details) - USD ($)	Sep. 30, 2018	Mar. 31, 2018
Details
Accounts Payable, Trade, Current	$ 817,171	$ 547,858
Accrued Liabilities, Current	$ 230,725	$ 208,321

XML 53 R42.htm IDEA: XBRL DOCUMENT

5. Convertible Promissory Notes: Convertible Debt (Details) - USD ($)	3 Months Ended	30 Months Ended
	Mar. 31, 2016	Sep. 30, 2018	Dec. 31, 2015
Details
Accreted Value of Convertible Promissory Notes	$ 957,495		$ 783,778
Convertbile Promissory Note Face Value	175,000
Discount Recognized due to Embedded Derivatives	(74,855)
Accretion Expense	$ 73,572
Accretion Expense, Including Loss on Conversion		$ 411,483
Conversion of Notes Transferred to Equity		$ (1,368,978)

XML 54 R43.htm IDEA: XBRL DOCUMENT

5. Convertible Promissory Notes: Schedule of Accreted Value of Bridge Notes Table Text Block (Details)	Mar. 31, 2017 USD ($)
Details
Face Value of Convertible Promissory Notes Issued	$ 2,455,000
Day One Derivative Loss Recognized During the Year	35,249
Discount Recognized at Issuance Due to Embedded Derivatives	(1,389,256)
Cash Financing Costs	(174,800)
Accretion Expense	630,797
Accreted Value of Promissory Notes	$ 1,556,990

XML 55 R44.htm IDEA: XBRL DOCUMENT

5. Convertible Promissory Notes: Schedule of Debt (Details)	Mar. 31, 2017 USD ($)
Details
Accreted value of convertible promissory note	$ 1,556,990
Accretion Expense of Bridge Notes	$ 879,416

XML 56 R45.htm IDEA: XBRL DOCUMENT

6. Derivative Liabilities: Schedule of Derivative Assets at Fair Value (Details) - Total - USD ($)	Sep. 30, 2018	Jun. 30, 2017	Mar. 31, 2017
Derivative Liability, Current		$ 4,074,312	$ 2,163,884
Derivative Liability, Fair Value, Gross Liability			3,569,249
Transferred to Equity Upon Conversion of Notes			(1,700,949)
Change in Fair Value of Derivatives			$ 42,128
Reversal of Fair Value	$ (21,540)
Transferred to Accumulated Deficit	(483,524)
Transferred to Additional Paid In Capital	$ (3,569,248)

XML 57 R46.htm IDEA: XBRL DOCUMENT

6. Derivative Liabilities: Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions (Details)	3 Months Ended
	Sep. 30, 2018
Dividend Yield	0.00%
Assumptions
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum	0.62%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum	1.14%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum	103.00%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum	118.00%
Remaining Term1	0.01
Remaining Term 2	1.0
Stock Price	2.50
Stock Price2	2.70

XML 58 R47.htm IDEA: XBRL DOCUMENT

7. Stockholders' Equity (deficiency): Schedule of Stockholders' Equity Note, Warrants or Rights (Details) - shares	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Mar. 31, 2017
Broker Warrants
Class of Warrant or Right, Outstanding	321,314	321,314	384,152	380,682
Broker Warrants \| Less Exercised
Class of Warrant or Right, Outstanding			(62,838)	(222,690)
Broker Warrants \| Less Expired
Class of Warrant or Right, Outstanding				(19,935)
Broker Warrants \| Add Issued
Class of Warrant or Right, Outstanding				246,095
Consultant Warrants
Class of Warrant or Right, Outstanding	1,097,055	703,722	669,972	916,466
Consultant Warrants \| Less Exercised
Class of Warrant or Right, Outstanding				(140,000)
Consultant Warrants \| Less Expired
Class of Warrant or Right, Outstanding			(31,250)	(380,300)
Consultant Warrants \| Add Issued
Class of Warrant or Right, Outstanding		393,333	65,000	273,806
Warrants with Convertible Notes
Class of Warrant or Right, Outstanding	2,734,530	2,734,530	2,734,530
Warrants with Convertible Notes \| Add Issued
Class of Warrant or Right, Outstanding				2,734,530
Private Placement Common Share Issuance Warrants
Class of Warrant or Right, Outstanding	1,163,722	1,163,722	1,163,722	390,744
Private Placement Common Share Issuance Warrants \| Add Issued
Class of Warrant or Right, Outstanding				772,978
Total
Class of Warrant or Right, Outstanding	5,316,621	4,923,288	4,952,376	1,687,892
Total \| Less Exercised
Class of Warrant or Right, Outstanding			(62,838)	(362,690)
Total \| Less Expired
Class of Warrant or Right, Outstanding			(31,250)	(400,235)
Total \| Add Issued
Class of Warrant or Right, Outstanding		393,333	65,000	4,027,409

XML 59 R48.htm IDEA: XBRL DOCUMENT

7. Stockholders' Equity (deficiency): Share-based Compensation, Stock Options, Activity (Details) - $ / shares	6 Months Ended	12 Months Ended	33 Months Ended
	Sep. 30, 2018	Dec. 31, 2015	Sep. 30, 2018	Mar. 31, 2018
Details
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures		3,591,000
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price		$ 0.0001
Share based compensation arrangement by share based payment award options exercised during period	(164,590)	(3,390,503)
Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price		$ 0.0001
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number		200,497		164,590
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price	$ 0.0001	$ 0.0001	$ 0.0001	$ 0.0001
Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period			(35,907)
Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price			$ 0.0001

XML 60 R49.htm IDEA: XBRL DOCUMENT

7. Stockholders' Equity (deficiency): Schedule of Stock Option Activities Table Text Block (Details) - $ / shares	15 Months Ended
	Sep. 30, 2018	Jun. 30, 2018
Details
Stock Options Granted	157,500	4,147,498
Stock Options Granted - Weighted Average Exercise Price	$ 3.2306	$ 3.2306
Stock Options Outstanding	4,304,998	4,147,498
Stock Options Outstanding - Weighted Average Exercise Price	$ 3.1795	$ 1.8337

XML 61 R50.htm IDEA: XBRL DOCUMENT

7. Stockholders' Equity (deficiency): Schedule of Assumptions Used (Details) - Stock Options Granted - Multi-Nomial Lattice	9 Months Ended	24 Months Ended
	Sep. 30, 2018 $ / shares	Dec. 31, 2017 $ / shares	Dec. 31, 2016 $ / shares
Stock Price	1.24	2.00	0.0001
Stock Price2	7.59	2.58
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum	1.98%	0.45%	0.04%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum	2.81%	1.47%	1.07%
Remaining Term 2	3.0	3.0	10.0
Remaining Term1		1.0
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum	97.80%	101.00%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum	145.99%	105.00%	94.00%
Expected Dividend Yield	0.00%	0.00%	0.00%
Fair Value Exercise Price Maximum	$ 1.032	$ 0.88	$ 0.74
Expected Forfeiture Rate, Minimum	0.00%	0.00%	5.00%
Expected Forfeiture Rate, Maximum		5.00%	20.00%

XML 62 R51.htm IDEA: XBRL DOCUMENT

8. Related Party Transactions and Balances: Schedule of Related Party Transactions (Details) - USD ($)	3 Months Ended		6 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Details
Compensation	$ 181,887	$ 120,052	$ 363,773	$ 270,104
Employee Benefits and Share-based Compensation	421,028	183,981	744,168	374,472
Related Party Tax Expense, Due to Affiliates, Current	$ 602,915	$ 304,033	$ 1,107,941	$ 644,576

XML 63 R52.htm IDEA: XBRL DOCUMENT

9. Commitments and Contingencies (Details) - USD ($)	1 Months Ended	3 Months Ended	12 Months Ended
9. Commitments and Contingencies (Details) - USD ($)	Jan. 31, 2016	Mar. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Details
Lease Operating Expenses	$ 16,530	$ 18,062	$ 17,536	$ 17,026

EXCEL 64 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 65 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 66 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 68 FilingSummary.xml IDEA: XBRL DOCUMENT 3.10.0.1 html 67 164 1 true 11 0 false 4 false false R1.htm 000010 - Document - Document and Entity Information Sheet http://www.biotricity.com/20180930/role/idr_DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 000020 - Statement - Biotricity, Inc. - Condensed Consolidated Balance Sheets Sheet http://www.biotricity.com/20180930/role/idr_BiotricityIncCondensedConsolidatedBalanceSheets Biotricity, Inc. - Condensed Consolidated Balance Sheets Statements 2 false false R3.htm 000030 - Statement - Statement of Financial Position - Parenthetical Sheet http://www.biotricity.com/20180930/role/idr_StatementOfFinancialPositionParenthetical Statement of Financial Position - Parenthetical Statements 3 false false R4.htm 000040 - Statement - Biotricity, Inc. - Condensed Consolidated Statements of Operations and Comprehensive Loss Sheet http://www.biotricity.com/20180930/role/idr_BiotricityIncCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss Biotricity, Inc. - Condensed Consolidated Statements of Operations and Comprehensive Loss Statements 4 false false R5.htm 000050 - Statement - Biotricity, Inc. - Condensed Consolidated Statements of Cash Flows Sheet http://www.biotricity.com/20180930/role/idr_BiotricityIncCondensedConsolidatedStatementsOfCashFlows Biotricity, Inc. - Condensed Consolidated Statements of Cash Flows Statements 5 false false R6.htm 000060 - Disclosure - 1. Nature of Operations Sheet http://www.biotricity.com/20180930/role/idr_Disclosure1NatureOfOperations 1. Nature of Operations Notes 6 false false R7.htm 000070 - Disclosure - 2. Basis of Presentation, Measurement and Consolidation Sheet http://www.biotricity.com/20180930/role/idr_Disclosure2BasisOfPresentationMeasurementAndConsolidation 2. Basis of Presentation, Measurement and Consolidation Notes 7 false false R8.htm 000080 - Disclosure - 3. Summary of Significant Accounting Policies Sheet http://www.biotricity.com/20180930/role/idr_Disclosure3SummaryOfSignificantAccountingPolicies 3. Summary of Significant Accounting Policies Notes 8 false false R9.htm 000090 - Disclosure - 4. Accounts Payable and Accrued Liabilities Sheet http://www.biotricity.com/20180930/role/idr_Disclosure4AccountsPayableAndAccruedLiabilities 4. Accounts Payable and Accrued Liabilities Notes 9 false false R10.htm 000100 - Disclosure - 5. Convertible Promissory Notes Notes http://www.biotricity.com/20180930/role/idr_Disclosure5ConvertiblePromissoryNotes 5. Convertible Promissory Notes Notes 10 false false R11.htm 000110 - Disclosure - 6. Derivative Liabilities Sheet http://www.biotricity.com/20180930/role/idr_Disclosure6DerivativeLiabilities 6. Derivative Liabilities Notes 11 false false R12.htm 000120 - Disclosure - 7. Stockholders' Equity (deficiency) Sheet http://www.biotricity.com/20180930/role/idr_Disclosure7StockholdersEquityDeficiency 7. Stockholders' Equity (deficiency) Notes 12 false false R13.htm 000130 - Disclosure - 8. Related Party Transactions and Balances Sheet http://www.biotricity.com/20180930/role/idr_Disclosure8RelatedPartyTransactionsAndBalances 8. Related Party Transactions and Balances Notes 13 false false R14.htm 000140 - Disclosure - 9. Commitments and Contingencies Sheet http://www.biotricity.com/20180930/role/idr_Disclosure9CommitmentsAndContingencies 9. Commitments and Contingencies Notes 14 false false R15.htm 000150 - Disclosure - 10. Subsequent Events Sheet http://www.biotricity.com/20180930/role/idr_Disclosure10SubsequentEvents 10. Subsequent Events Notes 15 false false R16.htm 000160 - Disclosure - 3. Summary of Significant Accounting Policies: Revenue Recognition (Policies) Sheet http://www.biotricity.com/20180930/role/idr_Disclosure3SummaryOfSignificantAccountingPoliciesRevenueRecognitionPolicies 3. Summary of Significant Accounting Policies: Revenue Recognition (Policies) Policies http://www.biotricity.com/20180930/role/idr_Disclosure3SummaryOfSignificantAccountingPolicies 16 false false R17.htm 000170 - Disclosure - 3. Summary of Significant Accounting Policies: Use of Estimates (Policies) Sheet http://www.biotricity.com/20180930/role/idr_Disclosure3SummaryOfSignificantAccountingPoliciesUseOfEstimatesPolicies 3. Summary of Significant Accounting Policies: Use of Estimates (Policies) Policies http://www.biotricity.com/20180930/role/idr_Disclosure3SummaryOfSignificantAccountingPolicies 17 false false R18.htm 000180 - Disclosure - 3. Summary of Significant Accounting Policies: Earnings (loss) Per Share (Policies) Sheet http://www.biotricity.com/20180930/role/idr_Disclosure3SummaryOfSignificantAccountingPoliciesEarningsLossPerSharePolicies 3. Summary of Significant Accounting Policies: Earnings (loss) Per Share (Policies) Policies http://www.biotricity.com/20180930/role/idr_Disclosure3SummaryOfSignificantAccountingPolicies 18 false false R19.htm 000190 - Disclosure - 3. Summary of Significant Accounting Policies: Cash (Policies) Sheet http://www.biotricity.com/20180930/role/idr_Disclosure3SummaryOfSignificantAccountingPoliciesCashPolicies 3. Summary of Significant Accounting Policies: Cash (Policies) Policies http://www.biotricity.com/20180930/role/idr_Disclosure3SummaryOfSignificantAccountingPolicies 19 false false R20.htm 000200 - Disclosure - 3. Summary of Significant Accounting Policies: Foreign Currency Translation (Policies) Sheet http://www.biotricity.com/20180930/role/idr_Disclosure3SummaryOfSignificantAccountingPoliciesForeignCurrencyTranslationPolicies 3. Summary of Significant Accounting Policies: Foreign Currency Translation (Policies) Policies http://www.biotricity.com/20180930/role/idr_Disclosure3SummaryOfSignificantAccountingPolicies 20 false false R21.htm 000210 - Disclosure - 3. Summary of Significant Accounting Policies: Accounts Receivable (Policies) Sheet http://www.biotricity.com/20180930/role/idr_Disclosure3SummaryOfSignificantAccountingPoliciesAccountsReceivablePolicies 3. Summary of Significant Accounting Policies: Accounts Receivable (Policies) Policies http://www.biotricity.com/20180930/role/idr_Disclosure3SummaryOfSignificantAccountingPolicies 21 false false R22.htm 000220 - Disclosure - 3. Summary of Significant Accounting Policies: Fair Value of Financial Instruments (Policies) Sheet http://www.biotricity.com/20180930/role/idr_Disclosure3SummaryOfSignificantAccountingPoliciesFairValueOfFinancialInstrumentsPolicies 3. Summary of Significant Accounting Policies: Fair Value of Financial Instruments (Policies) Policies http://www.biotricity.com/20180930/role/idr_Disclosure3SummaryOfSignificantAccountingPolicies 22 false false R23.htm 000230 - Disclosure - 3. Summary of Significant Accounting Policies: Operating Leases (Policies) Sheet http://www.biotricity.com/20180930/role/idr_Disclosure3SummaryOfSignificantAccountingPoliciesOperatingLeasesPolicies 3. Summary of Significant Accounting Policies: Operating Leases (Policies) Policies http://www.biotricity.com/20180930/role/idr_Disclosure3SummaryOfSignificantAccountingPolicies 23 false false R24.htm 000240 - Disclosure - 3. Summary of Significant Accounting Policies: Income Taxes (Policies) Sheet http://www.biotricity.com/20180930/role/idr_Disclosure3SummaryOfSignificantAccountingPoliciesIncomeTaxesPolicies 3. Summary of Significant Accounting Policies: Income Taxes (Policies) Policies http://www.biotricity.com/20180930/role/idr_Disclosure3SummaryOfSignificantAccountingPolicies 24 false false R25.htm 000250 - Disclosure - 3. Summary of Significant Accounting Policies: Research and Development (Policies) Sheet http://www.biotricity.com/20180930/role/idr_Disclosure3SummaryOfSignificantAccountingPoliciesResearchAndDevelopmentPolicies 3. Summary of Significant Accounting Policies: Research and Development (Policies) Policies http://www.biotricity.com/20180930/role/idr_Disclosure3SummaryOfSignificantAccountingPolicies 25 false false R26.htm 000260 - Disclosure - 3. Summary of Significant Accounting Policies: Stock Based Compensation (Policies) Sheet http://www.biotricity.com/20180930/role/idr_Disclosure3SummaryOfSignificantAccountingPoliciesStockBasedCompensationPolicies 3. Summary of Significant Accounting Policies: Stock Based Compensation (Policies) Policies http://www.biotricity.com/20180930/role/idr_Disclosure3SummaryOfSignificantAccountingPolicies 26 false false R27.htm 000270 - Disclosure - 3. Summary of Significant Accounting Policies: Convertible Notes Payable and Derivative Instruments (Policies) Notes http://www.biotricity.com/20180930/role/idr_Disclosure3SummaryOfSignificantAccountingPoliciesConvertibleNotesPayableAndDerivativeInstrumentsPolicies 3. Summary of Significant Accounting Policies: Convertible Notes Payable and Derivative Instruments (Policies) Policies http://www.biotricity.com/20180930/role/idr_Disclosure3SummaryOfSignificantAccountingPolicies 27 false false R28.htm 000280 - Disclosure - 3. Summary of Significant Accounting Policies: Recently Issued Accounting Pronouncements (Policies) Sheet http://www.biotricity.com/20180930/role/idr_Disclosure3SummaryOfSignificantAccountingPoliciesRecentlyIssuedAccountingPronouncementsPolicies 3. Summary of Significant Accounting Policies: Recently Issued Accounting Pronouncements (Policies) Policies http://www.biotricity.com/20180930/role/idr_Disclosure3SummaryOfSignificantAccountingPolicies 28 false false R29.htm 000290 - Disclosure - 4. Accounts Payable and Accrued Liabilities: Schedule of Accounts Payable and Accrued Liabilities (Tables) Sheet http://www.biotricity.com/20180930/role/idr_Disclosure4AccountsPayableAndAccruedLiabilitiesScheduleOfAccountsPayableAndAccruedLiabilitiesTables 4. Accounts Payable and Accrued Liabilities: Schedule of Accounts Payable and Accrued Liabilities (Tables) Tables 29 false false R30.htm 000300 - Disclosure - 5. Convertible Promissory Notes: Convertible Debt (Tables) Notes http://www.biotricity.com/20180930/role/idr_Disclosure5ConvertiblePromissoryNotesConvertibleDebtTables 5. Convertible Promissory Notes: Convertible Debt (Tables) Tables 30 false false R31.htm 000310 - Disclosure - 5. Convertible Promissory Notes: Schedule of Accreted Value of Bridge Notes Table Text Block (Tables) Notes http://www.biotricity.com/20180930/role/idr_Disclosure5ConvertiblePromissoryNotesScheduleOfAccretedValueOfBridgeNotesTableTextBlockTables 5. Convertible Promissory Notes: Schedule of Accreted Value of Bridge Notes Table Text Block (Tables) Tables 31 false false R32.htm 000320 - Disclosure - 5. Convertible Promissory Notes: Schedule of Debt (Tables) Notes http://www.biotricity.com/20180930/role/idr_Disclosure5ConvertiblePromissoryNotesScheduleOfDebtTables 5. Convertible Promissory Notes: Schedule of Debt (Tables) Tables 32 false false R33.htm 000330 - Disclosure - 6. Derivative Liabilities: Schedule of Derivative Assets at Fair Value (Tables) Sheet http://www.biotricity.com/20180930/role/idr_Disclosure6DerivativeLiabilitiesScheduleOfDerivativeAssetsAtFairValueTables 6. Derivative Liabilities: Schedule of Derivative Assets at Fair Value (Tables) Tables 33 false false R34.htm 000340 - Disclosure - 6. Derivative Liabilities: Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions (Tables) Sheet http://www.biotricity.com/20180930/role/idr_Disclosure6DerivativeLiabilitiesScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTables 6. Derivative Liabilities: Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions (Tables) Tables 34 false false R35.htm 000350 - Disclosure - 7. Stockholders' Equity (deficiency): Schedule of Stockholders' Equity Note, Warrants or Rights (Tables) Sheet http://www.biotricity.com/20180930/role/idr_Disclosure7StockholdersEquityDeficiencyScheduleOfStockholdersEquityNoteWarrantsOrRightsTables 7. Stockholders' Equity (deficiency): Schedule of Stockholders' Equity Note, Warrants or Rights (Tables) Tables http://www.biotricity.com/20180930/role/idr_Disclosure7StockholdersEquityDeficiency 35 false false R36.htm 000360 - Disclosure - 7. Stockholders' Equity (deficiency): Share-based Compensation, Stock Options, Activity (Tables) Sheet http://www.biotricity.com/20180930/role/idr_Disclosure7StockholdersEquityDeficiencyShareBasedCompensationStockOptionsActivityTables 7. Stockholders' Equity (deficiency): Share-based Compensation, Stock Options, Activity (Tables) Tables http://www.biotricity.com/20180930/role/idr_Disclosure7StockholdersEquityDeficiency 36 false false R37.htm 000370 - Disclosure - 7. Stockholders' Equity (deficiency): Schedule of Stock Option Activities Table Text Block (Tables) Sheet http://www.biotricity.com/20180930/role/idr_Disclosure7StockholdersEquityDeficiencyScheduleOfStockOptionActivitiesTableTextBlockTables 7. Stockholders' Equity (deficiency): Schedule of Stock Option Activities Table Text Block (Tables) Tables http://www.biotricity.com/20180930/role/idr_Disclosure7StockholdersEquityDeficiency 37 false false R38.htm 000380 - Disclosure - 7. Stockholders' Equity (deficiency): Schedule of Assumptions Used (Tables) Sheet http://www.biotricity.com/20180930/role/idr_Disclosure7StockholdersEquityDeficiencyScheduleOfAssumptionsUsedTables 7. Stockholders' Equity (deficiency): Schedule of Assumptions Used (Tables) Tables http://www.biotricity.com/20180930/role/idr_Disclosure7StockholdersEquityDeficiency 38 false false R39.htm 000390 - Disclosure - 8. Related Party Transactions and Balances: Schedule of Related Party Transactions (Tables) Sheet http://www.biotricity.com/20180930/role/idr_Disclosure8RelatedPartyTransactionsAndBalancesScheduleOfRelatedPartyTransactionsTables 8. Related Party Transactions and Balances: Schedule of Related Party Transactions (Tables) Tables 39 false false R40.htm 000400 - Disclosure - 1. Nature of Operations (Details) Sheet http://www.biotricity.com/20180930/role/idr_Disclosure1NatureOfOperationsDetails 1. Nature of Operations (Details) Details http://www.biotricity.com/20180930/role/idr_Disclosure1NatureOfOperations 40 false false R41.htm 000410 - Disclosure - 4. Accounts Payable and Accrued Liabilities: Schedule of Accounts Payable and Accrued Liabilities (Details) Sheet http://www.biotricity.com/20180930/role/idr_Disclosure4AccountsPayableAndAccruedLiabilitiesScheduleOfAccountsPayableAndAccruedLiabilitiesDetails 4. Accounts Payable and Accrued Liabilities: Schedule of Accounts Payable and Accrued Liabilities (Details) Details http://www.biotricity.com/20180930/role/idr_Disclosure4AccountsPayableAndAccruedLiabilitiesScheduleOfAccountsPayableAndAccruedLiabilitiesTables 41 false false R42.htm 000420 - Disclosure - 5. Convertible Promissory Notes: Convertible Debt (Details) Notes http://www.biotricity.com/20180930/role/idr_Disclosure5ConvertiblePromissoryNotesConvertibleDebtDetails 5. Convertible Promissory Notes: Convertible Debt (Details) Details http://www.biotricity.com/20180930/role/idr_Disclosure5ConvertiblePromissoryNotesConvertibleDebtTables 42 false false R43.htm 000430 - Disclosure - 5. Convertible Promissory Notes: Schedule of Accreted Value of Bridge Notes Table Text Block (Details) Notes http://www.biotricity.com/20180930/role/idr_Disclosure5ConvertiblePromissoryNotesScheduleOfAccretedValueOfBridgeNotesTableTextBlockDetails 5. Convertible Promissory Notes: Schedule of Accreted Value of Bridge Notes Table Text Block (Details) Details http://www.biotricity.com/20180930/role/idr_Disclosure5ConvertiblePromissoryNotesScheduleOfAccretedValueOfBridgeNotesTableTextBlockTables 43 false false R44.htm 000440 - Disclosure - 5. Convertible Promissory Notes: Schedule of Debt (Details) Notes http://www.biotricity.com/20180930/role/idr_Disclosure5ConvertiblePromissoryNotesScheduleOfDebtDetails 5. Convertible Promissory Notes: Schedule of Debt (Details) Details http://www.biotricity.com/20180930/role/idr_Disclosure5ConvertiblePromissoryNotesScheduleOfAccretedValueOfBridgeNotesTableTextBlockTables 44 false false R45.htm 000450 - Disclosure - 6. Derivative Liabilities: Schedule of Derivative Assets at Fair Value (Details) Sheet http://www.biotricity.com/20180930/role/idr_Disclosure6DerivativeLiabilitiesScheduleOfDerivativeAssetsAtFairValueDetails 6. Derivative Liabilities: Schedule of Derivative Assets at Fair Value (Details) Details http://www.biotricity.com/20180930/role/idr_Disclosure6DerivativeLiabilitiesScheduleOfDerivativeAssetsAtFairValueTables 45 false false R46.htm 000460 - Disclosure - 6. Derivative Liabilities: Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions (Details) Sheet http://www.biotricity.com/20180930/role/idr_Disclosure6DerivativeLiabilitiesScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsDetails 6. Derivative Liabilities: Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions (Details) Details http://www.biotricity.com/20180930/role/idr_Disclosure6DerivativeLiabilitiesScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTables 46 false false R47.htm 000470 - Disclosure - 7. Stockholders' Equity (deficiency): Schedule of Stockholders' Equity Note, Warrants or Rights (Details) Sheet http://www.biotricity.com/20180930/role/idr_Disclosure7StockholdersEquityDeficiencyScheduleOfStockholdersEquityNoteWarrantsOrRightsDetails 7. Stockholders' Equity (deficiency): Schedule of Stockholders' Equity Note, Warrants or Rights (Details) Details http://www.biotricity.com/20180930/role/idr_Disclosure7StockholdersEquityDeficiencyScheduleOfStockholdersEquityNoteWarrantsOrRightsTables 47 false false R48.htm 000480 - Disclosure - 7. Stockholders' Equity (deficiency): Share-based Compensation, Stock Options, Activity (Details) Sheet http://www.biotricity.com/20180930/role/idr_Disclosure7StockholdersEquityDeficiencyShareBasedCompensationStockOptionsActivityDetails 7. Stockholders' Equity (deficiency): Share-based Compensation, Stock Options, Activity (Details) Details http://www.biotricity.com/20180930/role/idr_Disclosure7StockholdersEquityDeficiencyScheduleOfStockholdersEquityNoteWarrantsOrRightsTables 48 false false R49.htm 000490 - Disclosure - 7. Stockholders' Equity (deficiency): Schedule of Stock Option Activities Table Text Block (Details) Sheet http://www.biotricity.com/20180930/role/idr_Disclosure7StockholdersEquityDeficiencyScheduleOfStockOptionActivitiesTableTextBlockDetails 7. Stockholders' Equity (deficiency): Schedule of Stock Option Activities Table Text Block (Details) Details http://www.biotricity.com/20180930/role/idr_Disclosure7StockholdersEquityDeficiencyScheduleOfStockholdersEquityNoteWarrantsOrRightsTables 49 false false R50.htm 000500 - Disclosure - 7. Stockholders' Equity (deficiency): Schedule of Assumptions Used (Details) Sheet http://www.biotricity.com/20180930/role/idr_Disclosure7StockholdersEquityDeficiencyScheduleOfAssumptionsUsedDetails 7. Stockholders' Equity (deficiency): Schedule of Assumptions Used (Details) Details http://www.biotricity.com/20180930/role/idr_Disclosure7StockholdersEquityDeficiencyScheduleOfStockholdersEquityNoteWarrantsOrRightsTables 50 false false R51.htm 000510 - Disclosure - 8. Related Party Transactions and Balances: Schedule of Related Party Transactions (Details) Sheet http://www.biotricity.com/20180930/role/idr_Disclosure8RelatedPartyTransactionsAndBalancesScheduleOfRelatedPartyTransactionsDetails 8. Related Party Transactions and Balances: Schedule of Related Party Transactions (Details) Details http://www.biotricity.com/20180930/role/idr_Disclosure8RelatedPartyTransactionsAndBalancesScheduleOfRelatedPartyTransactionsTables 51 false false R52.htm 000520 - Disclosure - 9. Commitments and Contingencies (Details) Sheet http://www.biotricity.com/20180930/role/idr_Disclosure9CommitmentsAndContingenciesDetails 9. Commitments and Contingencies (Details) Details http://www.biotricity.com/20180930/role/idr_Disclosure9CommitmentsAndContingencies 52 false false All Reports Book All Reports btcy-20180930.xml btcy-20180930.xsd btcy-20180930_cal.xml btcy-20180930_def.xml btcy-20180930_lab.xml btcy-20180930_pre.xml http://fasb.org/us-gaap/2017-01-31 http://xbrl.sec.gov/dei/2014-01-31 true true ZIP 70 0001511164-18-000658-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001511164-18-000658-xbrl.zip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end